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Résumé 
L'endothéline-1 (ET-1) et l'angiotensine II (Ang II) jouent un rôle important dans le 
maintien de la pression artérielle et l'homéostasie vasculaire. Une activité accrue de ces 
peptides vasoactifs est présumée contribuer au développement de pathologies vasculaires, 
telles que l'hypertension, l'athérosclérose, l'hypertrophie et la resténose. Ceci est causé par 
une activation excessive de plusieurs voies de signalisation hypertrophiques et 
prolifératives, qui incluent des membres de la famille des Mitogen Activated Protein 
Kinases (MAPK), ainsi que la famille phosphatidylinositol 3-kinase (PI3-K) / protéine 
kinase B (PKB).  Bien que l'activation de ces voies de signalisation soit bien élucidée, les 
éléments en amont responsables de l'activation des MAPK et de la PKB, induite par l'ET-1 
et Ang II, demeurent mal compris. Durant les dernières années, le concept de la 
transactivation de récepteurs et/ou non-récepteurs protéines tyrosine kinases (PTK) dans le 
déclenchement des événements de signalisation induits par les peptides vasoactifs a gagné 
beaucoup de reconnaissance. Nous avons récemment démontré que la PTK Insulin-like 
Growth Factor type-1 Receptor (IGF-1R) joue un rôle dans la transduction des signaux 
induits par l’H2O2, menant à la phosphorylation de la PKB.  Étant donné que les peptides 
vasoactifs génèrent des espèces réactives d'oxygène, telles que l’H2O2 lors de leur 
signalisation, nous avons examiné le rôle de d’IGF-1R dans la phosphorylation de la PKB 
et les réponses hypertrophiques dans les cellules muscle lisse vasculaires (CMLV) induites 
par l'ET-1 et Ang II. AG-1024, un inhibiteur spécifique de l'IGF-1R, a atténué la 
phosphorylation de la PKB induite à la fois par l'ET-1 et Ang II. Le traitement des CMLVs 
avec l’ET-1 et Ang II a également induit une phosphorylation des résidus tyrosine dans les 
sites d'autophosphorylation d'IGF-1R, celle-ci a été bloquée par l’AG-1024. En outre, l’ET-
1 et l’Ang II on tous les deux provoqué la phosphorylation de c-Src, une PTK non-
récepteur, bloqué par PP-2, inhibiteur spécifique de la famille Src.  La PP-2 a également 
inhibé la phosphorylation de PKB et d’IGF-1R induite par l’ET-1 et l’Ang II.  De plus, la 
synthèse de protéines ainsi que d’ADN, marqueurs de la prolifération cellulaire et de 
l’hypertrophie, ont également été atténuée par l’AG-1024 et le PP-2 
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Bien que ce travail démontre le rôle de c-Src dans la phosphorylation PKB induite 
par l'ET-1 et Ang II, son rôle dans l’activation des MAPK induit par l’ET-1 dans les 
CMLVs reste controversé. Par conséquent, nous avons examiné l'implication de c-Src dans 
l’activation de ERK 1/2, JNK et p38MAPK, par l'ET-1 et Ang II, ainsi que leur capacité à 
régulariser l’expression du facteur de transcription Early growth transcription factor-
1 « Egr-1 ». ET-1 et Ang II ont induit la phosphorylation de ERK 1/2, JNK et p38MAPK, 
et ont amplifié l'expression d'Egr-1 dans les CMLVs. Cette augmentation de la 
phosphorylation des MAPK a été diminuée par la PP-2, qui a aussi atténué l’expression 
d’Egr-1 induite par l’ET-1 et l’Ang II. Une preuve supplémentaire du rôle de c-Src dans ce 
processus a été obtenue en utilisant des fibroblastes embryonnaires de souris déficientes en 
c-Src (Src -/- MEF).  L’expression d’Egr-1, ainsi que l’activation des trois MAPKs par 
l’ET-1 ont été atténuées dans les cellules Src -/- par rapport au MEF exprimant des taux 
normaux Src.  En résumé, ces données suggèrent que l'IGF-1R et c-Src PTK jouent un rôle 
essentiel dans la régulation de la phosphorylation de PKB et des MAPK dans l’expression 
d’Egr-1, ainsi que dans les réponses hypertrophiques et prolifératives induites par l'ET-1 et 
Ang II dans les CMLVs. 
Mots-clés : Endotheline-1, Angiotensin II, PKB, MAPK, IGF-1R, c-Src, VSMC, Egr-1, 
prolifération, hypertrophie 
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Abstract 
Endothelin-1 (ET-1) and angiotensin II (Ang II) play important roles in maintaining 
blood pressure and vascular homeostasis, and a heightened activity of these vasoactive 
peptides is thought to contribute to the development of vascular pathologies, such as 
hypertension, atherosclerosis, hypertrophy and restenosis.  This is caused by an excessive 
activation of several growth and proliferative signaling pathways, which include members 
of the mitogen-activated protein kinase (MAPK) family, as well as the phosphatidylinositol 
3-kinase (PI3-K)/protein kinase B (PKB) pathway.  While the activation of these signaling 
pathways is well elucidated, the upstream elements responsible for ET-1 and Ang II-
induced MAPK and PI3-K/PKB activation remain poorly understood.  During the last 
several years, the concept of transactivation of receptor and/or non-receptor protein tyrosine 
kinases (PTK) in triggering vasoactive peptide-induced signaling events has gained much 
recognition.  We have recently demonstrated that insulin-like growth factor-1 receptor 
(IGF-1R) plays a role in tranducing the effect of H2O2, leading to PKB phosphorylation. 
Since vasoactive peptides elicit their responses through generation of reactive oxygen 
species, including H2O2, we investigated whether IGF-1R transactivation plays a similar 
role in ET-1 and Ang II-induced PKB phosphorylation and hypertrophic responses in 
VSMC. AG-1024, a specific inhibitor of IGF-1R, attenuated both ET-1 and Ang II-induced 
PKB phosphorylation in a dose-dependent manner. ET-1 and Ang II treatment also induced 
the phosphorylation of tyrosine residues in the autophosphorylation sites of IGF-1R, which 
was blocked by AG-1024.  In addition, both ET-1 and Ang II evoked tyrosine 
phosphorylation of c-Src, a non-receptor PTK, and pharmacological inhibition of c-Src 
PTK activity by PP-2, a specific inhibitor of Src-family tyrosine kinase, significantly 
reduced PKB phosphorylation as well as tyrosine phosphorylation of IGF-1R induced by 
the two vasoactive peptides. Furthermore, protein and DNA synthesis, markers of cell 
growth and proliferation, enhanced by ET-1 and Ang II were also attenuated by AG-1024 
and PP-2.  
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While this work demonstrates the role of c-Src in ET-1 and Ang II-induced PKB 
phosphorylation, its role in ET-1-induced MAPK signaling and  regulation of transcription 
factors, such as early growth response factor-1 (Egr-1), which was recently shown to be 
expressed in atherosclerotic plaque, remains controversial in VSMC. Therefore, we have 
also investigated the involvement of c-Src in ET-1 and Ang II-induced ERK 1/2, JNK and 
p38mapk activation, as well as Egr-1 regulation. ET-1 and Ang II-induced the 
phosphorylation of ERK 1/2, JNK and p38mapk, and enhanced the expression of Egr-1 in 
aortic VSMC.  This increased phosphorylation was decreased by PP-2.  Further proof for 
the role of c-Src in this process was obtained by using mouse embryonic fibroblasts (MEF) 
deficient in c-Src (Src -/- MEF). ET-1-induced Egr-1 expression, as well as MAPK 
activation, were found to be downregulated in Src -/- MEF, as compared to MEF 
expressing normal Src levels. In summary, these data demonstrate that IGF-1R and c-Src 
PTK play a critical role in mediating both PKB and MAPK phosphorylation and Egr-1 
expression, as well as hypertrophic and proliferative responses induced by ET-1 and Ang II 
in VSMC.  
Keywords: Endothelin-1, Angiotensin II, PKB, MAPK, IGF-1R, c-Src, VSMC, Egr-1, 
proliferation, hypertrophy 
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Chapter 1 
Introduction 
  
1.1 Obesity, Diabetes and Hypertension: The Modern Epidemic 
The insulin resistance syndrome, more commonly known as the metabolic 
syndrome, has been described as a cluster of multiple risk factors leading to the 
development of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD).  
Among these risk factors are obesity, irregular blood lipids (dyslipidemia), insulin 
resistance and hypertension 1.  These risk factors, beginning with insulin resistance, are 
caused by both genetic (where certain individuals or populations may be more likely to 
develop the metabolic syndrome due to their unique genetic background) and 
environmental/lifestyle factors, such as diet and exercise.  Globally, the incidence of 
metabolic syndrome is rising at an alarming rate 2, yet the true prevalence of the disease is 
unknown, partly due to the lack of an accepted definition to define the metabolic syndrome.  
To understand insulin resistance and the metabolic syndrome, and how this dysregulation of 
hormonal signaling affects various aspects of normal physiology and pathophysiological 
states, it is important to define insulin, and to understand its functions in normal physiology. 
Insulin is the primary hormone involved in blood glucose control.  In response to 
increasing blood glucose levels, pancreatic β-cells secrete insulin, which stimulates glucose 
uptake in muscle and fat tissues via stimulation of glucose transporter 4 (GLUT4) from 
intracellular sites to the plasma membrane 3 and triggers inhibition of gluconeogenesis and 
glucose release by the liver by stimulating glycogen synthesis and inhibiting glycogenolysis 
and gluconeogenesis, respectively.  In addition, insulin is an anabolic hormone, which 
promotes lipid synthesis and suppresses lipid degradation.  These actions are all mediated 
by an intricate signaling cascade initiated by the binding of insulin to its receptor.  An 
impaired insulin signaling and action results in a drastic decrease in glucose transport, 
glycogen synthesis, and lipid generation, leading to dysregulation of the physiological 
effects of insulin, which normally leads to insulin resistance, and T2DM 4.  When added to 
other environmental and genetic factors, this impaired signaling leads to symptoms of the 
metabolic syndrome, which can turn in to T2DM and CVD. 
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1.1.1 Insulin resistance and the metabolic syndrome 
Simply put, insulin resistance is a condition in which the body produces insulin, but 
cannot use it properly.  In a more scientific fashion, it is a condition in which insulin, 
exogenous or endogenous, produces an abnormally low biological response with respect to 
a decrease in blood glucose levels 5.  Insulin resistance is the earliest detectable metabolic 
trait of pre-diabetes, and possibly the most important risk factor in the development of Type 
2 diabetes mellitus (T2DM).  In the pre-diabetic state, or insulin resistance, serum insulin 
concentrations are elevated to compensate for insulin resistance in peripheral tissues, and to 
maintain a normal glucose balance.  This is a compensatory mechanism, known as 
hyperinsulinemia.   
Hyperinsulinemia exists to maintain normal glucose levels, or normoglycemia, 
during the prediabetic/insulin resistant state.  Even though normoglycemia may be 
maintained in some, it has been shown that other patients will have increased fasting 
glucose or impaired glucose tolerance (IGT) after a 2 hour oral glucose challenge, of 140 to 
199 mg/dL 6.  Hyperinsulinemia is a stress on the pancreas, and may, at some point, not be 
able to handle this increased work load, and as a result its insulin secretory response may 
decrease.  A decrease in insulin levels may cause a rise in blood glucose, leading to 
diabetes. 
 Today, it is almost impossible to speak of insulin resistance without talking about 
the metabolic syndrome.  In fact, after having done an in depth review of the literature on 
the subject, I have come to realize that if not for the clinical definition of insulin resistance, 
the terms metabolic syndrome and insulin resistance have come to be almost 
interchangeable.  Essentially, the metabolic syndrome is a constellation of abnormalities 
that is associated with increased risk for the development of T2DM and atherosclerotic 
vascular disease, such as heart disease and stroke 2. 
 As mentioned earlier, insulin levels may decrease after prolonged insulin resistance, 
yet in most of these insulin resistant individuals, large amounts of insulin continue to be 
secreted to overcome this defect in insulin action, thereby maintaining normal or near-
normal glucose tolerance.  While this compensatory hyperinsulinemia prevents the 
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development of hyperglycemia, these individuals run a risk of suffering from a certain 
degree of IGT, high plasma triglyceride (TG) and low high-density lipoprotein cholesterol 
(HDL-C), or “good cholesterol” levels, obesity, and most importantly, essential 
hypertension 7, 8.  These seem to constitute the cluster of risk factors leading to T2DM and 
CVD. 
 The first guide lines for the diagnosis of metabolic syndrome were presented in 
1998 by the World Health Organization (WHO) 9.  This definition was later modified by 
the European Group for the Study of Insulin Resistance (EGIR) to focus more on glucose 
intolerance and insulin resistance 10.  In 2001, the National Cholesterol Education 
Programme Adult Treatment Panel III (ATPIII) again revised the metabolic syndrome 
diagnosis criteria.  It is based more on plasma glucose levels and dyslipidemia, and omits 
insulin resistance as a criteria 11.   More recently, the American Heart Association (AHA) 
released its own criteria, which mirror the ATPIII, with the exception of stricter fasting 
glucose criteria 1.  The most recent definition of the metabolic syndrome criteria comes 
from the International Diabetes Federation, which names abdominal obesity and insulin 
resistance as the most important factors leading to metabolic syndrome 12.  Despite these 
more recent definitions, the most widely used definition and criteria to diagnose the 
metabolic syndrome remain those of the ATP III, and as such, we will concentrate on those 
criteria here.  The ATPIII identifies 5 components of the metabolic syndrome that relate to 
CVD: abdominal obesity (waist circumference), atherogenic dyslipidemia, high density 
lipoprotein (HDL) cholesterol levels, glucose intolerance, and high blood pressure 11.  
Visceral obesity is the form of obesity most strongly linked with insulin resistance 
and with the presence of related metabolic abnormalities of the metabolic syndrome.  
Clinically, it presents increased waist circumference. However, the mechanisms underlying 
the association between abdominal obesity and the metabolic syndrome are not fully 
understood.  It has been assumed that abdominal adipose tissue releases an excess of fatty 
acids and cytokines that contribute to insulin resistance.  For example, visceral adipose 
tissue secretes adipokines like adiponectin and inflammatory cytokines such as interleukin-
6 (IL-6) and tumor necrosis factor (TNF)-α, which contribute to the insulin resistant, 
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proinflammatory, and hypertensive states 13.  In fact, visceral adiposity and insulin 
resistance are connected by TNF-α at the molecular level.  Studies have shown that in 
adipocytes, TNF-α causes serine phosphorylation of IR and IRS-1, impairing insulin 
signaling.  This leads to increased lipolysis, as well as decreased adiponectin levels, and an 
increase in circulating free fatty acids (FFA) 14, 15 
Dyslipidemia and HDL levels present in routine lipoprotein analysis by high 
triglyceride levels, exceeding 200mg/dL and reduced concentrations of high density 
lipoproteins (HDL) cholesterol, usually below 40mg/dL 5.  In addition, it is characterized 
by other lipoprotein abnormalities, such as elevated apolipoprotein B, small low density 
lipoprotein (LDL) particles, caused by enriched triglycerides, and small HDL particles 5.  
The combination of these factors increases the atherogenicity of LDL, even though LDL 
levels are usually not increased.  Lipoprotein metabolism is regulated by genetic and 
environmental (diet, exercise or lack thereof) factors and both can aggravate dyslipidemia. 
Glucose intolerance presents as impaired fasting glucose (levels of 110 to 125 
mg/dL) or IGT (levels of 140 to 199 mg/dL) after a 2 hour oral glucose challenge, of 1.75 
Kg of glucose per Kg of body weight for children and 75 g of glucose for adults 6.  These 
glucose levels are intermediates between normal values and overt diabetes.  When glucose 
intolerance evolves into diabetes-level hyperglycemia due to the failure of the 
hyperinsulinemia mechanism described earlier, high glucose levels constitute a major, 
independent risk factor for CVD. 
Blood pressure has been shown to be elevated in overweight/obese patients with 
insulin resistance or glucose intolerance.  In fact, 50-60% of patients suffering from 
essential hypertension are insulin resistant to some degree 16. Blood pressure regulation is 
complex and affected by dietary factors, physical activity and renal/adrenal organ function. 
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1.2 The metabolic Syndrome, Hypertension and Cardiovascular 
Disease 
Obesity, diabetes, and the metabolic syndrome have clearly been shown to cause 
endothelial dysfunction 17.  Endothelial dysfunction is commonly characterised by reduced 
nitric oxide (NO) dependent activity, which leads to hypertension, coronary heart disease, 
and accelerated atherosclerosis 18.  Glucotoxicity (deleterious effects of hyperglycemia) and 
lipotoxicity (negative effects of increased plasma FFA and low HDL), as well as increased 
pro-inflammatory signaling are all adverse effects of the metabolic syndrome, which 
worsen insulin resistance, and contribute to endothelial dysfunction, hypertension and 
CVD. 
1.3 Hypertension 
Blood pressure is defined as the force that blood exerts on the vessel walls.  
Hypertension (HT), or high blood pressure, is a chronic medical condition characterized 
mainly by elevated arterial blood pressure 19.  The worldwide prevalence of hypertension is 
estimated to be at 1 billion people, and contributes to approximately 7.1 million deaths per 
year worldwide 20.  Persistent HT is a major risk factor contributing to pathophysiological 
events such as stroke, heart attack, heart failure and chronic renal failure  21.  In the United 
States, it is estimated that approximately 50 million people (almost 1 in 4 adults) suffer 
from hypertension 19, with proportions varying according to race, age, geographic location, 
gender and economic status.  To add to these factors, not all people suffering from HT 
suffer from the same type of HT, as multiple types of HT exist.  Furthermore, as blood 
pressure is not static, and varies from one minute to another in the day due to multiple 
external stimuli, it is difficult to define HT, in order to establish accepted treatment 
guidelines.  Here, I will define blood pressure and discuss several of the proposed 
definitions of HT, as well as several different types of HT, and the differences between 
them. 
  
 
6
1.3.1 Definition of hypertension  
Blood pressure is calculated by measurements of systolic pressure (SBP) over 
diastolic blood pressure (DBP), measured in millimeters of mercury (mmHg).  Systolic 
pressure is the peak pressure in the arteries, which occurs near the end of the cardiac cycle, 
during ventricular contraction.  Diastolic pressure is the lowest pressure in the arteries, 
occurring at the start of the cardiac cycle, when the ventricles are filling with blood.  It can 
be said that “normal” or healthy adult blood pressure, when taken at a resting state 
(normally how blood pressure is taken) is 115mmHg systolic over 75mmHg diastolic, read 
as 115/75 mmHg 22.  As mentioned earlier, blood pressure is not static, as it undergoes 
natural variations from one heart beat to another, in response to simple stimuli, such as 
movements, nutrients or metabolites in the circulation, exercise, disease and stress.  High 
blood pressure (or hypertension (HT)) can be clinically diagnosed by either a SBP above 
140mmHg or a DBP above 90 mmHg, measured at least twice, on at least 2 subsequent 
visits to have blood pressure taken 19.  Although these criteria help diagnose HT so that a 
patient can receive the proper treatment, recent studies show that a great deal of damage 
may have already occurred to the cardiovascular system by the time or before a patient’s 
blood pressure reaches 140/90 mmHg.  In fact, the Framingham Heart Study has shown 
that for every increase of 20/10 mmHg, from a base blood pressure of 120/80 mmHg, the 
risk of development of cardiovascular disease doubles 23.  Further to this data which 
highlights the increased risk of cardiovascular complications associated with blood pressure 
levels that used to be considered normal, the Joint National Committee on prevention, 
detection, evaluation and treatment of high blood pressure (JNC) convened to re-evaluate 
the definition of hypertension 22.  In this new definition, blood pressure is separated into 4 
different categories (Table 1): 
Normal: This category is composed of individuals with an SBP under 120 mmHg and a 
DBP under 80 mmHg. 
• Prehypertension: This category is composed of individuals with an SBP between 
120-139 mmHg and a DBP between 80-89 mmHg. 
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• Stage 1 hypertension: This category is composed of individuals with an SBP 
between 140-159 mmHg and a DBP between 90-99 mmHg. 
• Stage 2 hypertension: This category is composed of individuals with an SBP over 
160 mmHg and a DBP over 100 mmHg. 
Longutidinal studies, such as the Framingham Heart Study, have shown the long-term 
effects of prolonged hypertension.  Based on such studies and others, the new JNC 
definitions have made it easier to diagnose hypertension and the increased blood pressure 
conditions which precede HT.  By adding a category to include “pre-hypertensive” patients 
(Table 1), individuals in whom early intervention could reduce blood pressure could easily 
be identified.  These patients would be counseled to adopt lifestyle changes, which may not 
only lower blood pressure, but help prevent the progression of HT with age, and may 
prevent HT altogether 22.  It is important to note however, that the prehypertension category 
does not imply that an individual suffers from HT.  This category was created to identify 
patients at risk of developing HT, such as individuals suffering from obesity, diabetes and 
kidney disease.  While there is no pharmacological therapy suggested to treat the increase 
in blood pressure in the prehypertenvise group, patients in both stage 1 and stage 2 
hypertension groups must receive pharmacological therapy, in addition to lifestyle changes, 
to decrease HT, and its associated risks, such as angina, myocardial infarction, stroke or 
chronic kidney disease 24.  Lifestyle changes include weight reduction through decreased 
caloric intake and exercise (Table 2), the adoption of an exercise/physical activity plan 
consisting of moderate exercise (at least 30 minute moderate walk 3 to 4 times per week), a 
reduction in dietary sodium intake (Table 2), as well as limiting the consumption of alcohol 
to no more than 2 drinks per day for men and 1 drink per day for women 24.  Adoption of 
lifestyle changes alone have been shown to reduce SBP by 2-20 mmHg 25-28, prevent/delay 
the incidence hypertension and increase the efficiency of antihypertensive pharmacological 
therapy 29.  When the adoption of lifestyle changes is not sufficient, pharmacological 
therapies must be included in treatment plans.  These pharmacological therapies include 
diuretics, angiotensin converting enzyme (ACE) inhibitors, angiotensin II (Ang II) 
antagonists, and α- and β-blockers.  Unfortunately, not all people suffering from HT suffer 
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from the same type of HT, as multiple forms of HT exist, and as such, treatments must be 
personalized. 
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1.3.2 Varying forms of hypertension 
 As mentioned above, multiple forms of HT exist, and specific classifications have 
been defined to identify them.  HT is classified under 2 main categories: essential, or 
idiopathic HT, and secondary HT.   
Essential hypertension (EHT) is diagnosed when no clear medical cause can be 
identified to explain the increased blood pressure 30.  This is the most common type of 
hypertension, with approximately 95% of all HT being diagnosed at EHT 19, 30.  It is 
unassociated with secondary causes, such as renovascular disease, renal failure, 
pheochromocytoma, aldosteronism or monogenic HT 19.  Multiple pathophysiological 
factors have been suggested to contribute to the development of essential HT, among them, 
obesity, high sodium intake, high alcohol intake, and inadequate potassium and calcium 
intake 31-37.  It is for this reason that HT has been termed a heterogeneous disorder, as 
different patients have different causal factors leading to HT 19.  Insulin resistance (IR) 
and/or glucose intolerance has also been shown to play an important role in the 
development of EHT.  Blood pressure has been shown to be elevated in overweight/obese 
patients with IR.  In fact, 50-60% of patients suffering from EHT are insulin resistant to 
some degree 16.  Blood pressure regulation is complex and affected by dietary factors, 
physical activity and renal/adrenal organ function. 
To complicate matters further, the presence of obesity, IR and EHT are hallmarks of 
the metabolic syndrome, a constellation of abnormalities that is associated with an 
increased risk of development of type 2 diabetes mellitus (T2DM) and atherosclerotic 
vascular disease, such as heart disease and stroke.  Obesity, diabetes, and the metabolic 
syndrome have clearly been shown to cause endothelial dysfunction 17, commonly 
characterized by reduced nitric oxide production, leading to HT, coronary heart disease and 
accelerated atherosclerosis 18. 
Secondary hypertension (SHT), unlike EHT, is caused by an identifiable 
secondary cause, usually a pre-existing medical condition, such as congestive heart failure, 
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liver damage, kidney damage, hormonal irregularities, certain types of cancers and different 
types of medications 38.  It is less frequent as well, affecting only about 5% of people with 
HT 38.  Here, I will briefly describe SHT associated to 1) chronic kidney disease and 2) 
gestational hypertension, which are two of the more common forms of SHT encountered. 
Chronic kidney (renal) disease, also known as renal parenchymal disease, is the 
most common cause of SHT.  HT may be an early sign of renal disease and may be present 
even before a decline in renal function, yet it is mostly caused by renal artery stenosis.  
Renal artery stenosis causes the kidney attached to the constricted arteries to become 
ischemic, leading to an increased activation of the renin-angiotensin system (RAS) 39.  An 
increased production of Ang II leads to augmented aldosterone secretion, causing sodium 
and water retention, leading to hypertension 39, 40.  Renal artery stenosis may be unilateral, 
affecting the artery going only to one kidney, or bilateral, affecting the arteries going to 
both kidneys.  The latter is the most common cause of renal failure.  In the case of 
unilateral stenosis, volume overload of the affected kidney is avoided, as the contralateral 
kidney responds to the rise in blood pressure through increased excretion of sodium 
through the urine, or natriuresis 41.  In the case of bilateral stenosis, or in patients with only 
one functional kidney, there is no compensatory diuresis, thus inhibiting sodium excretion. 
Open surgical revascularization was at one point the only treatment available for 
renal artery stenosis.  In fact, this method is still the primary treatment used in patients 
where the stenosis extends into segmental arteries, or involves multiple small arteries or the 
early branching primary renal artery 41.  Balloon angioplasty and especially renal artery 
stent insertion have also become popular “surgical” treatments, especially with the 
development of stents coated with different types of medications 42.  Pharmacological 
treatment options include angiotensin-converting enzyme inhibitors, angiotensin receptor 
blockers and calcium channel blockers, which are recommended for the treatment of 
unilateral renal artery stenosis-induced hypertension only.  However, caution must be 
exercised with the use of these medications, and their administration must be carefully 
monitored by constant laboratory testing, as they may cause acute renal failure 41, 43.  These 
treatments are, for the most part, very successful in terms of restoring blood pressure to 
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normal levels, as well as preventing further renal, endocrine or cardiac complications, such 
as atherosclerosis, cardiovascular disease, heart failure and stroke.  Unlike EHT, adoption 
of healthy lifestyle changes will not cure HT due to renal artery stenosis, but will certainly 
cause no harm! 
Gestational hypertension (GHT) is another type of secondary hypertension.  
Gestational HT is defined as the onset of HT more than 20 weeks into the pregnancy 44.  To 
be considered GHT, blood pressure must return to normal within 12 weeks after the birth.  
Therefore, the diagnosis of GHT is often made in retrospect 45.  GHT is the most common 
medical complication of pregnancy 44.  Treatments for GHT are very limited, due to the fact 
that most antihypertensive medications have been found to be teratogenic to some degree. 
It is also a temporary diagnosis, which may include the eventual development of 
preeclampsia 46.  Up to 50% of women diagnosed with GHT develop preeclampsia 47, 
which is defined as the development of hypertension and proteinuria after 20 weeks of 
gestation, even into the first week postpartum 48. Preeclampsia is a condition endangering 
both the mother and the fetus, and is responsible for up to 20% of maternal mortality, as 
well as the majority of morbidities, prenatal deaths, preterm births and fetus growth 
restrictions 48.  Treatment options for GHT and preeclampsia are limited, as many 
pharmacological treatments may pose severe risks to the fetus 45.  The most common 
antihypertensive used in GHT is the sympathetic nervous system inhibitor α-methyldopa, 
which has shown few or no lasting side effects to the mother or foetus 45, yet in depth 
studies on methyldopa, as well as many other classes of antihypertensives, are lacking.  For 
the most part, treatment of GHT includes bed rest and limiting movement, and if the 
pregnancy is close to term, labour is induced.  If the development of preeclampsia occurs, 
the most common treatment is for labour to be induced, especially if gestation is close to or 
at 32 weeks 45, 48. 
Cardiovascular Diseases 
According to the World Health Organization (WHO), more people die of 
cardiovascular diseases (CVD) yearly than any other cause or pathological condition, with 
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approximately 17.3 million deaths due to CVDs in 2008, a number which is predicted to 
rise to 23.6 million by the year 2030 49.  Alterations in vascular smooth muscle cell 
(VSMC) growth, migration, proliferation and plasticity is believed to contribute to 
abnormal vascular functions associated with or leading to CVDs, such as hypertension, 
atherosclerosis, and stenosis after angioplasty 50-52.  Under normal physiological conditions, 
vasoactive peptides, such as angiotensin II (Ang II) and endothelin-1 (ET-1), normalize 
blood pressure through the regulation of salt and/or water homeostasis, sympathetic nervous 
system modulation, as well as VSMC contraction and relaxation 53-56.  Increased levels of 
both ET-1 and Ang II, present in certain pathophysiological states, such as essential 
hypertension, obesity, or advanced stages of diabetes, have been suggested to contribute to 
the pathogenesis of CVDs, by activating signaling events intimately linked to migration and 
proliferation of VSMC 53, 57-59. 
1.4 Endothelins 
Originally identified in 1988 by Yanagisawa et al. from porcine aortic endothelial 
cell cultures 60, endothelin (ET) is the most potent vasoconstrictor peptide known.  Today, 
ET has been characterized in almost all organs and physiological systems, and remains one 
of the most important regulators of blood pressure, sodium and water homeostasis in the 
body 61.  ET also exhibits important mitogenic and inotropic properties, can stimulate the 
renin-angiotensin-aldosterone system (RAAS) as well as the sympathetic nervous system 
(SNS) 54-56.  The general role of ET is to increase vascular tone and blood pressure in 
response to potential hypotensive states.  However, through its mitogenic properties, ET is 
thought to play an important role in vascular remodeling associated with hypertension, 
which contributes to the development of various CVDs 62, by increasing cell proliferation, 
hypertrophy and cell migration, through the activation of several signal transduction 
pathways linked to these events in the cardiovascular system 63, 64. 
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1.4.1 Structure, Regulation and Biosynthesis of ET-1 
 Three members of the mammalian ET gene family exist and have been 
characterized: ET-1, ET-2 and ET-3 61.  All three ET peptides are 21 amino acids long 
connected by two interchain disulfide bonds (Cys1-Cys15 and Cys3-Cys11) at the N-
terminal end, with a cluster of three polar charged side chains on amino acid residues 8-10 
and a hydrophobic C-terminus (residues 16-21) containing the aromatic indole side chain at 
Trp21, essential for its loop configuration and its bioactivity 61 (Figure 1).  The ET-2 
peptide shares a 90% sequence homology with ET-1, varies from it by only two amino acids 
(Trp6-Leu7), while ET-3 shares 71 % sequence homology with ET-1 and ET-2, and varies 
by six amino acids (Thr2, Phe4-Thr5-Tyr6-Lys7 and Tyr14).  ET-1 is encoded by a gene on 
chromosome 6 in humans (chromosome 13 in mouse), while ET-2 and ET-3 are encoded by 
independent genes located on chromosomes 1 and 20, respectively 65.  The sequences for all 
ET family members are preserved in mammals, and are related to the sarafotoxin snake 
venom 66 (Figure 1).  Among the three ET peptides, ET-1 is the most important isopeptide 
in the vasculature. 
 Multiple stimuli, including hypoxia, shear stress, lipoproteins, hormones and growth 
factors, free radicals and endotoxins, can induce and/or increase ET-1 generation, while 
others, such as nitric oxide (NO), natriuretic peptides, nitrovasodilators, heparin and 
prostaglandins, all of which increase intracellular cyclic guanosine monophosphate (cGMP) 
levels, inhibit ET-1 production 67.  Production of ET-1 is regulated by the preproET-1 gene, 
at the transcriptional level 68.  Binding sites for multiple regulatory elements, such 
activating protein 1 (AP-1), CAAT-binding nuclear factor 1 (NF-1), nuclear factor of 
activated T-cells (NFAT)-binding domains and GATA binding protein 2 are located in the 
5’ promoter region of the preproET-1 gene, which mediate ET-1 mRNA induction by 
several factors, including Ang II and transforming growth factor-β (TGF-β) 69.  The 
adenine-uracil-rich motifs present in the non-translated 3’ region mediate selective 
destabilization of preproET-1 mRNA, contributing to the relatively short biological half-life 
of ET-1 (15-20 minutes) 65. 
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Figure 1: Structure of the Endothelins. Amino acid sequences of the three members of 
the endothelin family and of the structurally related snake venom toxin sarafotoxin S6b.  
All three ET peptides are 21 amino acids long connected by two interchain disulfide bonds 
(Cys1-Cys15 and Cys3-Cys11) at the N-terminal end ET-1 (top right) is a 21 amino acid 
cyclic peptide with two disulphide bridges joining the cysteine residues at positions 1-15 
and 3-11. Grey circles indicate where amino acids differ from those of endothelin-1. 
(Haynes WG, J. Hypertens 1998, 16(8):1081-98) 
 
  
 
17
Compared to all other cell types, ET-1 is primarily produced in vascular endothelial cells, 
which express high levels of ET-1 mRNA, preproET-1 mRNA and its converting enzyme 
65.  ET-1 has also been shown to be produced by the heart, kidney, the posterior pituitary 
gland and the CNS 67.  ET-1 is also expressed in VSMC, yet its production in this cell type 
is 100 fold less than in endothelial cells 70.  While ET-2 is secreted by heart, kidney and 
endothelial cells (albeit in limited quantities), ET-3 does not seem to be present in 
endothelial cells, and is secreted mainly by the CNS, gastro-intestinal (GI) and endocrine 
systems 71, 72.   
The formation of the mature ET-1 peptide is preceded by multiple steps, including 
the cleavage of precursor peptides. Human ET-1 mRNA encodes a 212 amino acid peptide 
named preproET-1 61.  The signal sequence is then cleaved by a signal peptidase to form 
proET-1, which is further cleaved by dibasic-pair-specific endopeptidases, including furin 
and PC7, to from bigET-1, a 38 amino acid peptide whose vasoconstrictor efficacy is two 
orders of magnitude less than that of the mature ET-1 peptide 73.  BigET-1 is then cleaved 
between Trp21 and Val22 by one of several endothelin converting enzymes (ECE) to form 
the mature 21 amino acid ET-1 peptide (Figure 2). 
Three isoforms (ECE-1, ECE-2 and ECE-3) of ECE have been identified, all 
belonging to a family of zinc peptidases and related to neutral endopeptidase-24.11 and Kell 
protein, but not to angiotensin converting enzyme (ACE).  ECE-1 is the isoform 
predominantly found in endothelial cells, and has the greatest affinity for BigET-1, but has 
been found to proteolyze other peptides as well.  Four isoforms of ECE-1 exist (ECE-1a, -
1b, -1c and -1d) and all are derived from alternative splicing of the same gene 74, 75.  ECE-
1a is primarily expressed in intracellular vesicles and on the cell surface of ET-1 “producer” 
cells, such as endothelial cells, while ECE-1b is located mostly near the trans-Golgi 
network, in the endosomal compartment of “responder” cells, such as VSMC.  ECE-1b is 
then transported to the plasma membrane where it is responsible for the cleavage of 
extracellular BigET-1 61, 76.   ECE-1c and ECE-1d are both located on the extracellular face 
of the plasma membrane 73. 
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 ECE-2 hydrolyzes ET-1, and has a 60% homology with ECE-1.  It also has four 
isoforms, which vary at the amino acid terminus level, possibly responsible for their 
different intracellular localization 77.  The optimal functional pH of ECE-2 is 5.5, and it has 
virtually no activity at pH 7.0, indicating that ECE-2 is involved in intracellular processes, 
particularly at the level of the trans-Golgi network 61, 77.  ECE-1 and ECE-2 are relatively 
selective for big ET-1, having much less activity in cleaving big ET-2 and big ET-3, yet 
ECE-1 and ECE-2 knockout mice still display significant levels of ET-1, indicating that ET-
1 formation may also be regulated by other proteases and/or enzymes, yet their 
physiological relevance is not clear 78.  While ECE-3 has been identified, studies have 
demonstrated that it has a preferential activity for ET-3 76. 
In healthy subjects, circulating concentrations of ET-1 in venous plasma are in the 
range 0.1-10 pmol/l 79.  While these concentrations are lower than the concentrations able to 
induce vascular constriction in vivo and in vitro, ET-1 concentrations at the interface 
between VSMC and endothelial cells are many times higher 61, 70.  This is supported by 
studies demonstrating that ET-1 is secreted by cultured endothelial cells into the basolateral 
(towards VSMC) compartment and not apically 80.  In a similar fashion, renal tubule cells 
secrete ET-1 towards the interstitium, and only minimally into the urine 61.  As such, rather 
than acting as a circulating endocrine peptide, ET-1 acts primarily as a paracrine factor, 
affecting local cell and tissue metabolism.  Consequently, ET-1 levels in circulation do not 
reflect its full physiological impact.  This phenomenon has led to the use of venous plasma 
BigET-1 and inactive ET-1 C-terminal fragment concentrations as markers for endothelial 
ET-1 synthesis, as they better reflect the quantities of ET-1 generated, as opposed to 
measuring ET-1 generation.  This is due to the efficient clearance mechanism of ET-1, 
owing to its short half life (approx. one minute, although its pressor effects are maintained 
for up to one hour) and the unusual binding characteristics of the ET receptors for their 
ligand, which is almost irreversible 81, 82. 
Circulating ET-1 is eliminated mainly by the kidney, liver and lungs, the latter of 
which is responsible for more than 50% of the elimination of ET-1 in humans 81.  ET is 
degraded mainly by endopeptidases, such as neutral endopeptidase (NEP), found in the 
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proximal tubules of the kidney, and cathepsin G, generated in vascular endothelial and 
pulmonary epithelial cells 83.  ET-1-binding to its cell-surface receptors and subsequent 
lysosomal internalization and degradation are also important mechanisms in ET-1 
clearance.  This theory stems from studies showing that pulmonary clearance of labelled 
ET-1 can be blocked by pre-treatment of the cells with a large dose of unlabelled ET-1, 
suggesting that ET-1 clearance is receptor-dependent 84.  Investigations have also shown an 
increase in plasma ET-1 levels following a pharmacological blockade of the ETB receptor 
85, yet in most studies the pharmacological blockade of the ETA receptor had little impact on 
plasma ET-1 levels 61.  However, studies using specific disease models in which there is 
thought to be some degree of ETB dysfunction, such as the ETB-deficient rat, or the DOCA-
salt hypertensive rat model, pharmacological blockade of the ETA receptor led to an 
increase in circulating ET-1 levels 84, 86.  As such, it cannot be concluded that the ETA 
receptor does not play a role in ET clearance.  Moreover, plasma ET levels are increased 
within 15 minutes of ET receptor blockade, without any effect on C-terminal fragment and 
Big ET-1 concentrations, confirming that the increase in ET levels is not entirely due to 
peptide synthesis, but is mediated by ET-1 receptor displacement 87, 88.     
1.4.2 ET-1 Receptors 
All mammalian ET receptors are coded from two separate genes 61.  ETA and ETB 
are the two main ET-1 receptor subtypes through which ET-1 exerts its biological effects in 
a paracrine/autocrine fashion.  Both of these receptors have been cloned in humans 89, 90, 
and belong to the rhodopsin class A of seven transmembrane guanine nucleotide-binding 
protein (G protein)-coupled receptors (GPCRs), which signal through activation of G 
proteins.  GPCRs have an approximate 400 amino acid sequence with an N-terminal 
extracellular region and C-terminal intracellular region, and contain seven 22-27 
hydrophobic amino acid transmembrane domains.     
The ETA receptor contains 427 amino acids, and its gene is located on chromosome 
4.  ETA has the strongest affinity for ET-1, yet binds ET-2 to a lesser or equal extent, and 
can also bind ET-3, albeit to a much lessor extent that ET-2 and ET-1 91.  Studies have 
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recently reported the existence of splice variants of the ETA receptor in the rat anterior 
pituitary gland, of which one variant was found to have reduced efficacy in stimulating 
adenylyl cyclise activity and mobilizing intracellular calcium (Ca2+) 92.  Nevertheless, it 
remains to be seen if these splice variants exist in other tissues and have a significant 
physiological contribution. 
The ETB receptor, whose gene is located on chromosome 13, contains 442 amino 
acids, and has the capacity to bind all ET peptides with equal affinity 89, 93.  Several splice 
variants of the ETB receptor have been identified.  One in particular contains an additional 
10 amino acids, is found only in humans, and appears not to present any differences in 
cellular signalling events 94.  A second ETB receptor variant was found to have important 
differences in the cytoplasm domain and the 3’-untranslated domain, yet this splice variant 
is thought to function primarily as a clearance receptor, as it has shown little to no cellular 
signalling activity 95.  An ETB receptor splice variant has also been discovered in the rat 
brain and possibly other tissues, yet its functional characteristics have yet to be identified 96.  
ETB receptors are found predominantly in endothelial and renal tubule cells, yet are 
expressed in smaller quantities in VSMC, cardiomyocytes, hepatocytes, osteoblasts, 
neurons, epithelial cells and fibroblasts 61, 90. 
ET receptors couple to the Gi, Gq, Gs and Gα12/13 members of the G protein family, 
regulating various signalling cascades, including adenylyl cyclases, nitric oxide synthase 
(NOS), serine/threonine kinases, tyrosine kinases, cyclooxygenases, amongst others 61, 69.  
More often than not, ETA and ETB receptors have opposite actions, depending on their 
localization, even in the same organ, yet many exceptions exist.  For example, in the 
vasculature, both ETA and ETB receptors located on VSMC induce ET-1-induced 
vasoconstriction, cell adhesion and cell growth (Figure 2).  In opposition, ETB receptor 
binding of ET-1 in endothelial cells induces vasorelaxation, through the release of nitric 
oxide (NO) and prostacyclin on to VSMC 97, as well as contributing to the prevention of 
endothelial cell apoptosis, inhibition of ECE-1 expression and increase in ET-1 clearance 98 
(Figure 2).  Many pharmacological ET receptor agonists and antagonists have been  
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Figure 2: Factors affecting regulation of ET-1 synthesis and its subsequent ET receptor mediated actions on 
vascular smooth muscle cells. The generation and secretion of ET-1 is regulated by multiple factors, including 
hypoxia, shear stress and various growth factors and peptides. The formation of the mature ET-1 peptide is preceded 
by multiple steps.  In humans, ET-1 mRNA encodes a 212 amino acid peptide named preproET-1, which is cleaved 
by a signal peptidase to form proET-1.  ProET-1 is again cleaved by dibasic-pair-specific endopeptidases, including 
furin and PC7, to from bigET-1, a 38 amino acid peptide. BigET-1 is then cleaved between Trp21 and Val22 by one 
of several endothelin converting enzymes (ECE) to form the mature 21 amino acid ET-1 peptide.  In the vasculature, 
binding of ET-1 to ETA and ETB receptors on VSMCs induces vasoconstriction, cell adhesion and cell growth. In 
opposition, binding of ET-1 to ETB receptor on endothelial cells induces vasorelaxation, through the release of nitric 
oxide (NO) and prostacyclin on to VSMCs. ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; CNP, C-
type natriuretic peptide; TGF-β, transforming growth factor β.(Adapted from Remuzzi, G. et al., Nat.Rev.Drug. Disc 
2002, 1(12):986-1001) 
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developed and used to better identify and understand the role of ET receptors in 
physiological states.  For example, BQ123 and BQ788 are highly selective ETA and ETB 
receptor antagonists, respectively, while sarafotoxin 6c is a powerful and highly selective 
ETB receptor agonist 99.  Orally active ET receptor antagonists have also been developed 
and used clinically, such as Bosentan, an ETA/B receptor antagonist, as well as Sitaxsentan, a 
selective ETA receptor inhibitor 99.  Use of such compounds has also helped to identify the 
phenomenon of ETA and ETB receptor heterodimerization, possibly affecting receptor 
functionality, since ETA/ETB heterodimers were shown to have delayed ET receptor 
internalization and a prolonged increase in intracellular Ca2+ in response to ET-1 100, 101. 
1.4.3 Biological actions of ET-1 
1.4.3.1 ET-1 in the vasculature and heart 
Hickey et al. were the first to demonstrate that media taken from cultured 
endothelial cells produced constriction in classic muscle bath preparations 102.  Yanagisawa 
et al. later isolated and purified the peptide and gave it the name endothelin, stemming from 
its endothelial cell origin 60 and demonstrated that a bolus injection of ET caused a transient 
hypotension immediately followed by a prolonged increase in blood pressure 60.  Later 
studies indicated that these effects are due to ETB and ETA receptor, respectively.  However, 
further detailed studies have shown that ETB receptor is also implicated in vasoconstriction 
and induction of hypertensive effects of ET.  In VSMC, ETA and ETB activation by ET 
leads to the vasoconstrictor response of ET (Figure 2).  Both receptor types were shown to 
be present on the plasma membrane, cytosol, nuclear envelope membrane and the 
nucleplasm of human VSMC 103. 
On the other hand, ETB activation by ET in the endothelium leads to the transient 
vasodilatation response described earlier, usually followed by vasoconstriction (Figure 2).  
Studies have attributed this vasodilation to the generation of NO via the activation of 
endothelial NOS (eNOS).  Activation of eNOS is thought to occur through ET-1-induced 
protein kinase B (PKB) phosphorylation and activation in endothelial cells 104.  The 
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subsequent ETB receptor-dependent vasoconstriction mediated by ET-1 varies, however, 
from one vascular bed to another 61.  Veins seem to have a more potent ETB receptor-
dependent vasoconstriction action than arteries, yet the functional implication of these 
findings remains to be determined 105.  Results from several investigations have suggested 
that NO release and vasodilatation are mediated by ETB1 receptor isotype, while the 
subsequent vasoconstriction requires ETB2 receptor isotype 106.  It is interesting to note that 
hypotension does not occur when ET concentrations rise slowly, as opposed to a bolus dose 
107. As mentioned earlier, ET response varies from one vascular bed to another.  Renal and 
coronary vascular beds are the most sentitive to the systemic vasoconstrictor effects of ET-
1, however, hindquarter skeletal muscle beds display only a minimal ET-1-induced 
constriction 108-110.  Mesenteric vascular beds, like their coronary counter parts, have a 
potent ET-1-induced vasoconstrictor response 110 (Figure 3).  The concentration and 
localisation of the different ET receptors in these vascular beds may be the cause of this 
varying degree of ET-1-induced response.  In VSMC, ET-1 is known to also act as a 
mitogenic factor, as long-term treatment of VSMC resulted in an increased growth and 
proliferation of this cell type, which was shown to be mediated through ET-1-induced ETA 
receptors activation 111, 112 (Figure 3).  As well as being a mitogenic peptide in VSMC, ET-1 
also displays co-mitogenic properties, potentiating the effects of such growth factors as 
epidermal growth factor (EGF), platelet derived growth factor (PDGF) and basic fibroblast 
growth factor (bFGF) 112. 
In the heart, the regulation of cardiac function regulated by the ET system has been 
fairly well studied, particularly the role of ET in cardiac pathophysiological conditions, such 
as cardiac hypertrophy, ischemia/reperfusion injury, arrhythmias and congestive heart 
failure 61 (Figure 3).  In terms of production, there is some controversy as to whether or not 
cardiomyocytes produce ET-1.  Several studies have reported ET-1 mRNA, mature peptide 
and/or production in rat and chick neonatal cardiomyocytes, as well as adult porcine 
cardiomyocytes 113-116.  In contrast, others have demonstrated the absence of ET-1 mRNA in 
cardiomyocytes from adult pig and rat hearts 117, 118.  This has led to the speculation that 
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neonatal or embryonic hearts may produce larger amounts of ET-1 than healthy adult, 
which may produce small amounts 61. 
While it may only be produced in small amounts in the heart, ET-1 secreted from 
VSMC and/or endothelial cells has an impact on cardiomyocyte function 119.  In general, ET 
has positive inotropic effects on the heart, which is to say an increase in cardiac 
contractility, yet this varies from species to species, ET dose and duration of exposure, 
sympathetic nerve activity, underlying cardiac pathology and other contributing factors 
(reviewed in 120).  Several studies have shown an increase in cardiomyocyte contractility by 
ET-1 in several species, including mouse, rat, dog and human, yet other studies have 
detected little or no ET-1-enhanced cardiomyocyte contractility, possibly due to the 
aforementioned factors 121-125.  Despite the fact that the inotropic effects of exogenous ET-1 
were examined in these studies, they did not look at the inotropic effect of endogenous ET-
1.  In studies where the ET-1 gene was knocked out specifically in mouse cardiomyocytes, 
the mice displayed an increase in cardiac cell apoptosis associated with the development of 
a dilated cardiomyopathy as of seven months of age.  Until then, no difference in left 
ventricular function was observed.  These studies suggest that while ET-1 production by 
cardiomyocytes in required for their survival, it may not be crucial for a normal heart 
function for a large part of the animals’ life 126.  In a similar fashion, mice in which the ETA 
receptor gene was deleted, specifically in cardiomyocytes, displayed normal baseline and 
Ang II-induced cardiac contractility, suggesting that ET-1-induced cardiomyocyte 
contractility is not of physiological relevance 127.  These conclusions are based on the 
hypothesis that the ETA receptor is responsible for the inotropic effects of ET (reviewed in 
61, 128).  However, diffusion of BQ123, a selective pharmacological inhibitor of ETA receptor 
subtype, into left coronary artery of patients presenting with atypical chest pain, reduced 
contractility.  These results confirm that ET exerts a positive inotropic effect via ETA 
receptor 129.  Cardiac contractility in response to endogenous ET was also examined in vitro, 
in studies examining the response of cardiac muscle to stretch test.  An increase in both 
rapid and slow cardiac muscle shortening and/or developed force, due to the Frank-Starling 
mechanism and slow force response, respectively, was observed after myocardial stretch, 
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with the study concluding that ET may be involved in slow force response 130.  This was 
confirmed by studies showing that ETA receptor antagonism inhibited slow force response 
in cat cardiac papillary muscle after mechanical stretch 131, yet had no effect on the Frank-
Starling response in intact hearts of normal rats 132, substantiating the notion that 
cardiomyocyte-derived endogenous ET is important to cardiac adjustments, and plays a 
physiological role 61. 
1.4.3.2 ET-1 in the nervous system 
ET is known to play an important role in the development of the neural crest and of 
enteric neurons, as well as of peripheral sympathetic ganglia which modulate systemic 
hemodynamics 133, 134, where both ET-1 and ET-3 production has been demonstrated in 
neurons cultured from superior cervical ganglion (SCG) 135, as well as in the dorsal root 
ganglia 136.  These results demonstrate a clear presence of ET in neurons within the 
sympathetic ganglia.  Spontaneously hypertensive rats (SHR) have been shown to have 
increased SCG ET-1 levels, as compared to Wistar Kyoto rats (WKY), yet it is not clear as 
to whether or not this is a significant contributing factor to the increased hypertensive state 
of SHR 137. 
 
ET mRNA and mature peptides are also present in regions of the hypothalamus and 
brain stem known to regulate brain function, such as the paraventricular nuclei, dorsal 
motor nucleus of the vagus nerve, medulla oblongata, choroid plexus and rostral brain 
regions 136, 138.  Intracerebroventricular (ICV) administration of ET-1 or ET-3 caused an 
increase in blood pressure and a decrease in heart rate in conscious rats, effects which were 
reversed by paraventricular nuclei produced NO, suggesting that the hypertensive effect of 
centrally administered ET may involve baroreflex activity, yet direct ET-induced baroreflex 
modulation is not clearly demonstrated 139, 140.  ET-1 ICV injection was also shown to 
produce a pressor response in SHR and WKY 141.  Furthermore, ETA receptor blockade 
decreased blood pressure in SHR, but not in WKY, suggesting that endogenous ET-1 from 
the central nervous system (CNS) causes a tonic hypertensive effect through the ETA 
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receptor in SHR 141.  Earlier, Yamamoto et al. reported that ICV ET-1 injections stimulate 
vasopressin secretion leading to increased blood pressure with a reduction in renal water 
and electrolyte excretion 142 (Figure 3).  It has been also reported that ET, via both 
sympathetic nervous system and the hypothalamo-pituitary-adrenal axis, and through its 
interaction with brain natriuretic peptide (BNP) in the CNS, may regulate cardiovascular 
and hormonal functions 143. 
Studies have also demonstrated that ET peptides have the capacity to modulate the 
release of classical neurotransmitters and influence action potential generation (Figure 3), 
through the implication of the ETB receptor, which plays a role in modulation of ATP 
release, and the ETA receptor, which is implicated in catecholamine biosynthesis 144, 145.  It 
may be concluded from these investigations that ET-1, through the activation of ETB 
receptor Gi proteins, can inhibit ATP release by decreasing Ca2+ influx through L-type Ca2+ 
channels 61.  In summary, the ET system is present in sympathetic ganglia, and is involved 
in cardiac and vascular innervations, release of neurotransmitters and action potential 
generation, and as such, participates both directly and indirectly in the regulation of blood 
pressure. 
ET-1 can also affect baroreceptor activity (Figure 3), yet this mechanism is not fully 
understood 61.  In the dog, baroreceptor activity is inhibited by direct exposure to ET-1 146; 
however, perfusion of low concentrations (1 nM) of ET-1 in isolated rat carotid sinus 
increased baroreceptor activity, while perfusion with high concentration (10-100 nM) 
decreased it 147.  These results suggest that the paracrine actions of ET-1 on baroreceptors 
modulate baroreflex activity and alter blood pressure 61.  In summary, the CNS can 
synthesize and bind ET through its baroreceptors, leading to a modulation in systemic 
hemodynamics, yet the mechanisms through which these events take place are still vague. 
1.4.3.3 ET-1 in the kidney 
Early studies following the discovery of ET-1 in endothelial cells found that ET-1 
was produced in large quantities in the kidney, an organ which was identified as a major 
player in the ET system 148.  In fact, the inner medulla of the kidney was shown to contain 
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the greatest concentration of immunoreactive ET-1 in the whole body, using the pig as a 
model 148.  Later studies showed that every cell type in the kidney had the capacity to 
synthesize ET-1 and also contained ET receptors, which were predominantly abundant in 
the vasculature and the medullar regions 61, and that the kidney was up to 10-fold more 
sensitive to the vascular effects of ET-1 than other organ beds 149, 150.  As such, it is not 
unexpected that the ET system is capable of regulating kidney function and multiple renal 
functional parameters, such as total and regional blood flow, sodium (Na) and water 
excretion, drug transporters and acid/base control, cell proliferation, inflammation and 
glomerular filtration rate (GFR).  The renal ET system has also been shown to play an 
important role in regulating renal injury and disease progression in several pathological 
conditions 69 (Figure 3). 
Exogenously administered high doses of ET-1 have been shown to reduce renal 
blood flow and GFR in both animals and humans 151-154.  These effects have been linked to 
decreased Na and water excretion 155.  In studies where ET receptor agonists were 
administered prior to intravenous administration of BigET-1, ET-1 or ET-3, there was an 
increase in Na excretion 156-159, but others shown the opposite 160-162.  Concentrations of ET 
seem to dictate the type of response elicited, yet it should be noted that the control of 
urinary Na excretion by the renal ET system cannot be fully identified by experiments 
which have a generalized effect on the kidney. 
Evidence from studies using systemic administration of ET seems to be more 
concrete.  These studies have shown an increase in urinary water excretion 160-162, a 
natriuretic, diuretic and hypotensive effect of ET in the renal medulla.  Also, by using 
transgenic mice exhibiting collecting duct-specific knockout of ET-1 that were given either 
a normal or high-sodium diet, or given regular water intake, and whose blood pressure and 
metabolites were examined, Kohan et al. confirmed that ET-1 promotes sodium and water 
excretion 163, 164.  The potential mechanisms by which ET-1 may increase Na and water 
excretion are the inhibition of tubular Na+/K+-ATPase activity in the proximal tubule and 
collecting duct 165, and the effects of anti-diuretic hormone (ADH) on tubular osmotic 
permeability, leading to a decrease in water re-absorption in the collecting duct 166. 
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Similarly to other tissues, the vascular effects in the kidney are mediated by the 
activation of either ETB and/or ETA receptors.  Many investigations have shown that ET 
receptor subtype varies in the kidney in a species-specific manner, and as such, one species 
may contain more of one receptor subtype than another.  In humans, it has been suggested 
that approximately 70% of the ET receptors in the renal cortex and the medulla are of the 
ETB receptor subtype 167.  In terms of response, the natriuretic and diuretic effects of ET-1 
appear to occur via ETB receptor activation, since these effects were blocked solely by ETB 
receptor antagonism, and not by ETA receptor antagonist treatment 168.  Furthermore, ETB 
receptor knockout mice have been shown to be hypertensive, with an increased renal 
retention of sodium 169.  In summary, the majority of studies seem to conclude that an 
increase in blood volume is associated with an increase in renal ET-1 production, 
suggesting that endogenous ET-1 produced by the kidney has an overall natriuretic effect. 
1.4.3.4 ET-1 and the endocrine system 
 While certain corticosteroids, such as cortisol,  and thyroid hormones can affect 
blood pressure, it is not their primary role to do so and as such, do not interact as much with 
the ET system.  On the other hand, hormones such as aldosterone, catecholamines, 
natriuretic peptides and Ang II directly impact on blood pressure regulation and interact 
with the ET system, which has been shown to stimulate their secretion.  The adrenal gland 
is one such example.  Both human and animal adrenal glands have been shown to produce 
ET-1, with the discovery of ET-1 mRNA present in these glands 170-173.  ET-1 stimulates 
both cortical and medullo adrenal hormones, enhances the release of aldosterone from 
isolated cortical zona glomerulosa cells and stimulates adrenaline release from medullary 
chromaffin cells 174, 175.  
 ET can also stimulate production and release of atrial natriuretic peptide (ANP) by 
the myocardium 61 (Figure 3).  In rat studies, ET-3 infusion was able to cause an increase in 
plasma ANP levels 176.  ET-1 was also able to cause ANP plasma level increases, along with 
natriuresis, which was blocked by administration of an anti-ANP antibody 177.  ET-1 can 
also increase ANP peptide and mRNA production in isolated rat adult and neonatal atrial 
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myocytes 178, as well as in ventricular myocytes 179.  In fact, ET-1 is the most potent 
secretagogue known to date 180.  It can also lead to increases in brain natriuretic peptide 
(BNP) mRNA and peptide in cultured rat atrial and ventricular myocytes 152, 181.  While ET-
1 may potently increase natriuretic peptides, their biological effects are often opposite.  For 
instance, ET-induced renal vasoconstriction is prevented by ANP, while ANP-induced 
vasorelaxation is inhibited ET-1 in rat aortic SMC, through a decrease in cGMP levels 182, 
183.  In cardiac myocytes, ET-1 was able to inhibit cardiac natriuretic peptide (CNP)-
induced increases in cGMP and decreases in contractility 184.  ANP was also able to 
decrease basal, ANG II- and thrombin-induced ET-1 synthesis in human endothelial cells 
185.  In summary, while local cardiac ET-1 can generate natriuretic peptide production, ANP 
can then in turn downregulate the cardiac and vascular effects of ET-1. 
Adipose tissue is another important player in the endocrine system which may be 
affected by ET-1 actions.  ET-1 was shown to inhibit adiponectin secretion through a 
phosphatidylinositol 4, 5-bisphosphate (PIP2)/actin-dependent mechanism in basal and 
insulin-stimulated 3T3-L1 adipocytes 186.  A decrease in adiponectin expression and 
secretion by white adipose tissue has been positively correlated with a decrease in insulin 
sensitivity and observed in insulin-resistant states such as obesity, type 2 diabetes and CVD 
186 (Figure 3).  A recent study has demonstrated that stimulation of adipocytes with ET-1 
leads to an increased secretion of Interleukin-6 (IL-6), a pro-inflammatory cytokine.  
Increased levels of IL-6 are also thought to contribute to insulin-resistance and CVD 
(Figure 3).  These studies imply that increased levels of IL-6 mediate ET-1-induced insulin 
resistance 187. 
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Figure 3: Biological actions of ET-1 on various systems leading to multiple 
pathophysiological states. ET-1 plays an important role in maintaining blood pressure and 
vascular homeostasis, yet a heightened ET-1 activity can lead to increases in systemic and 
pulmonary vasoconstriction, cardiac cell hypertrophy and proliferation, water and sodium 
retention, modulations in baroreceptor activity and modulation of various hormones.  
These physiological changes are thought to contribute to the development of vascular 
pathologies, such as hypertension, atherosclerosis, restenosis, arrhythmias, congestive 
heart failure, kidney disease, glucose intolerance and diabetes.  
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1.5 Role of ET-1 in cardiovascular disease 
The significant implication of ET-1 in multiple cellular functions and in many 
physiological systems signifies that a dysregulation of the ET system should lead to the 
development of multiple cardiovascular pathophysiological states, such as hypertension, 
atherosclerosis, cardiac hypertrophy, congestive heart failure and coronary artery disease, 
as well as CVDs linked to diabetes, pulmonary hypertension, kidney failure and other 
important processes (reviewed in 61). 
1.5.1 Role of ET-1 in essential and experimental hypertension 
 Studies investigating the role of ET in essential hypertension have revealed no 
change in plasma concentrations of ET-1 in hypertensive patients as compared to plasma 
concentrations of normotensive patients 188, most probably due to the fact that ET-1 is 
generally produced and acts in an autocrine and/or paracrine fashion.  As such, plasma 
concentrations of ET-1 are not an accurate indicator of essential hypertension.  However, 
other factors, such as age, smoking and renal dysfunction, seem to lead to more significant 
increases in ET-1 levels than does essential hypertension 189.  Ethnicity also seems to play a 
significant role in the measurement of ET-1 levels in hypertensive patients, as increased 
plasma ET-1 levels were observed in hypertensive African Americans 190.  While ET-1 
levels may not be a clear indicator of hypertension, it is interesting to note that increased 
levels of preproET-1 are regularly detectable in the endothelium of small arteries of 
patients with moderate or severe hypertension 191, correlating with the enhanced role of 
hypertrophic signalling caused by increased ET-1 levels.  In VSMC, increased levels of 
ET-1 protein and mRNA have been shown to lead to the formation of larger elastic and 
muscular arteries in hypertensive patients 192.  Despite the difficulty in detecting ET-1 due 
to its low levels in plasma, increased ET-1 signaling is thought to contribute to 
hypertensive states, based on studies using ETA or ETB receptor antagonism (Figure 3).  
ETA receptor antagonism led to a greater vasodilation response in forearm vessels of 
patients with essential hypertension, as compared with normotensive subjects, in whom 
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vasodilation was also observed 193.  In contrast,   ETB antagonism induced forearm 
resistance artery vasoconstriction in normotensive subjects, yet led to vasodilation and 
increased forearm circulation of hypertensive subjects 194, 195, indicating that a 
vasoconstrictor effect of ETB receptors are found in hypertensive but not normotensive 
individuals.  An increased expression of vasoconstricting ETB receptors on VSMC of 
African Americans may explain, in part, the important role of the ET system in these 
hypertensive patients 190.  Furthermore, selective, as well as dual-acting ET receptor 
blockers can reduce systemic blood pressure, as described in an Australian study of 293 
patients with mild-to-moderate essential hypertension which were treated with Bosentan, an 
ETA/ETB receptor antagonist 196.  The reduction in blood pressure by Bosentan was similar 
to that observed in patients treated with the angiotensin converting enzyme (ACE) inhibitor 
enalapril 196.  Darusentan, a selective ETA receptor antagonist, also significantly reduced 
blood pressure in hypertensive human patients 197, without elevation of liver enzymes, a 
side-effect of Bosentan.   
While pharmacotherapy may be one means to help combat hypertension, physical 
activity and an active lifestyle have been long lauded for its beneficial effects.  In fact, 
recent data indicates that moderate aerobic exercise reduces ET-1-mediated vasoconstrictor 
tone 198 (Table 2). These reductions in the activation of the ET-1 system by aerobic exercise 
could contribute to the known beneficial effects of exercise in the treatment and/or 
prevention of hypertension and CVDs. 
The pressor actions of ET-1 are also thought to contribute to the pathogenesis of 
CVDs in animal and experimental models of hypertension 60.  Significant increases in ET-1 
plasma concentrations are observed in certain models of hypertension, such as 
deoxycorticosterone acetate (DOCA) salt-hypertensive rats, DOCA salt-treated 
spontaneously hypertensive rats (SHR), Dahl salt-sensitive rats, Ang II-induced 
hypertension, 1-kidney 1-clip Goldblatt hypertensive rats, and stroke-prone SHR (reviewed 
in 199).  All are experimental models of hypertension that exhibit an increase in systemic 
levels of ET-1.  This increase in ET-1 production and signalling has been associated with 
the remodelling and hypertrophy of the vasculature, including resistance arteries 200.  
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Pharmacological antagonism of either one or both ET receptors led to regression of growth 
and hypertrophy, as well as a decrease in blood pressure. 
Proliferation of VSMC in blood vessels of the aforementioned models of 
experimental models of hypertention, induced by ET-1, may be mediated partly by 
increased ROS production.  Several studies have reported that ET-1 activates NADPH 
oxidase in VSMC and in blood vessels, leading to an increased ROS production 201-203.  
Similar results were seen in studies using an aldosterone-induced hypertensive model, 
where systolic blood pressure, plasma ET, systemic oxidative stress, and vascular NADPH 
activity were all increased and were associated with an increase in small artery 
hypertrophic remodeling  204.   
1.5.2 Role of ET-1 in atherosclerosis and heart failure 
The main characteristics of atherosclerosis vary and include a wide range of events, 
such as endothelial cell injury, vessel inflammation, infiltration of monocytes in the vessel 
wall, release of growth factors and cytokines, lipid accumulation in foam cells and 
migration of VSMCs to the intima region of the artery (reviewed in 205) (Figure 4).  Due to 
its hypertrophic and pro-inflammatory effects, ET-1 plays a major role in the development 
of atherosclerosis, in addition to its role as a blood pressure modulator 206, through 
elevation of ET-1 protein and receptor levels in experimental models of atherosclerosis and 
in human coronary artery atherosclerotic plaques 207-209.   ECE-1 has also been shown to be 
significantly increased in apolipoprotein E-deficient (apoE) atherosclerotic mice 210, adding 
yet another arm of the ET system to the development of atherosclerosis.  ETA receptor 
antagonism was able to reduce atheroma formation in these atherosclerotic apoE mice 211.  
The same study also revealed that chronic ETA receptor blockade normalized NO-mediated 
endothelial dysfunction, an important component in the development of atherosclerosis 211.  
Furthermore, through infusion of BQ123, an ETA receptor antagonist, Bohm et al. observed 
an improvement in coronary vascular function in patients with coronary artery disease, 
suggesting that ET receptor blockade may be a possible therapeutic strategy to improve 
coronary vascular function in patients with atherosclerosis 212.   
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Ballinger et al. have also recently contributed to the notion of development of 
atherosclerosis by ET-1 through the ETA receptor in studies showing that ETA receptor 
activation by ET-1 led to an increase in the size of glycosaminoglycans (GAG) on 
chondroitin/dermatan sulfate proteoglycans synthesized by VSMC 213.  This increase in 
GAG size lead to an increase in low density lipoprotein (LDL) binding, and increased 
vessel lipid binding is a known early event in human coronary artery atherosclerosis 213. 
In addition to atherosclerosis, increased ET-1 levels have also been associated with 
animal and human heart failure 214, 215 (Figure 3), and studies have established a positive 
correlation between ET-1 plasma levels and cardiac hemodynamics and function in patients 
with congestive heart failure 216.  Low cardiac output, a common symptom of heart failure, 
leads to an increase in ET-1 production.  This phenomenon has been demonstrated in 
models of low cardiac output and in models of low ventricular filling pressures, produced 
by constriction of the thoracic inferior vena cava 217.  The increased production of ET-1 can 
in turn stimulate the secretion of multiple neurohormones, which can cause long-term 
effects on the heart, and contribute to the development and progression of heart failure 218.  
A possible treatment option may be the blockade of ETA and/or ETB receptors (reviewed in 
219).  Initial studies in patients with symptomatic heart failure, such as the REACH study 
(Research on Endothelin Antagonism in Chronic Heart Failure) and the ENABLE 
(Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) trial 
showed no improvements in clinical status of patients upon treatment with ET antagonists, 
and were prematurely stopped due to unexpected increases of adverse events, such as 
hypotension and abnormal liver function 220, 221.  However, others have demonstrated the 
beneficial effects of ETA and/or ETB receptor blockade in limiting the complications of 
heart failure 222, 223.  Amongst several pharmacological compounds, Bosentan was able to 
improve and pulmonary hemodynamics in heart failure patients 222.  Similar results were 
observed in a 3-year clinical study of end-stage heart failure patients with pulmonary 
hypertension, on a waiting list for cardiac transplantation 223.  Bosentan was able to 
significantly improve hemodynamic parameters in these patients, and increased their one-
year survival rates on the cardiac transplantation waiting list by 20% 223.  Despite these and 
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other positive results, more research is needed in this area to adjust treatment dosages with 
the goal of reducing negative side effects or to develop more potent, less toxic molecules to 
help improve the quality of life of heart failure patients through ET-1 cascade interactions. 
1.6 Angiotensin II and the Renin-Angiotensin-system (RAS) 
 The RAS is one of the principal hormonal systems regulating blood pressure, blood 
flow, fluid volume and electrolyte balance in the body 224.  As well as being part of the 
endocrine system, it also acts in both a paracrine and autocrine fashion on local tissues and 
organs.  Angiotensin II (Ang II) is the primary effector of this system and has been found to 
play a role in most, if not all, organs, including the heart and vasculature, brain and 
kidneys, having both necessary beneficial functions and pathological effects (reviewed in 
53).  Short term stimulation leads to vasoconstriction and salt/water homeostasis, which 
leads to the regulation of blood pressure.  Long term exposure, or chronic stimulation, has 
been shown to stimulate hypertrophic effects in VSMCs, as well as being involved in 
cardiac hypertrophy and remodeling, in-stent restenosis, renal fibrosis and a host of other 
mechanisms leading to other cardiopathophysiological states 53. 
1.6.1 Structure, Regulation and Biosynthesis of Angiotensin II through 
the RAS 
 To understand the full extent of its structure and regulation, the biosynthesis of Ang 
II by the RAS must first be described in detail.   
 Classically, the substrate of the RAS system is angiotensinogen (AGT), a plasma α-
glycoprotein, part of the serpin serine-protease inhibitor family, synthesized by the liver 
and always present in the plasma in high concentration.  AGT mRNA has also been 
recently discovered in brain, male and female reproductive systems, heart, vasculature and 
skin (reviewed in 225).  AGT is cleaved in the circulation by the aspartyl protease renin, an 
enzyme secreted from the granular cells of the juxtaglomerular apparatus of the kidney, 
usually in response to a decreased NaCl sensing by the macula densa of the distal tubules in 
the kidney, extracellular fluid volume or blood pressure (Figure 5). 
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Figure 5: Synthesis of Angiotensin II (Ang II) by the renin-angiotensin system (RAS).  
Angiotensinogen, a plasma α-glycoprotein, synthesized by the liver and always present in the 
plasma in high concentration, is cleaved in the circulation by the aspartyl protease renin, an 
enzyme secreted from the granular cells of the juxtaglomerular apparatus of the kidney, 
usually in response to a decreased NaCl, extracellular fluid or blood pressure, to form the 
decapeptide angiotensin I.  During passage through the lungs via pulmonary circulation, Ang I 
is again cleaved to form the octapeptide angiotensin II (Ang II) by the dipeptidyl 
carboxypeptidase angiotensin I converting enzyme (ACE), a membrane-bound 
metalloproteinase predominantly expressed in high concentrations on endothelial cell surface 
in the pulmonary circulation. Ang II can then lead to multiple physiological effects through 
activation of its two main membrane bound receptors, Ang II type 1 receptor (AT1R) and Ang 
II type 2 receptor (AT2R). (Adapted from Angus PW et al., J Gastroenterol Hepatol 2008, 
23(9):1327-38)  
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  Once secreted into the blood, renin will cleave a leucine-valine bond (in humans, or a 
leucine-leucine bond in other species) of AGT to form the decapeptide angiotensin I (Ang 
I).  During passage through the lungs via pulmonary circulation, Ang I is again cleaved to 
form the octapeptide angiotensin II (Ang II) (Figure 5).  The dipeptidyl carboxypeptidase 
angiotensin I converting enzyme (ACE), a membrane-bound metalloproteinase 
predominantly expressed in high concentrations on endothelial cell surface in the 
pulmonary circulation, is responsible for the cleavage of Ang I to form Ang II, by cleavage 
of the C-terminal histidine and leucine amino acids of Ang I 226. 
 Ang II, also known as Ang (1-8) (Figure 6), is an 8 amino acid peptide (free amino 
group-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-free carboxyl group) 227.  Free N-terminal and C-
terminal groups allow for further cleavage of Ang II to generate smaller peptides, such as 
the formation of Ang (2-8) (Figure 6), also known as Ang III, formed by the removal of the 
N-terminus amino acid aspartic acid (Asp) by Aminopeptidase A (APA).  The Ang III 
peptide consists of seven amino acids starting from the second amino acid of Ang II 228.  
Ang III is biologically active, with approximately 40% of the vasocontricting properties 
and 100% of the aldosterone stimulating properties of Ang II.  Ang III can be further 
cleaved at its Arg-Val N-terminal bond by aminopeptidase N or B to form Ang IV (known 
as Ang (3-8)) 229 (Figure 6).  Ang IV has been shown to affect the central nervous system, 
and has been shown to signal through its own distinct receptor (AT4R), with some of its 
actions opposing those of Ang II 229.  Another angiotensin peptide, Ang (1-7), is formed 
from the cleavage of either Ang I by APA, ACE, neutral endopeptidase (NEP) and 
prolylendopeptidase (PEP) on both N- and C-terminal amino acid bonds, or by cleavage of 
Ang II by APA and ACE2, an ACE homologue that acts as a carboxypeptidase by 
selectively removing the C-terminal Phe amino acid from Ang II 230.  Both Ang (1-7) and 
ACE2 have recently been demonstrated to have biological activity leading to vasodilation 
and many other actions, opposing the vasoconstrictor actions of Ang II 230. 
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Figure 6: Structure of Angiotensins.  Angiotensin I (Ang I) is a decapeptide (Ang-(1-10)) formed by 
the cleavage of angiotensinogen by the aspartyl protease renin.  This peptide can be fragmented by 
several different enzymes, such as Angiotensin I converting enzyme 1 or 2 (ACE1 or ACE2) to form 
other biologically active angiotensin peptides, such as Angiotensin II (Ang II). Ang II, also known as 
Ang (1-8), is an 8 amino acid peptide.  Free N-terminal and C-terminal groups allow for further 
cleavage of Ang II to generate smaller peptides, such as the formation of Ang III (2-8) formed by the 
removal of the N-terminus amino acid aspartic acid (Asp) by Aminopeptidase A (APA). Ang III is also 
biologically active, with approximately 40% of the vasocontricting properties and 100% of the 
aldosterone stimulating properties of Ang II.  Ang III can be further cleaved at its Arg-Val N-terminal 
bond by aminopeptidase N (APN) to form Ang IV (known as Ang (3-8)).  Another angiotensin peptide, 
Ang (1-7), is formed from the cleavage of either Ang I by APA, ACE, neutral endopeptidase (NEP) 
and prolylendopeptidase (PEP) on both N- and C-terminal amino acid bonds, or by cleavage of Ang II 
by APA and ACE2, an ACE homologue that acts as a carboxypeptidase by selectively removing the C-
terminal Phe amino acid from Ang II.  Amino acids are given numerical values, where 1, aspartic acid; 
2, arginine; 3, valine; 4, tyrosine; 5, isoleucine; 6, histidine; 7, proline; 8, phenylalanine; 9, histidine; 
10, leucine. (Angus PW et al., J Gastroenterol Hepatol 2008, 23(9):1327-38).  
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1.6.2 Ang II Receptors 
 The effects of Ang II are mediated by two main membrane bound receptors, Ang II 
type 1 receptor (AT1R) and Ang II type 2 receptor (AT2R), both of which have been cloned 
and characterized 231, 232.  AT3R and AT4R subtypes have also been described 233, 234, yet 
these subtypes have not been fully characterized and do not account for the main vasoactive 
effects of Ang II 235. 
 The AT1R is a seven transmembrane-domain G protein-coupled receptor, activating 
PLC through the heterotrimeric Gq protein, although it may also signal through Gi, G11/13, 
and Gs 236.  The AT1R has an approximate molecular weight of 50 kDa and is composed of 
359 amino acids.  It has four extracellular (including the N-terminus), four intracellular 
(including the C-terminus) and seven α-helical transmembrane domains.  The N-terminus, 
first and third extracellular loops contain the epitopes for peptide binding 53.  AGTR1, the 
gene which codes for AT1R, is located on chromosome 3q21-25, spanning approximately 
60kb and includes five exons and four introns 237.  Multiple factors have been shown to 
regulate AGTR1 expression, such as LDL, insulin, IGF-1, hyperglycemia, hypoxia and 
sodium chloride, only to name a few 53.  
 The AT1R is widely distributed throughout the cardiovascular systems and is also 
abundantly found in the renal, endocrine and nervous systems in humans 237.  In the 
vasculature, VSMC present high levels of AT1R, while low levels of AT1R are detected in 
the adventitia 237.  Through myocardial biopsies, high levels of AT1R were also discovered 
in atrial and ventricular myocytes, as well as fibroblasts, of the human heart 238.  As 
compared to humans, rodents have two functionally distinct subtypes of the AT1R, the 
AT1AR and the AT1BR.  Both have more than 95% amino acid sequence homology between 
themselves 239.  While angiotensin receptors do not have an intrinsic kinase activity, they 
are phosphorylated on serine, threonine and tyrosine residues, which are important for 
receptor activation, regulation and desensitization responses 240. 
  
 
41
 Like the AT1R, the AT2R is also a GPCR consisting of 363 amino acide, with an 
approximate molecular weight of 44 kDa.  The AT2R only has a 30% homology with the 
AT1R and the AGTR2 gene coding the AT2R is located on chromosome X 241.  AT2R is 
mainly expressed in fetal mesenchyme, uterine smooth muscle, brain, ovary, adrenal 
medulla and heart, and plays an important modulatory role during embryonic development 
241.  AT2R expression decreases rapidly, however, after birth.  In adults, this receptor is 
expressed mainly in pancreas, heart, kidney, adrenal brain and vascular tissues (reviewed in 
235).  Furthermore, unlike the AT1R, the AT2R does not undergo receptor internalization, 
and has been shown to counteract several of the vasoconstrictor effects of the AT1R 242. 
Most of the vascular effects of Ang II are mediated by the AT1R 53.  This receptor is 
responsible for the vasoconstrictor effects of Ang II, as well as vascular cell hypertrophy 
and retention of sodium.  AT1R activation has also been shown to increase ROS 
production, as well as taking part in the induction of inflammatory and fibrotic processes in 
the vasculature, such as superoxide production, endothelin secretion, lipid peroxidation and 
adhesion molecule expression (reviewed in 243).  Ang II can mediate these effects either by 
direct AT1R activation, or by indirectly causing the secretion of other growth factors, 
vasoactive peptides or inflammatory cytokines, through a cross talk with other intracellular 
signaling cascades.  In general, the hypertrophic effects of Ang II are mediated by the 
activation of pathways that involving the phosphorylation of tyrosine residues of certain 
proteins, generally leading to enhanced gene expression (reviewed in 235). 
The exact physiological roles of the AT2R have yet to be elucidated, yet it seems 
that as a general rule, the AT2R antagonizes several of the Ang II-induced AT1R activated 
events, inducing vasodilation, apoptosis and inhibiting cell growth and hypertrophy 244.  
The physiological relevance of AT2R blood pressure regulation was initially demonstrated 
with the overexpression of this receptor in VSMC of transgenic mice, in which Ang II 
infusion did not lead to an increase in blood pressure, but did so in wild type mice 245.  
Aortic explants from the AT2R overexpressing transgenic mice had an increased cGMP 
production, as well as a decreased Ang II-induced vascular constriction.  The results of this 
study also showed that the AT2R in VSMC is responsible for an increased production of 
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bradykinin, leading to a stimulation of the NO/cGMP cascade, which in turn promotes 
vasodilation 245.  Despite these results, the AT2R has also been shown to be implicated in 
certain pathophysiological conditions.  For example, the ratio of AT2R to AT1R increases 
dramatically in the heart of heart failure patients 246.  It has also been reported that the level 
of AT2R increased in vascular inflammation and injury 247.  AT2R activation has also been 
shown to have pro-inflammatory and hypertrophic effects, such as NF-κβ activation, 
leading to vascular and cardiac hypertrophy 248-250.  These contradictory results concerning 
the AT2R emphasize our limited understanding of the signaling and physiological role of 
the AT2R. 
1.6.3 Biological actions of Ang II 
1.6.3.1 Ang II and the RAS in the vasculature and heart 
 While renin in the vascular wall is quite difficult to detect due to very low 
concentrations, renin mRNA been detected in both human and rat vessels 225, 251.  ACE is 
abundant in both the vasculature and heart, and is localized predominantly on endothelial 
cell surface, with smaller quantities present in the adventitia and minute levels found in 
VSMC, yet ACE levels in VSMC have been shown to increase in certain 
pathophysiological states, such as neointimal formation 252, 253 (Figure 7).  Both AT1R and 
AT2R are present in the vasculature, albeit in different cell types.  Cultured VSMC were 
shown to express only the AT1R, while cultured endothelial cells were shown to express 
both AT1R and AT2R 231, 254.  Nonetheless, AT2R distribution in vascular cell types is still a 
matter of debate, as recent studies have suggested AT2R expression in VSMC as well 255. 
 RAS in the vasculature contributes to the regulation of cardiovascular homeostasis, 
through the opposing effects of the two Ang II receptor subtypes and their impact on 
vascular function.  While it is difficult to distinguish the effects of vessel wall generated 
Ang II to those of plasma generated Ang II in in vivo studies, several studies have been 
successful in demonstrating the conversion of Ang I to Ang II in isolated perfused rat 
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hindquarters, which was inhibited by ACE inhibition, demonstrating the presence of a 
functional RAS system in the vasculature contributing to the formation of local Ang II 256.   
 Similarly to the vasculature, difficulties in distinguishing between plasma-born and 
intra-cardiac produced Ang II in the heart have been encountered.  Even so, the actions of 
RAS inhibitors, such as ACE inhibitors and Ang II receptor blockers, on the heart can be 
explained by modulation at the local cellular level.  Such is the case of cardiac remodeling 
225. 
 Several studies have demonstrated the presence, albeit low, of renin mRNA in 
cardiac tissue 251, 257, 258.  Transgenic rats carrying a genomic construct of the mouse Ren-2 
gene under control of its own promoter expressed high levels of renin mRNA in the heart 
259, providing further proof that at least in certain species, the heart is source of extrarenal 
renin production.  Cardiac ACE production is also quite evident and can easily be measured 
in both rat and human heart tissue 251, 260.  As for cardiac Ang I and Ang II, studies using 
radiolabeled peptides have demonstrated that more than 90% of Ang I and more than 75% 
of Ang II are synthesized locally in the heart 261. 
1.6.3.2 Ang II in the nervous system 
 The existence of the RAS system in the nervous system and the brain has been 
known since the early 1960’s, through cross-circulation studies in dogs demonstrating 
interactions between Ang II and the central nervous system leading to an increase in blood 
pressure 262.  Shortly thereafter, renin activity was reported in the human brain, and renin 
mRNA was confirmed in synaptosomes, as well as in the rat and mouse brain 263, 264.  The 
hypothalamus, pituitary and pineal glands seem to be the regions of the brain exhibiting 
high renin-like activity 265, 266.  Renin protein and mRNA is also measurable in astrocytes, 
neurons and glia cells in human, rat and mouse samples 263, 266, 267.  More recently, renin 
promoter activity was detected in mouse astrocytes and neurons 268, leaving little room for 
doubt that brain renin truly exists. 
 ACE is also clearly expressed throughout multiple regions of the brain, including 
the choroid plexus, caudate putamen, cerebellum, brain stem and the hippocampus 269, and 
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seems to colocalize with renin in synaptosomal fractions of several brain regions, including 
the thalamus, hypothalamus and posterior pituitary gland 264.  The detection of Ang II in the 
brain is also quite clear and distinguishable, since the blood-brain barrier was shown to be 
impenetrable to Ang II 270.  The highest levels of brain Ang II are detected in the 
hypothalamus, pituitary gland and cerebral cortex, yet is also present in the cerebellum, 
hippocampus, olfactory bulb and brain stem 271. 
 Angiotensin receptors have easily been detected in brain tissue 272.  While both 
AT1AR and AT1BR mRNA have been detected in the hippocampus, cingulated cortex and 
choroid plexus of the rat brain, much higher levels of AT1BR than AT1AR were detected in 
the anterior pituitary gland 273.  It is widely accepted that the AT1AR seems to be involved 
in the control of central blood pressure, while the AT1BR controls drinking responses in 
rodents such as mice 274.  AT2R was also detected in several brain regions, including nuclei 
of the thalamic, medial geniculate and optic tract regions 275.  Distribution of AT1R and 
AT2R in the mouse brain closely resembles that of the rat, yet in human brain tissue, only 
the AT1R was detected in the forebrain, midbrain, pontine, medullary spinal cord and 
choroid plexus, while both AT1R and AT2R were detected in the molecular layer of the 
cerebellum, in contrast to results obtained from rat cerebellum 276.  Unlike other tissues, 
however, the brain and nervous system are also rich in AT4R, which binds Ang IV, which 
seems to be implicated in stress, spatial learning and memory acquisition 277.  These Ang 
IV binding sites seem to be abundant in cortex, hippocampus, amygdale and thalamus of 
mice, while rat AT4R were also present in the piriform cortex, habenulae, colliculi and the 
arcuate nucleus of the hypothalamus 278, 279.  Despite this plethora of knowledge, it still 
seems that brain Ang II receptors remain to be characterized.  A study demonstrated that 
the majority of Ang II receptors in the gerbil brain differed from the AT1R, AT2R and the 
AT4R 280.  As such, extensive research remains to be accomplished to fully characterize the 
RAS system in the brain and nervous system.  The RAS functional impact on blood 
pressure regulation, drinking and food intake, effect on the blood-brain barrier, central 
actions on the reproductive system, as well as its actions on motor control, behavior and 
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emotions and the visual system are quite evident and well documented (reviewed in 225) 
(Figure 7). 
1.6.3.3 Ang II in the kidney 
The intrarenal RAS system has been studied to an extensive length, yet difficulties 
in determining the contributions of plasma Ang delivered to regions of the kidney from 
locally produced renal Angiotensin still exist, as the RAS is known to act in an endocrine, 
paracrine, autocrine and intracrine fashion 281.  Nonetheless, the kidney is unique, as every 
component of the RAS has been detected and compartmentalized in the tubular and 
interstitial networks 282, with renal Ang II found in levels much greater than can be 
explained by delivery from arterial blood flow.  These results substantiate the notion that 
the majority of the Ang II concentrations found in renal tissues are generated locally from 
angiontensinogen (either delivered to the kidney or locally produced in proximal tubular 
cells) 283, 284. 
Renin is present in the kidney, secreted by cells in the juxtaglomerular apparatus, 
which is then channeled to the renal interstitium, leading to production of renal Ang I 285.  
ACE is present in the kidney, and found in abundance in the proximal and distal tubules, as 
well as in the collecting ducts and in renal endothelial cells 286.  As such, all components 
required to produce Ang II are present in the nephron. 
The activation of AT1R and AT2R, which are distributed in various regions of the 
kidney, are responsible for most of the actions of Ang II on renal function.  The AT1R is 
abundantly present in the proximal tubule, the ascending limb of the loop of Henle, the vasa 
recta, arcuate arteries, and juxtaglomerular cells 287.  In rodents, the AT1AR seems to be 
expressed on the renal microvasculature in both the cortex and medulla, afferent and 
efferent arterioles VSMC, epithelial cells of the thick ascending limb of Henle, the 
proximal tubular apical and basolateral membranes, as well as mesangial cells, distal 
tubules, collecting ducts, and cells of the macula densa (reviewed in 282).  It should be 
noted, however, that afferent arterioles express both the AT1AR and AT1BR, while efferent 
arterioles express only the AT1AR 288.  Multiple studies have suggested the importance of 
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the intrarenal RAS sytem and the angiotensin receptors in the regulation of blood pressure.  
Amongst them, Coffman et al. clearly reported a 20mmHg decrease in blood pressure in a 
kidney specific AT1AR knock-out mouse displaying normal AT1AR expression in all other 
tissues 289.  Further evidence from both clinical and experimental kidney transplant studies 
have shown that kidney recipients had higher blood pressure post-transplantation if the 
kidney came from a hypertensive or high blood pressure prone donor 290, strengthening the 
role of the intrarenal RAS system in the pathobiology of hypertension (Figure 7).  The 
endocrine role of the RAS system and Ang II was described earlier in the introduction of 
the RAS, and as such, will not be repeated here. 
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Figure 7: Biological actions of Ang II on various systems leading to multiple 
pathophysiological states. Ang II plays an important role in maintaining blood pressure 
and vascular homeostasis, yet a modulation in Ang II production and signaling events can 
lead to increases in systemic and pulmonary vasoconstriction, cell hypertrophy and 
proliferation, water and sodium retention, changes in neurotransmitter secretion and SNS 
activity, and modulation of various hormones.  These physiological changes are thought to 
contribute to the development of vascular pathologies, such as hypertension, 
atherosclerosis, restenosis, arrhythmias, congestive heart failure, kidney disease, glucose 
intolerance and diabetes.  
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1.7 Role of Ang II in Cardiovascular Disease 
1.7.1 Role of Ang II in hypertension 
While the abnormalities leading to the development of essential hypertension 
remain obscure, recent studies have suggested that Ang II and the RAS play a critical role 
in the development of renal dysfunction and essential hypertension 291 (Figure 7).  This 
notion stems from the effectiveness of ACE inhibitors and Ang II receptor blockers in the 
treatment of essential hypertension, even in subjects with relatively normal Ang II plasma 
levels 292.  Other studies have shown that transplantation of a kidney from a hypertensive 
subject to a normotensive recipient causes hypertension in the latter and transplantation of a 
kidney from a normotensive subject to a hypertensive patient cures the latter’s 
hypertension, in both human and animal experiments (reviewed in 291), further supporting 
the involvement of Ang II and the RAS system in the development of essential 
hypertension.  Other studies have also added a more novel mechanism, oxidative stress, 
which can be activated by both ET-1 and Ang II, and leads to multiple pressor effects 
potentiating Ang II’s vasocontricting effects, in the development of essential hypertension 
293 (Figure 7). 
Several experimental models of hypertension involving modulation of the RAS 
system also exist and have been and continue to be useful in elucidating the role of Ang II 
in the development of hypertension.  One such model is the Goldblatt two kidney one clip 
model, where one renal artery is constricted and the other untouched, resulting in a 
sustained increase in blood pressure due to increased plasma renin and subsequent increase 
in Ang II production, as salt and water retention remain normal due to one intact kidney 294.  
Approximately six weeks into the kidney constriction, the increase in Ang II levels will 
lead to excessive aldosterone release from the adrenal cortex, causing salt and water 
retention, at which point the hypertension of this model will become volume dependent 294 
(Figure 7).  Subcutaneous infusion of low doses of Ang II for a prolonged period of time 
(usually four to eight weeks) is also effective in causing hypertension in animal models 295.  
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Recent studies have also placed the importance of Ang II and the RAS in genetic models of 
hypertension, such as the SHR, where chronic RAS inhibition improved medularry blood 
flow, increased renal perfusion and response to Ang II, as well as blocking the development 
of hypertension in SHR 296 
1.7.2 Role of Ang II in atherosclerosis and heart failure 
Atherosclerosis is a pathology affecting whole arteries and can lead to damage to 
multiple organs, as well as myocardial and cerebral infarction and peripheral artery disease.  
The development of atherosclerotic plaque involves the migration and proliferation of 
VSMC whose phenotype changes as the disease progresses 53.  Atherosclerosis is caused by 
an accumulation of focal or diffuse lipid-packed and fibro-proliferative plaque in the vessel 
intima, leading to narrowing of the vessel lumen, which is different from the concentric 
medial thickening observed in hypertension.  Many researchers regard atherosclerosis as 
being an inflammatory disease, with Ang II leading to the progression and destabilization 
of atherosclerotic plaque through its pro-inflammatory actions 297 (Figure 7).   
Both systemic and local RAS and Ang II-AT1R signaling contribute to the 
development of atherosclerosis, through the ability of Ang II to increase expression of 
certain adhesion molecules (which promote monocyte invasion into the vasculature), 
chemokines and cytokines.  These molecules cause endothelial cell dysfunction, 
proliferation of VSMC and oxidation and uptake of LDL, through the Ang II-induced ROS 
generation by VSMCs 298.  In more advanced stages of atherosclerosis, MMP and PAI-1 
expression are stimulated by Ang II, which causes a destabilization of atherosclerotic 
plaque 299, 300.  Experimentally, ACE inhibitors have been used to strengthen the link 
between Ang II and atherosclerosis in a large number of animal studies.  The 
atherosclerosis-prone apoE-deficient (apoE-/-) mouse is one of the more frequently used 
atherosclerosis animal models.  In a recent study, treatment with fosinopril, an ACE 
inhibitor, of the apoE-/- mouse for a period of 12 weeks reduced atherosclerotic lesions by 
up to 70% 301.  Other studies using olmesartan, an AT1R blocker, have observed a potent 
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suppression in atherosclerotic lesion formation in apoE-/- mice 302.  These studies 
strengthened the notion that Ang II-AT1R signaling inhibition reduces the size of 
atherosclerotic lesions, but also stabilizes atherosclerotic plaque 302.  In contrast, several 
studies have shown that stimulation of AT2R leads to an inhibition of atherosclerosis 
through inhibition of oxidative stress.  These studies also indicated that AT1R blockers 
have the capacity to stimulate AT2R, as shown in a study using valsartan, whose anti-
atherosclerotic effects were attenuated in AT2R-deficient mice 303. 
In regards to heart failure, local Ang II concentrations have been found to be 
dramatically increased in the failing heart, with cardiac Ang II production increasing as 
heart failure progresses 304 (Figure 7).  However, the full role of Ang II and the RAS in 
heart failure are not completely understood, as studies have shown contradictory results.  
For example, several transgenic mouse models overexpressing one or several components 
of the cardiac RAS have been used in experimentation, with some showing increases in 
ventricular hypertrophy and fibrosis and others maintaining normal cardiac size and 
function (reviewed in 305).  Others have further demonstrated that hemodynamic changes 
play a greater role in ventricular hypertrophy than do local Ang II levels 306.  More recent 
studies using transgenic mice expressing cardiac myocyte specific Ang II-producing fusion 
protein have shown that Ang II does not alter ventricular size or cardiac function if 
hemodynamic loading remains intact, yet in hypertensive animals, cardiac Ang II potently 
enhanced inflammatory responses and oxidative stress, which lead to an increase in cardiac 
cell death 306, 307.  These results clearly indicate that Ang II plays a role in heart failure, yet 
the precise mechanisms by which it does so remain obscure.  What seems to be a general 
consensus in many studies, however, is the role of oxidative stress generated by both ET-1 
and Ang II on the vasculature and the heart, in addition to their hypertrophic and 
proliferative effects on those systems, leading to varied cardiovascular pathologies.  To 
fully understand these effects, we must identify the signaling cascades activated by ET-1 
and Ang II, which can lead to both physiological and pathophysiological events. 
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1.8 ET-1 and Ang II-induced signalling events in VSMC 
As mentioned earlier, ET-1 and Ang II signal through ETA/ETB receptors and 
AT1R/ AT2R, respectively.  Both of these receptors belong to the GPCR family of seven 
transmembrane-domain G-protein bound receptors.  G proteins of the GPCRs are 
heterotrimetric proteins composed of three distinct subunits; α, β and γ subunits 308 (Figure 
8). The GDP bound form of α binds tightly to βγ and is inactive, whereas the GTP bound 
form of α dissociates from βγ and serves as a regulator of effector proteins. Both α-GTP 
and βγ subunits can interact with effectors. This activation cycle is terminated by intrinsic 
GTPase activity of α-subunit. The GDP-bound form of the α-subunit has a high affinity for 
βγ subunit, with which it re-associates to form the heterotrimer in the basal resting state 308.  
Gαq is associated to the activation of phospholipase C (PLC), leading to the formation of 
inositol 1,4,5-trisphosphate (IP3) and diacyglycerol (DAG), modulating downstream 
calcium signaling to activate calcium/calmodulin and protein kinase C (PKC), leading to 
the activation of the PI3-K/PKB and MAPK pathways 309, 310 (Figure 8). 
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Figure 8: Vasoactive peptide-induced activation of the phosphoinositide cascade through 
GPCR activation in VSMC. ET-1 and Ang II signal through ETA/ETB receptors and AT1R/ 
AT2R, respectively.  Both of these receptors belong to the GPCR family of seven transmembrane-
domain G-protein bound receptors. The GDP bound form of Gα binds tightly to Gβγ and is 
inactive, whereas the GTP bound form of Gα dissociates from Gβγ and serves as a regulator of 
effector proteins. Both Gα-GTP and Gβγ subunits can interact with effectors. This activation cycle 
is terminated by intrinsic GTPase activity of α-subunit. The GDP-bound form of the α-subunit has 
a high affinity for βγ subunit, with which it re-associates to form the heterotrimer in the basal 
resting state.  Gαq is associated to the activation of phospholipase C (PLC), leading to the 
formation of inositol 1,4,5-trisphosphate (IP3) and diacyglycerol (DAG), modulating downstream 
calcium signaling to activate calcium/calmodulin and protein kinase C (PKC), leading to the 
activation of the PI3-K/PKB and MAPK pathways.  
  
 
53
1.8.1 ET-1 and Ang II-induced activation of the phosphatidylinositol 3-
kinase (PI3-K)/protein kinase B (PKB) pathway 
PI3-Ks are a family of lipid kinases that phosphorylate the D3 hydroxyl group (3’-
OH) of the inositol ring in phosphatidyl inositol (PI) 311.  Products of the PI3-K reaction 
include phosphatidylinositol-3-monophosphate (PIP), phosphatidylinositol-3,4-
bisphosphate (PIP2) and phosphatidylinositol-3, 4, 5-trisphosphate (PIP3) 312.  This lipid 
kinase has been divided into classes I, II and III.  Class I PI3-Ks are heterodimeric proteins, 
each of which consists of a 110 kDa catalytic subunit and an associated regulatory subunit.  
This class is further divided into classes IA and IB, of which class IA has three isoforms (α, 
β and δ) of the catalytic p110 subunit and several forms of regulatory subunits (p85α, 
p55α, p50α, p85β  and p55γ).  Class IB, on the other hand, has only one member of the 
catalytic subunit called p110γ and one form of the regulatory subunit p101.  Class IA is 
activated by receptor PTK (RPTK), while class IB is activated by GPCR 313.  In vitro, PI, 
PIP, and PIP2 are phosphorylated by class I PI3-K enzymes to form PIP, PIP2 and PIP3.  In 
vivo, phosphorylation of PIP2 is favored, which is responsible for the formation of PIP3 313, 
314. 
Class II PI3-Ks, consisting of two major mammalian subclasses, α and β, contain a 
carboxy-terminal C2 domain, a protein module originally observed in PKC molecules, with 
phospholipid binding sites.  There are no known regulatory subunits in this class, which 
may not even be necessary.  
Class III PI3-Ks are thought to represent the primordial PI3-K that gave existence to 
the other classes, due to the fact that it is the only class of PI3-K enzymes present in yeast.  
PI is the only substrate recognized by this class and is phosphorylated to generate PI3P 315, 
316.  Class III PI3-Ks induce local increases in PIP3, which are thought to be required for 
agonist-independent membrane trafficking processes 316. 
Generally, the p85 subunit of PI3-K binds to and is activated by IRS-1, in turn 
activating the p110 catalytic subunit of PI3-K, which catalyses the phosphorylation PI 
lipids, forming PIP3 and PIP2 317 (Figure 9).  It is important to note that PI3-K activation in 
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response to other growth factors, e.g. EGF, PDFG, etc, has been shown to signal through an 
IRS-independent pathway, leading to PKB activation 318, 319.  Following PI3-K activation, 
formation of PIP3 and PIP2 generates recognition sites for Pleckstrin Homology (PH) 
domain containing proteins, principally 3’-phosphoinositide-dependent kinase 1 (PDK1), 
which is translocated to the plasma membrane along with PKB 317, 320, and other related 
serine/threonine protein kinases, which are responsible for phosphorylating and activating 
several downstream signaling protein kinases, such as PKB, protein kinase C-zeta (PKC-ζ), 
and p70 ribosomal S6 kinase (p70s6k) 321, 322 (Figure 9).  PKB is a 57 kDa protein, given its 
name due to its high homology with protein kinase A (PKA) and PKC.  PKB, also known as 
Akt, exists as three isoforms, PKBα/Akt1, PKBβ/Akt2 and PKBγ/Akt3 323.  All PKB 
isoforms have an amino-terminal PH domain, a central catalytic Ser/Thr kinase domain and 
a carboxy-terminal regulatory domain that contains the hydrophobic motif (HM) 324, 325.  
PDK1, which is thought to be constitutively active, phosphorylates Thr 308 in PKB 326, 
stabilizing the activation loop in an active form.  This phosphorylation is a prerequisite for 
kinase activation, but phosphorylation of Ser 473 is necessary for full PKB activation.  The 
nature of putative Ser 473-PKB kinase called PDK2 is still controversial 327, although 
several candidates have been suggested 328.  Aside from its well characterized role as 
regulator of glucose transport, glycogen synthesis, gluconeogenesis and lipogenesis, PKB 
also plays an important role in protein synthesis, cell growth and cell survival 329-333 (Figure 
9). 
Several studies have demonstrated a role of the PI3-K/PKB pathway in vasoactive 
peptide-induced signaling events in multiple cell types, including VSMC, cardiomyocytes 
and human umbilical vein endothelial cells, leading to increased cell survival, hypertrophy 
and proliferation.  These physiological responses contribute to the development of 
cardiovascular diseases, such as atherosclerosis and stenosis after angioplasty 64, 203, 334, 335. 
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Figure 9: Vasoactive peptide-induced activation of the PI3-K/PKB cascade in VSMC.  ET-1 and Ang 
II bind to their respective GPCRs, causing enhanced activity of PLCβ through Gαq/11 activation, leading to 
the conversion of phosphatidylinositol 4, 5 biphosphate (PIP2) to inositol 1, 4, 5 trisphosphate (IP3) and 
diacylglycerol (DAG).  This increase in IP3 causes an elevation of intracellular calcium (Ca2+) and DAG-
dependent PKC activation.  PKC/ Ca2+ or other signaling intermediates activate R- and/or NR-PTKs, like 
EGFR, IGF-1R, PYK2 and c-Src, by inducing their phosphorylation on target tyrosine residues.  Activation 
of these PTKs leads to the phosphorylation of docking proteins, such as IRS-1. Phosphorylated  IRS-1  
and/or  R-PTK bind to the p85 subunit of PI3-K and lead to its activation.  Activated PI3-K catalyzes the 
phosphorylation of PIP2 to phosphatidylinositol 3, 4, 5 triphosphate (PIP3).  PIP3 recruits PKB and PDK-
1/2, Pleckstrin homology (PH) domain-containing proteins, to the plasma membrane, where PDK-1 and -2 
phosphorylate PKB on threonine and serine residues, which in turn phosphorylates several downstream 
effectors, which contribute to protein synthesis, cell growth, survival, and gene transcription.  
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1.8.2 ET-1 and Ang II-induced activation of the Mitogen-Activated 
Protein Kinase (MAPK) pathway 
MAPKs constitute a family of serine/threonine protein kinases which are widely 
conserved among eukaryotes, and are involved in many cellular responses, such as cell 
proliferation, cell differentiation, cell movement and cell death 336, 337.  In mammalian cells, 
5 MAPK families have been identified, including ERK1/2, c-Jun N-terminal kinase 1, 2 
and 3 (JNK1/2/3), also called stress-activated protein kinase (SAPK), p38α/β/γ/δ MAPK, 
ERK5 and ERK7 336, 337. 
 The groups of vertebrate MAPK studied most extensively to date are ERK1/2, 
JNKs, and p38 kinases 336, 337.  ERK1/2 are stimulated by mitogens, such as polypeptide 
growth factors (IGF-1, platelet-derived growth factor (PDGF), colony stimulating factor-1 
(CSF-1), etc.) as well as insulin and phorbol 12-myristate 13-acetate (PMA).  In contrast, 
SAPKs and p38 MAPK are potently induced by a wide variety of stressors, including 
ultraviolet irradiation, gamma irradiation, anisomycin, heat shock and chemotherapeutic 
drugs, yet recent studies have also implicated SAPK/JNK and p38 MAPK in vasoactive 
peptide-induced proliferative responses 338-344.  The JNK and p38 MAPK pathways are also 
activated by ischemia or reperfusion after ischemia, and by inflammatory cytokines 345.  
 The ERK 1/2, JNK and p38 MAPK pathways follow a similar sequence of 
activation, in which a stimulus activates a MAPKKK, which will then activate a MAPKK, 
which is an upstream activator of MAPK, the final effector of the cellular response.  
MAPKKKs are Ser/Thr kinases, and are activated through phosphorylation and/or as a 
result of their interaction with a small GTP-binding protein of the Ras/Rho family in 
response to extracellular stimuli (Figure 10).  Activation of MAPKKKs phosphorylate and 
activate MAPKKs, which then phosphorylates Thr and Tyr residues in the activation loop 
of the kinase, stimulating MAPK activity (Figure 10). Once activated, MAPKs 
phosphorylate target substrates on Ser or Thr residues followed by a proline.  ERK1/2 is the 
primary MAPK activated (Figure 10).  This pathway consists of the MAPKKKs (A-Raf, B-
Raf and Raf-1), the MAPKKs (mitogen and extracellular signal regulated kinase 1 and 2 
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(MEK1/2)), and the MAPKs (ERK1 and ERK2) (Figure 10).  Signals from activated 
receptor tyrosine kinase (RTK) or GPCR to Raf/MEK/ERK are transmitted through 
different isoforms of the small GTP-binding protein such as Ras.  As mentioned earlier, 
IGF-1R transduces its effect through IRS proteins, where phosphorylated IRS serves as a 
docking site for Grb-2/Son of Sevenless (SOS), whereas Grb-2/SOS binds directly on the 
activated EGFR to turn on MAPK signaling.  This triggers a conformational change in Ras, 
a GTP exchanger, resulting in its activation (Figure 10).  Once activated, Ras binds to a 
wide range of downstream effector proteins, including isoforms of the Ser/Thr kinase Raf.  
Raf then binds to, and phosphorylates, the dual-specificity protein kinase MEK-1 and -2, 
the latter of which phosphorylates ERK1/2 within a conserved Thr-Glu-Tyr (TEY) motif in 
their activation loop.  ERK1/2 can then be translocated to the nucleus where it can 
phosphorylate and activate a number of transcription factors involved in gene activation 337, 
346 (Figure 10).  It can also activate a number of cytosolic proteins, such as p90rsk through 
its proline directed Ser/Thr kinase activity.  Other members of the MAPK family, such as 
JNK and p38 MAPK, are activated in a similar fashion and mediate cellular functions by 
phosphorylating downstream targets. 
Overwhelming evidence exists to support a vasoactive peptide-induced MAPK 
activation in multiple systems, including oligodendrocyte progenitor cells, pancreatic 
stellate cell, aortic and mesenteric artery-derived VSMC, increasing cell growth and 
hypertrophy, leading to complications such as atrial fibrillation due to left ventricle 
hypertrophy, vascular remodelling, cardiac hypertrophy and coronary artery disease 203, 347-
351. 
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Figure 10: Vasoactive peptide-induced activation of the MAPK pathway in VSMC.  ET-1 and Ang II 
bind to their respective GPCRs, causing enhanced activity of PLCβ through Gαq/11 activation, leading to the 
conversion of phosphatidylinositol 4, 5 biphosphate (PIP2) to inositol 1, 4, 5 trisphosphate (IP3) and 
diacylglycerol (DAG).  This increase in IP3 causes an elevation of intracellular calcium (Ca2+) and DAG-
dependent PKC activation.  PKC/ Ca2+ or other signaling intermediates activate R- and/or NR-PTKs, like 
EGFR, IGF-1R, PYK2 and c-Src, by inducing their phosphorylation on target tyrosine residues.  Activation of 
these PTKs leads to the phosphorylation of docking proteins, such as IRS-1, which serve as docking sites for 
Grb-2/SOS.  The latter can bind directly to activated R-PTK, triggering a conformational change in Ras, a 
GTP exchanger, resulting in its activation.  Once activated, Ras binds to Raf, a Ser/Thr kinase, which binds to 
and phosphorylates the dual-specificity protein kinases MEK-1/2, which phosphorylate ERK1/2.  ERK1/2 can 
then translocate to the nucleus, and regulate cell growth, proliferation and hypertrophy through 
phosphorylation of transcription factors. Other members of the MAPK family, such as JNK and p38 MAPK, 
are activated in a similar fashion and mediate cellular functions by phosphorylating downstream targets.  
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1.8.3 ET-1 and Ang II-induced transactivation of receptor and non-
receptor protein tyrosine kinases (R-/NR-PTK) 
Activation of growth factor receptor and/or non-receptor protein tyrosine kinases (R-PTK 
or NR-PTK) has been implicated in transducing the downstream effects of GPCR, leading 
to the stimulation of the PI3-K/PKB and MAPK cascades, which are involved in mediating 
the migratory, proliferative, and hypertrophic responses of ET-1 and Ang II 50. GPCR 
ligands activate R- and/or NR-PTKs through a process termed “transactivation”.  Daub et 
al. first identified this process in 1996, by showing that ET-1 enhanced the tyrosine 
phosphorylation of epidermal growth factor receptor (EGFR) 352.   
1.8.3.1 Epidermal Growth Factor Receptor (EGFR) 
The EGFR is one of four members belonging to the Erythroblastic Leukemia Viral 
Oncogene (erbB) family of R-PTK.  As such, EGFR is also known as ErbB1 (ErbB2, 
ErbB3, and ErbB4 are the other 3 members of this family).  This family of transmembrane 
receptors undergoes homodimerization or heterodimerization to induce 
autophosphorylation and receptor tyrosine kinase activation in response to ligand binding 
353, 354.  The EGFR is universally expressed in a variety of cell types, and is most abundant 
in epithelial cells and many cancer cells 353, 355, 356.  This receptor contains an extracellular 
ligand binding domain, a single transmembrane domain and a cytoplasmic tyrosine kinase 
autophosphorylation and regulatory domain (reviewed in 357).  Recent work has shown that 
in basal conditions, the kinase domain of the EGFR exists in an autoinhibitory 
conformational state, and ligand binding-induced dimerization and changes in conformation 
allow its autophosphorylation, resulting in its activation 358.  This event activates the 
intrinsic tyrosine kinase activity of the intracellular domain, leading to receptor 
autophosphorylation on several key tyrosine residues located in the COOH-terminal tail of 
the receptor 359.  These phosphorylated tyrosine residues then act as docking sites for SH2 
and phosphotyrosine-binding domain containing cytoplasmic proteins, such as Grb-2/SOS 
and the p85 subunit of PI3-K 360, involved in the activation of multiple signaling pathways, 
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including MAPK and PKB.  Both ligand-dependent and -independent mechanisms for its 
activation have been suggested 361.  To date, seven different ligands, in addition to EGF, are 
known to bind to the EGFR and cause its activation 362, 363.   
Multiple studies have shown that Ang II, and more recently, ET-1, can cause the 
activation, and subsequent phosphorylation of EGFR through receptor transactivation, a 
phenomenon stemming from the binding of Ang II to its AT1R 364, and ET-1 to the ETA 
receptor 365.  Furthermore, a role of ETB receptor in ET-1-induced EGFR transactivation 
has also been demonstrated in VSMC, through the use of the N-terminally truncated or full-
length ETB receptor 365.  ET-1 and Ang II-induced EGFR activation has been demonstrated 
in multiple cell types, including VSMC, cardiomyocytes, intestinal epithelial cells, 
preglomerular VSM, C9 cells and pancreatic stellate cells 351, 366-373.  Ang II and ET-1-
induced ERK1/2 and PKB phosphorylation were also found to be EGFR-dependent based 
on studies using pharmacological inhibitors of EGFR, like AG1478 and PD153035.  For 
example, Ang II-induced p38 MAPK and ERK1/2 phosphorylation was attenuated by 
AG1478 339.  Furthermore, Ang II-induced PKB phosphorylation was associated with 
EGFR transactivation in rat aorta VSMC and in intestinal epithelial IEC-18 cells 369, 374.  
ET-1-induced ERK1/2 phosphorylation through EGFR activation was also demonstrated in 
rat cardiomyocytes as well as in rat renal tubular cells 372, 375.  More importantly, the 
transactivation of EGFR by ET-1 and Ang II has been suggested to play an important role 
in vasoactive peptide-induced physiological responses linked to MAPK and PKB signaling, 
such as growth, hypertrophy and proliferation, in multiple cell types, including VSMC 364, 
367, 372, 376.  For example, ET-1-induced EGFR transactivation has been implicated in protein 
and DNA synthesis and c-Fos gene transcription in VSMC 373, 377.  In addition, a role of 
EGFR in vascular contraction in mouse aortic ring segments and rabbit basilary artery rings 
has been reported 378, 379. 
It is well known that VSMC from spontaneously hypertensive rats (SHR) exhibit 
exaggerated cell proliferation compared to VSMC from normotensive Wistar Kyoto 
(WKY) rats 380.  This was thought to occur due to elevated levels of Giα proteins in VSMC 
from SHR.  However, recent reports suggest that endogenously produced ET-1 and Ang II 
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contribute to the enhanced proliferation of VSMC from SHR, through EGFR 
transactivation 381, linking growth factor receptor transactivation to the deleterious 
hypertrophic effects of elevated ET-1 and Ang II levels found in hypertensive states.  In 
these studies, EGFR, AT1R, ETA and ETB receptor inhibition decreased exaggerated 
ERK1/2 phosphorylation found in VSMC from SHR to levels found in VSMC from WKY, 
suggesting that endogenous ET-1 and Ang II-induced MAPK signaling contributes to the 
enhanced cell growth of VSMC in SHR through EGFR transactivation 381. 
1.8.3.2 Insulin-like Growth Factor Type 1 Receptor (IGF-1R) 
IGF-1R, another transmembrane R-PTK, is a tetrameric protein consisting of 2 α- 
and 2 β-subunits, and has a high degree of homology with the insulin receptor 382. IGF-1R 
is activated by IGF-1 and associated growth factors, such as IGF-2, albeit with lower 
affinity.  Importantly, IGF-1R differs from other R-PTKs in that it exists on the cell surface 
as a covalent dimeric structure, which requires domain rearrangement for activation 383, 
whereas other R-PTKs, like the EGFR described earlier, dimerize or oligomerize upon 
ligand binding to trigger receptor activation 384.  The α-subunit of IGF-1R contains the IGF-
1-binding site.  The β-subunit comprises an intracellular PTK domain that is critical for 
transducing most of the downstream signaling 382.  The α-chain and the 195 residues of the 
β-chain make up the extracellular part of the IGF-1R 383. The mature α2β2 receptor also has 
a single transmembrane sequence (906-929 residues) and a 408-residue cytoplasmic 
domain, which possesses tyrosine kinase activity. The N-terminal half of the IGF-1R also 
contains 2 homology domains, L1 and L2, separated by the Cys-rich region (Cys148 to 
Cys298).  It has been shown that residues 131-315 (Cys-rich and L1 and L2 flanking 
regions) are required for binding IGF-1 385.  This cytoplasmic domain is flanked by 2 
regulatory regions: a juxtamembrane region, which plays a major role in docking of IR 
substrates (IRSs), Shc  and receptor internalization 386, and a 108-residue long carboxy-
terminal tail consisting of 2 phosphotyrosine-binding sites 386, 387.  IGF-1-binding to 
extracellular α-subunits triggers a conformational change in the β-subunit, resulting in its 
trans-autophosphorylation in multiple tyrosine residues and evoking the PTK catalytic 
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activity of the receptor 388. Activated IGF-1R phosphorylates several downstream 
substrates, such as Shc and IRSs 1-4, in multiple tyrosine residues 389, 390.  Phosphorylated 
IRSs serve as docking proteins for many SH2 domain-containing molecules, including 
growth factor receptor-binding protein 2 (Grb2), the p85 subunit of PI3-K, NcK and SH-
phosphatase 2 Grb2 binding to the activated receptor, which recruits SOS, leading to the 
subsequent activation of the MAPK and/or PI3-K/PKB pathways 391, 392.   
While EGFR transactivation by vasoactive peptides has been well described, the 
requirement of IGF-1R in vasoactive peptide-induced signaling is only more recently 
coming to light in studies showing a requirement of IGF-1R activation in AngII-induced 
downstream signaling 393.  These studies bridge the gap with studies done over a decade 
ago, demonstrating the stimulatory effect of AngII on the tyrosine phosphorylation of IGF-
1R β-subunit as well as on IRS-1 rat aortic VSMC 394.  Ang II treatment enhanced tyrosine 
phosphorylation of the β-subunit of IGF-1R in smooth muscle cells (SMC) isolated from 
porcine arteries 395.  IGF-1 neutralizing antibody was also used in these experiments, 
confirming that Ang II-induced IGF-1R phosphorylation was in fact ligand-independent 395.  
While this study also showed that AngII-induced phosphorylation of p85 and p70s6k was 
significantly attenuated by pre-treatment of SMC with AG1024, a selective 
pharmacological inhibitor of IGF-1R-PTK activity, this drug failed to attenuate AngII-
induced ERK1/2 activation 395.  In contrast, AG1024 attenuated AngII-induced 
phosphorylation of ERK1/2/5 and p38MAPK in mesenteric VSMC 396, 397.  Further 
consolidating the potential cross-talk of between the Ang II and IGF-1/IGF-1R systems are 
studies showing that Ang II increases IGF-1mRNA and protein in heart tissue and VSMC 
398, 399, and that IGF-1 can increase AT1R expression in VSMC 400.  Moreover, Nguyen et 
al. have also demonstrated that IGF-1R antisense-induced reduction in IGF-1R was 
associated with an inhibition of Ang II-induced vascular responses, as well as AT1R 
expression and functionality, in spontaneously hypertensive rats (SHR) and Wistar Kyoto 
rats (WKY) 401, 402.  These, and other studies showing that dominant negative or antisense 
oligonucleotide of IGF-1R are able to attenuate neointima formation in an injured carotid 
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artery rat model 403, support a potential pathogenic role of upregulated IGF-1R signalling in 
vascular disease. 
1.8.3.3 c-Src 
 c-Src, also known as Src or p60c-Src, is a NR-PTK and is the cellular homologue of 
the v-Src avian oncogene of the Rous sarcoma virus, a chicken tumour virus, discovered by 
Peyton Rous 404.  It is a member of the Src family of NR-TK, which contains 10 other 
members, including Blk, Brk, Fgr, Frk, Fyn, Hck, Lck, Lyn, Src, Srm, and Yes 405.  Src 
family of NR-TK play a vital role in cell differentiation, proliferation, and survival 
signaling mechanisms, as well as in cell adhesion, morphology and motility (reviewed in 
406).  Src, Yes and Fyn are ubiquitously expressed in all cells, yet expression levels vary 
among certain cell types, such as platelets, neurons, and osteoclasts, which have been found 
to express 5–200-fold higher levels of Src protein than other cells 407.  Structurally, each 
member of the Src family contains a short N-terminal membrane anchor, or SH4 domain, 
which contains a 14 carbon myristoyl group.  This domain is followed by a poorly-
conserved ‘unique’ region of 40 to 70 residues, an SH3 domain of 50 residues, which can 
bind to specific proline-rich sequences, an SH2 domain of 100 residues, which can bind to 
Tyr phosphorylation sites, an SH2-linker domain rich in proline residues, an SH1 250 
residue tyrosine kinase catalytic domain, and a short C-terminal regulatory region 
containing conserved tyrosine residues 407.  Each domain of the Src structure plays an 
important role in Src function.  For example, studies have demonstrated that myristoylation 
allows the membrane localization of Src and is essential for proper functioning of Src in 
cells 407, yet others have demonstrated that myristoylated Src is found free in the cytosol, 
and as such, does not guarantee Src binding to the cell membrane 406.  Myristoylation takes 
place on the myristoyl-rich SH4 (N-terminal) domain, which then binds to the cell 
membrane.  The SH1 domain is the most conserved domain in all the tyrosine kinases, and 
contains an ATP-binding domain.  Tyr 416/418 (416 in chicken and 418 in human) and Tyr 
527/530 (527 in chicken and 530 in human) are the two major tyrosine phosphorylation 
sites which regulate Src activity.  Phosphorylation of Tyr 416/418, through an auto-
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phosphorylation mechanism, is required for full c-Src activity, while phosphorylation of 
Tyr 527/530, a site located in the C-terminal regulatory region, is a negative regulator, 
whose phosphorylation inhibits c-Src activity 408.  In a physiologically normal state, c-Src is 
found in an inactive state, or “closed” conformation, where the phosphorylated Tyr 527/530 
site is linked to the SH2 domain, and the SH2-linker domain is bound to the SH3 domain, 
keeping the Tyr 416/418 dephosphorylated.  Dephosphorylation of Tyr 527/530 causes a 
conformational change and disrupts the bond of this site with the SH2 domain, thus 
“opening” the conformation of the c-Src molecule, allowing for access of ATP to the 
catalytic site and release of ADP, leading to its auto-phosphorylation on Tyr 416/418, and 
causing c-Src activation 409.  In growth factor receptor signaling, the SH2 domain of c-Src 
binds to Tyr phosphorylated subunits of the growth factor receptor in question, leading to a 
conformational change and allowing for Tyr 416/418 phosphorylation and subsequent c-Src 
activation. 
In the vasculature, especially VSMC, GPCR-linked contractile responses, induced 
by Ang II and phenylephrine, have been associated with c-Src activation 410, 411.  
Furthermore, the use of PP-1 and PP-2, pyrazolopyrimidine-based selective inhibitors of 
Src family tyrosine kinases 412, has indicated a role of Src in mediating H2O2, ET-1 and 
Ang II-induced transactivation of the EGFR and PDGFR in several cell types 64, 413-416.  ET-
1 and Ang II-induced MAPK activation has also been reported to be primarily dependent on 
the activation of c-Src in different cell types, including VSMC 417.  In Src-deficient VMSC 
derived from c-Src knockout mice, activation of ERK1/2 by Ang II was significantly 
decreased, as compared to VSMC from wild type mice 418, 419.  c-Src rescue in these cells 
through retroviral vector transfection caused a significant increase in Ang II-induced 
ERK1/2 phosphorylation, demonstrating that c-Src activation is necessary for Ang II-
induced signal transduction in VSMC 419.   
Both c-Src and IGF-1R have been implicated in the activation of NAD(P)H oxidase 
system 396, and since both ET-1 and Ang II trigger their effect through the generation of 
ROS 203, activation of IGF-1R and c-Src may be an early event in tranducing vasoactive 
peptide-induced ROS generation, leading to the activation of growth promoting and 
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hypertrophic signaling pathways.  In fact, c-Src has also been shown to be activated in 
response to ROS, including H2O2, in different cell types 414, 416, 420-422.  Furthermore, 
through the use of PP-1 and PP-2, a role of c-Src in mediating H2O2–induced ERK1/2 
phosphorylation in VSMCs derived from mesenteric arteries 423, in CHO-IR cells 422 and in 
renal cells 414, 424 has been shown.  A requirement of c-Src has also been shown in H2O2-
induced PKB phosphorylation CHO-IR cells 422, renal cells 414, rat-2 fibroblasts 425 and, 
more recently, in A10 VSMCs 421.  Thus, c-Src appears to play a key role in signaling the 
effects of  H2O2, as well as vasoactive peptides. 
1.8.3.4 Proline-rich Tyrosine Kinase (PYK2) 
 PYK2 is a cytosolic Ca2+-dependent, proline-rich tyrosine kinase 426, also known as 
calcium-dependent tyrosine kinase, cell adhesion kinase β, or related adhesion focal 
tyrosine kinase (RAFTK), as it has a similar overall structural organization to the focal 
adhesion kinase (FAK) non-receptor tyrosine kinases 427.  Like FAK, PYK2 has a C-
terminal focal-adhesion targeting domain, a catalytic tyrosine kinase domain which is 
centrally located, an unstructured proline-rich region, and a N-terminal FERM domain, 
which can bind and auto-inhibit the kinase activity of the tyrosine kinase domain 428.  
However, recent reports demonstrate that the PYK2 FERM domain and the FAK FERM 
domain regulate the activity of PYK2 and FAK, respectively, but do so in different ways 
429, indicating a role of the PYK2 FERM domain in the regulation of PYK2 activity 429.  
PYK2 is activated by autophosphorylation in Tyr 402, located in its catalytic domain.  
PYK2 has been proposed to facilitate the linkage between integrin receptors, 
heterodimeric transmembrane receptors that connect the extracellular matrix to the 
cytoskeleton, and the activation of signaling pathways, such as the PI3-K/PKB and MAPK 
pathways 426, 430.  Additionally, G-protein-associated ERK signaling was shown to be 
enhanced by PYK2 overexpression 426, which is further supported by studies showing that 
PYK2 inactivation, or mutation of its auto-phosphorylation sites, attenuates G-protein-
induced ERK phospohorylation 431.  Moreover, the increases in intracellular Ca2+ and PKC 
activation via Gαq activation by Ang II have been well characterized, and appear to be the 
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main mechanism by which PYK2 is phosphorylated on Tyr 402, and thus fully activated 
by, Ang II 432.  The activated PYK2 forms a complex with shc and Grb/SOS, resulting in 
the activation of the Ras/MAPK and PI3-K pathways 433.  ET-1 was also shown to induce 
PYK2 phosphorylation in several cell types, including rabbit and rat VSMC 203, 349, 434.  
This phosphorylation was blocked by BQ123, an ETA receptor inhibitor, but not by BQ788, 
an ETB receptor blocker, demonstrating that ET-1-induced PYK2 phosphorylation is 
dependent of ETA receptor activation 434.  Furthermore, this study also showed that the Ca2+ 
channel blocker SK&F 96365 inhibited ET-1-induced PYK2 phosphorylation, linking ET-
1-induced PYK2 phosphorylation to an increase in Ca2+ levels caused by ETA receptor G-
protein activation 434, similar to Ang II-induced PYK2 phosphorylation 435.  Furthermore, 
vasoactive peptide-induced MAPK and PKB activation have been linked to c-Src and 
PYK2 complex formation with either EGFR and/or IGF-1R, leading to their subsequent 
activation and downstream signaling 436, 437.  However, a recent report has suggested that 
Ang II activates MAPK signaling through a c-Src-dependent mechanism, while ET-1 
activates MAPK signaling through a c-Src-independent mechanism 418.  Thus, PYK2 may 
activate EGFR signaling in a c-Src-independent fashion, yet the mechanism through which 
ET-1 signals MAPK activation still remains controversial.  Nevertheless, it is quite evident 
that PYK2 plays an important role in mediating vasoactive peptide-induced signaling 
pathways involved in cell migration, proliferation, and hypertrophy. 
1.8.3.5 Potential mechanisms contributing to ET-1 and Ang II-induced R-/NR-PTK 
transactivation 
While the precise events that trigger the transactivation of R-/NR-PTK in response 
to vasoactive peptides are not clear, several mechanisms have been suggested.  Studies 
have shown that inhibitors of matrix metalloproteinases (MMP), such as GM6001 and 
doxycyclin, attenuated ET-1 and Ang II-induced EGFR transactivation 438, 439.  MMPs act 
mainly by disrupting the link between growth factors and their transmembrane precursors, 
as is the case for heparin-bound-EGF (HB-EGF), allowing EGF to bind to EGFR, and 
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leading to tyrosine kinase activation and stimulation of hypertrophic and growth promoting 
signaling cascades 440. 
Another proposed mechanism of R-PTK transactivation by vasoactive peptides is 
through their capacity to induce the generation of reactive oxygen species (ROS).  ET-1 has 
been shown to activate reduced nicotinamide adenine dinucleotide phosphate (NAD(P)H) 
oxidase, resulting in ROS generation in endothelial cells 441, and increased H2O2 levels via 
ETA receptor binding in pulmonary smooth muscle cells 442.  This increase in ROS 
generation has been linked with the ET-1-induced activation of ERK1/2, JNK, p38 MAPK, 
PKB and PYK2 203, 443.  For its part, Ang II has also been shown to induce ROS generation 
in multiple cell types, including cardiomyocytes, endothelial cells and VSMC 444-446, which 
appears to play a direct role in Ang II-induced vascular hypertrophy through the activation 
of hypertrophic signaling pathways 447, 448.  ET-1-induced ROS generation in VSMC was 
suppressed by N-Acetylcysteine (NAc), a ROS scavenger, and diphenyleneiodonium (DPI), 
an inhibitor of NAD(P)H oxidase 203.  DPI and NAc pre-treatment of VSMC also inhibited 
ET-1-induced ERK1/2, PKB, and PYK2 phosphorylation, demonstrating that ROS are 
critical mediators of ET-1-induced signaling events linked to growth-promoting 
proliferative and hypertrophic pathways in VSMCs.  Observations that both ROS e.g. 
H2O2, and vasoactive peptides, induce the tyrosine phosphorylation of IGF-1R and EGFR, 
and pharmacological blockade or genetic ablation of the R- and/or NR-PTK activity 
resulted in the attenuation of ET-1 and Ang II-induced ERK1/2 and PKB phosphorylation 
have suggested that ROS may serve as intermediates to enhance the tyrosine 
phosphorylation of R- and NR-PTKs 64, 415, 421, 423, 449.  It should be noted that ROS 
molecules have been shown to inhibit the activity of protein tyrosine phosphatases 
(PTPases), such as PTP-1B 450, and SH-2 domain-containing tyrosine phosphatase-2 (SHP-
2) 451. PTPase inhibition can cause a shift in the phosphorylation-dephosphorylation cycle, 
leading to a net increase of tyrosine phosphorylation of R- and/or NR-PTK421, 422, which 
may contribute to the activation of the ERK1/2 and PKB signaling cascades.  It has also 
been reported that PTEN, which catalyzes PIP3 dephosphorylation, becomes inactivated by 
oxidation of Cys 124 in its catalytic domain subsequent to treatment with H2O2 or ROS-
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generating peptides 452-455, leading to an increase of PIP3 levels and a subsequent increase in 
PKB activation. 
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1.9 Objectives of the present study 
Among various growth factor PTKs, the role of transactivation of EGFR in 
promoting the downstream responses to both ET-1 and Ang II in VSMC has been studied 
in some detail. Ang II has also been shown to induce tyrosine phosphorylation of EGFR in 
VSMC and a role of EGFR transactivation in Ang II-induced activation of ERK1/2 and 
PKB signaling, hypertrophy and proliferation of VSMC has been reported. Similarly, a 
critical role of EGFR transactivation in mediating ET-1-induced signaling events such as 
ERK1/2, p70S6K activation as well as protein and DNA synthesis, gene expression has been 
reported in several cell types.  However, in contrast to the well-studied role of EGFR 
transactivation in mediating the responses of both of these vasoactive peptides, the 
involvement of other growth factor receptors in this process has not been investigated in 
detail. Furthermore, the role of c-Src, a non-receptor tyrosine kinase, in ET-1-induced 
MAPK signaling remains controversial in VSMC. While both ET-1 and Ang II seem to 
activate PKB through the same c-Src-dependent mechanism, a recent report has suggested 
that Ang II activates MAPK signaling through a c-Src-dependent mechanism, whereas ET-
1 activates MAPK signaling through a c-Src-independent mechanism 418.  In addition, 
studies have suggested that the early growth transcription factor-1 (Egr-1) plays an 
important role in multiple cardiovascular pathological processes, including the pathogenesis 
of atherosclerotic lesions and neointimal thickening after vascular injury.  While a growing 
number of studies have examined Egr-1 expression in response to Ang II in several cell 
types, including VSMC, little is known on ET-1-induced Egr-1 responses in VSMC.  
Our laboratory has previously demonstrated that transactivation of insulin-like 
growth factor type 1 receptor (IGF-1R) plays a key role in triggering H2O2-induced 
phosphorylation of PKB in VSMC and that a cross-talk exists between the c-Src family of 
PTK and IGF-1R in mediating this effect.  Since ET-1 and Ang II have been shown to 
increase the production of ROS, such as O2 - and H2O2 in VSMC, the objective of the 
present study was to elucidate the following aims: 
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1. Whether IGF-1R transactivation contributes to ET-1 and Ang II-induced activation 
of PKB and on hypertrophic and proliferative responses in VSMC. 
 
2. Study the role of a cross talk between c-Src and IGF-1R PTK in ET-1 and Ang II-
induced activation of PKB and subsequent hypertrophic and proliferative events 
induced by these vasoactive peptides. 
 
3. Examine if the non-receptor protein tyrosine kinase c-Src differentially regulates 
ET-1 and Ang II-induced ERK 1/2, JNK and p38MAPK activation. 
 
4. Study a possible role of c-Src NR-PTK in ET-1 and Ang II-induced modulation of 
early growth transcription factor-1 (Egr-1) in VSMC. 
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Chapter 2 
Role of insulin-like growth factor 1 receptor and c-Src in 
endothelin-1 and angiotensin II-induced PKB 
phosphorylation, and hypertrophic and proliferative 
responses, in vascular smooth muscle cells. 
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2.1 Abstract  
Endothelin-1 (ET-1) and angiotensin II (Ang II) are believed to contribute to the pathogenesis 
of vascular abnormalities such as hypertension, atherosclerosis, hypertrophy and restenosis. 
During the last several years, the concept of transactivation of growth factor receptors, such 
as epidermal growth factor receptor (EGFR) in triggering vasoactive peptide-induced 
signaling events, has gained much recognition. We demonstrated that insulin-like growth 
factor-1 receptor (IGF-1R) plays a role in tranducing the effect of H2O2, leading to protein 
kinase B (PKB) phosphorylation. Since vasoactive peptides elicit their responses through 
generation of reactive oxygen species, including H2O2, we investigated whether IGF-1R 
transactivation plays a similar role in ET-1 and Ang II-induced PKB phosphorylation and 
hypertrophic responses in VSMC. AG-1024, a specific inhibitor of IGF-1R protein tyrosine 
kinase (PTK), attenuated both ET-1 and Ang II-induced PKB phosphorylation in a dose-
dependent manner. ET-1 and Ang II treatment also induced the phosphorylation of tyrosine 
residues in the autophosphorylation sites of IGF-1R, which was blocked by AG-1024. In 
addition, both ET-1 and Ang II evoked tyrosine phosphorylation of c-Src, a non-receptor 
PTK, and pharmacological inhibition of c-Src PTK activity by PP-2, a specific inhibitor of 
Src-family tyrosine kinase, significantly reduced PKB phosphorylation as well as tyrosine 
phosphorylation of IGF-1R induced by the two vasoactive peptides. Furthermore, protein and 
DNA synthesis enhanced by ET-1 and Ang II were also attenuated by AG-1024 and PP-2. In 
conclusion, these data suggest that IGF-1R and c-Src PTK play a critical role in mediating 
PKB phosphorylation as well as hypertrophic and proliferative responses induced by ET-1 
and Ang II in A-10 VSMC. 
 
Key words: Endothelin-1, Angiotensin II, IGF-1R, c-Src, PKB, Growth, VSMC. 
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2.2 Introduction 
 Endothelin-1 (ET-1) and angiotensin II (Ang II) are considered important vasoactive 
peptides in the vascular system. ET-1 is a potent vasoconstrictor peptide (Webb 1997) 
predominantly secreted by endothelial cells, whereas Ang II is the main component of the 
renin-angiotensin system (Touyz and Schiffrin 2000). Both of these vasoactive peptides exert 
their biological effects through interaction with specific heterotrimeric GTP binding protein 
coupled receptor (GPCR) in vascular smooth muscle cell (VSMC) (Bouallegue et al. 2007a; 
Touyz and Schiffrin 2000). ET-1 exerts its biological actions through the activation of two 
receptor subtypes, ETA and ETB (Arai et al. 1990; Sakurai et al. 1990), whereas Ang II acts 
via AT1 and AT2 receptors (de Gasparo et al. 2000). In recent years, it has become evident 
that both peptides play a critical role in vascular complications such as atherosclerosis 
(Mathew et al. 1996), hypertension (Haynes and Webb 1998) and restenosis after angioplasty 
(Burke et al. 1997). These actions are believed to be mediated through the activation of 
multiple signaling pathways which include: the mitogen-activated protein kinases (MAPKs), 
including extracellular signal-regulated kinases 1/2 (ERK1/2); c-Jun-NH2-terminal kinase 
(JNK) and p38mapk (Bogoyevitch et al. 1994; Yamboliev et al. 1998; Yoshizumi et al. 1998; 
Sorokin et al. 2001; Bouallegue et al. 2007a); as well as phosphatidylinositol 3-kinase (PI-
3K) and its downstream effectors such as protein kinase B (PKB) (Foschi et al. 1997; 
Bouallegue et al. 2007a). An intermediary role of the transactivation of growth factor 
receptor protein tyrosine kinases (PTK) in transducing ET-1 and Ang II-induced signaling 
responses has been suggested (Yamauchi et al. 2002; Kodama et al. 2002; Kodama et al. 
2003; Sorokin et al. 2001; Flamant et al. 2003). Among various growth factor PTK, the role 
of transactivation of epidermal growth factor receptor (EGFR) in promoting the downstream 
responses to both ET-1 and Ang II in VSMC has been studied in some detail (Chansel et al. 
2006; Li and Malik 2005). Ang II has also been shown to induce tyrosine phosphorylation of 
EGFR in VSMC (Eguchi et al. 1999b; Eguchi et al. 1999a) and a role of EGFR 
transactivation in Ang II-induced activation of ERK1/2 and PKB signaling, hypertrophy and 
proliferation of VSMC has been reported (Eguchi et al. 1999a; Ohtsu et al. 2006; Bokemeyer 
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et al. 2000; Eguchi et al. 2001; Li and Malik 2005). Similarly, a critical role of EGFR 
transactivation in mediating ET-1-induced signaling events such as ERK1/2, p70S6K 
activation as well as protein and DNA synthesis, gene expression (Iwasaki et al. 1998) and 
contraction (Chansel et al. 2006; Kawanabe et al. 2004) has been reported in several cell 
types. However, in contrast to the well-studied role of EGFR transactivation in mediating the 
responses of both of these vasoactive peptides, the involvement of other growth factor 
receptors in this process has not been investigated in detail. We have demonstrated that 
transactivation of insulin-like growth factor type 1 receptor (IGF-1R) plays a key role in 
triggering H2O2-induced phosphorylation of PKB in VSMC and that cross-talk exists 
between the c-Src family of PTK and IGF-1R in mediating this effect (Azar et al. 2007). 
Since ET-1 and Ang II have been shown to increase the production of reactive oxygen 
species (ROS) such as O2- and H2O2 in VSMC (Daou and Srivastava 2004; Griendling et al. 
1994; Cheng et al. 1999), we investigated whether IGF-1R transactivation also contributes to 
ET-1 and Ang II-induced activation of PKB and on hypertrophic and proliferative responses 
in VSMC and whether c-Src plays a role in this process. 
2.3 Materials and Methods 
2.3.1 Materials 
ET-1 and Ang II were purchased from American Peptide Inc (USA). AG-1024, PP-2 
and PP-3 were from obtained from Calbiochem. The phospho-specific-Ser473-PKB, total 
PKB and horseradish peroxidase-conjugated anti-rabbit antibodies were procured from 
New England Biolabs (Beverly, MA). Anti-phospho-specific-IGF-1R (phospho-
Tyr1131/1135/1136) and anti-phospho-specific-c-Src (phospho-Tyr418) antibodies were obtained 
from Biosource. Anti-IGF-1R and anti-cSrc antibodies were obtained from Santa Cruz 
Biotech (Santa Cruz, CA). The enhanced chemiluminescence (ECL) detection system kit 
was purchased from Amersham Pharmacia Biotech (Baie d’Urfé, QC, Canada). Leucine L-
(4,5-3H) and (3H) Thymidine were obtained from MP Biomedicals (OH, USA) 
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2.3.2 Methods 
Cell culture 
A-10 VSMC were maintained in culture with DMEM containing 10% fetal bovine serum at 
370 C in a humidified atmosphere of 5% CO2, as previously described (Bouallegue et al. 
2007b). Cells were grown to 80-90% confluence in 60-mm plates and incubated in serum-
free DMEM 5h prior to the treatments. 
 
Cell lysis and Immunoblotting  
Cells incubated in the absence or presence of various agents were washed twice with ice-cold 
PBS and lysed in 200 μl of buffer (25 mM Tris-HCl, pH 7.5, 25 mM NaCl, 1 mM Na 
orthovanadate, 10 mM Na fluoride, 10 mM Na pyrophosphate, 2 mM benzamidine, 2 mM 
ethylenebis(oxyethylenenitrolo)-tetraacetic acid, 2 mM ethylenediamine tetraacetic acid, 1 
mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin, 1% Triton X-100, 0.1% sodium 
dodecyl sulfate (SDS), and 0.5 μg/ml leupeptin) on ice. Cell lysates were centrifuged at 
12,000g for 10 min at 40 C. Protein concentrations were measured by Bradford assay. Equal 
amounts of protein were subjected to 7.5% SDS-polyacrylamide gel (SDS-PAGE), 
transferred to PVDF membranes (Millipore, MA, USA) and incubated with respective 
primary antibodies, polyclonal phospho-specific-Ser473-PKB (1:1,000) or phospho-cSrc 
(1:2,000) or phosphor-IGF-1R (1:1,000) antibodies. The antigen-antibody complex was 
detected by horseradish peroxidase-conjugated second antibody (1:2000) and protein bands 
were visualized by ECL. The intensity of specific bands was quantified by NIH Image 
software as described previously (Pandey et al. 1999). 
 
Measurement of [3H]Leucine and [3H]Thymidine incorporation. 
Subconfluent A-10 VSMC were plated in 24-well plates and treated for 20 h with ET-1 or 
Ang II (100nM). To assess the role of IGF-1R or c-Src, cells were pretreated for 30 min with 
5 µM of AG-1024 or PP-2, respectively, prior to stimulation with either ET-1 or Ang II. 
Protein and DNA synthesis were assessed by addition of 2 μCi/mL of [3H]leucine or 
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[3H]Thymidine respectively as described previously (Bouallegue et al. 2007b). Following the 
completion of the experimental protocol, A-10 cells were washed four times with ice-cold 
NaCl (150 mM) and incubated with 1 ml of cold 5% trichloroacetic acid for 30 min. 
Subsequently, cells were washed twice with ice-cold water and incubated with 500 μl of 0.4 
N NaOH. Aliquots were counted in a scintillation counter to determine the incorporation of 
radioactivity. 
 
Statistics 
The data are means ± SE of three individual experiments. Statistical significance was 
determined with paired or unpaired Student’s t test. 
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2.4 Results  
2.4.1 Attenuation of ET-1 and Ang II-induced PKB phosphorylation by 
AG-1024 in A-10 VSMCs. 
 Both ET-1 and Ang II have been shown to transactivate EGFR in many cell types 
(Kodama et al. 2002; Iwasaki et al. 1998) and an important role of this transactivation in 
mediating ET-1-induced ERK1/2 activation has been reported (Iwasaki et al. 1998). 
However, involvement of IGF-1R in ET-1 and Ang II-induced phosphorylation of PKB has 
not been investigated in VSMC. Therefore, by using AG-1024 (3-bromo-5-t-butyl-4-
hydroxy-benzylidenemalonitrile), a specific pharmacological inhibitor of IGF-1R-PTK 
activity (Parrizas et al. 1997), we examined the involvement of IGF-1R in this process. As 
shown in Fig.1, pretreatment of A-10 VSMCs with AG-1024 for 30 min dose-dependently 
attenuated both ET-1 and Ang II-induced phosphorylation of PKB and 10μM AG-1024 was 
found to completely abrogate PKB phosphorylation induced by both these vasoactive 
peptides. 
2.4.2 ET-1 and Ang II induce tyrosine phosphorylation of IGF-1R  
 Since tyrosine phosphorylation of IGF-1R β subunit is essential for its activation, we 
examined whether stimulation of cells with these two vasopeptides would result in an 
enhanced tyrosine phosphorylation of IGF-1R β subunit. This was achieved by using a 
phospho-specific antibody that recognizes IGF-1R phosphorylated on tyrosine residues 1131, 
1135 and 1136, critical sites of autophosphorylation necessary for the activation of IGF-1R 
(Hernandez-Sanchez et al. 1995). As shown in Fig.2, both ET-1 and Ang II were able to 
evoke an increase in tyrosine phosphorylation of IGF-1R, which was blocked by pretreatment 
of cells with AG-1024. 
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2.4.3 Attenuation of ET-1 and Ang II-induced PKB phosphorylation by 
PP-2 in A-10 VSMCs. 
The Src family of non-receptor PTKs has been implicated in triggering some 
signaling responses of Ang II (Eguchi et al. 1999b) and ET-1(Shah et al. 2006), however, 
involvement of these PTKs in mediating ET-1 and Ang II-induced PKB phosphorylation in 
VSMC has not been examined. Therefore, by using PP-2 (4-amino-5-(4-chlorophenyl)-7-(t-
butyl)pyrazole(3,4-d) pyrimidine), a specific blocker of Src-family PTK (Hanke et al. 1996), 
we investigated the role of Src PTK in this process. As shown in Fig.3, pretreatment of 
VSMC with PP-2 prior to stimulation with ET-1 or Ang II inhibited PKB phosphorylation 
induced by both ET-1 and Ang II in a dose-dependent manner. At 5 μM, PP-2 almost 
completely inhibited PKB phosphorylation. However, PP-3 (4-amino-7-phenylpyrazole(3,4-
d) pyrimidine), an inactive analog of PP-2, had no effect. 
2.4.4 ET-1 and Ang II induce tyrosine phosphorylation of c-Src  
Since c-Src activation requires enhancement in the phosphorylation of a Tyr 418 
conserved tyrosine residue (referring to human Src sequence) located in its activation loop 
(Thomas and Brugge 1997), we determined whether ET-41 and Ang II were capable of 
inducing phosphorylation of this tyrosine residue in A-10 VSMC. As shown in Fig.4, both 
ET-1 and Ang II treatment resulted in increased phosphorylation of Tyr418 on c-Src. 
Moreover, pretreatment with PP-2 prior to stimulation of cells with these vasoactive peptides 
blocked this response, yet PP-3 had no effect (Fig.4).  
2.4.5 Attenuation of ET-1 and Ang II-induced tyrosine phosphorylation of 
IGF-1R β subunit by PP-2.  
c-Src has been shown to increase the phosphorylation of autophosphorylation sites of 
the IGF-1R β subunit both in vitro and in vivo (Peterson et al. 1996). Therefore, we 
determined the contribution of c-Src in ET-1 and Ang II-induced tyrosine phosphorylation of 
IGF-1R β subunit in A-10 VSMC. As shown in Fig.5, pretreatment of VSMC with PP-2 
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significantly attenuated vasoactive peptide-induced phosphorylation of IGF-1R β subunit. 
PP-3, on the other hand, was unable to inhibit IGF-1R phosphorylation induced by vasoactive 
peptides (Fig.5)  
2.4.6 Lack of Involvement of IGF-1R in ET-1/Ang II-induced c-Src 
phosphorylation. 
We have shown that H2O2-induced c-Src phosphorylation is mediated through IGF-
1R PTK  (Azar  et al. 2006). As a result, we investigated whether a similar mechanism was 
also involved in vasoactive peptide-induced increase in c-Src phosphorylation. As shown in 
Fig.6, pretreatment of cells with AG-1024 failed to inhibit Tyr418 phosphorylation of c-Src by 
either ET-1 or Ang II treatment.  
2.4.7 Attenuation of ET-1 and Ang II-induced protein and DNA synthesis 
by AG-1024 and PP-2.  
Both ET-1 and Ang II have been shown to induce increases in protein and DNA 
synthesis in mediating cell hypertrophy and proliferation (Bouallegue et al. 2007b; Di et al. 
2005; Haider et al. 2002; Yang et al. 2005; Hashim et al. 2006). Therefore, we examined 
whether IGF-1R and/or c-Src-PTK contributed in mediating the effect of ET-1 or Ang II on 
protein and DNA synthesis in A-10 VSMC. As shown in Fig.7, both of these vasoactive 
peptides increased the rate of protein (Fig.7.A) and DNA (Fig.7.B) synthesis, as determined 
by incorporation of [3H] Leucine into total cellular proteins and [3H] Thymidine into DNA of 
VSMC, respectively. However, the blockade of IGF-1R by AG-1024 or c-Src PTK activity 
by PP-2 significantly decreased both protein and DNA synthesis induced by these two 
vasoactive peptides. PP-3, an inactive analog of PP-2 had no effect (Fig.7). 
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2.5 Discussion 
There is an increasing body of evidence that suggests an important role of growth 
factor receptor transactivation in mediating vasoactive peptide-induced signaling pathways in 
VSMC. Among various growth factor receptors, the transactivation of EGFR has been 
studied in great detail in response to Ang II. However, transactivation of IGF-1R in triggering 
the responses of both ET-1 and Ang II remains poorly characterized. We provide evidence to 
suggest that ET-1 and Ang II, important GPCR ligands with a critical role in the pathogenesis 
of hypertensive vascular disease, induce the phosphorylation of PKB in an IGF-1R-
dependent fashion. We also show that both of these vasoactive peptides enhance the 
phosphorylation of key tyrosine residues in the autophosphorylation site of IGF-1R β subunit. 
Although Ang II has been shown to increase tyrosine phosphorylation of IGF-1R in VSMC 
(Lauzier et al. 2007; Zahradka et al. 2004; Du et al. 1996), and a role of IGF-1R 
transactivation in Ang II-induced phosphorylation of ERK1/2 and p70S6K has been suggested, 
no studies investigating the role of IGF-1R transactivation in either ET-1 or Ang II induced 
PKB phosphorylation in VSMC have been conducted. Thus, to our knowledge, the results 
reported here are the first to identify an involvement of IGF-1R in tranducing the downstream 
effects of ET-1 and Ang II in activating PKB in VSMC.  
 Another important finding of these studies is that the Src family of non-receptor PTKs 
are key mediators of ET-1/Ang II-induced PKB phosphorylation. We demonstrated that both 
of these vasoactive peptides can induce phosphorylation of Tyr 418 located in the activation 
loop of c-Src and that pharmacological blockade of c-Src-PTK activity not only inhibited ET-
1 and Ang II evoked phosphorylation of PKB, but also blocked IGF-1R tyrosine 
phosphorylation. These data suggest that c-Src is upstream of IGF-1R in the signaling 
cascade leading to PKB phosphorylation by both ET-1 and Ang II in VSMC. In fact, 
previous studies have shown that c-Src can catalyze the phosphorylation of IGF-1R β subunit 
on the same tyrosine residues that are autophosphorylated subsequent to the binding of IGF-
1R to its receptor (Peterson et al. 1996). Thus, c-Src-induced phosphorylation of these sites in 
IGF-1R in VSMC can trigger downstream effects leading to PKB phosphorylation. Earlier 
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work reported the phosphorylation of c-Src by ET-1 (Shah et al. 2006; Mishra et al. 2005) 
and Ang II (Eguchi et al. 1999b; Kyaw et al. 2004), and a requirement of c-Src in ET-1 and 
Ang II-induced PKB and p70S6K activation has been demonstrated (Bokemeyer et al. 2000; 
Zahradka et al. 2004). However, current studies indicate that c-Src activation is essential in 
triggering IGF-1R phosphorylation by ET-1 and, provide the molecular basis by which the 
ligand-independent transactivation of IGF-1R occurs in VSMC in response to vasoactive 
peptides. 
Both c-Src and IGF-1R have been implicated in the activation of NAD(P)H oxidase 
system (Touyz et al. 2003b; Touyz et al. 2003a), and since both ET-1and Ang II trigger their 
effect through ROS generation (Daou and Srivastava 2004; Touyz et al. 2004), it may be 
suggested that phosphorylation and activation of IGF-1R and c-Src is one of the early events 
in tranducing the signals of ET-1 and Ang II for ROS generation and subsequent activation of 
signaling pathways, linked to cellular hypertrophy and proliferation. This notion is supported 
by our results showing that blockade of IGF-1R PTK by AG-1024 or c-Src by PP-2 not only 
attenuated PKB phosphorylation but also attenuated protein as well as DNA synthesis 
induced by ET-1 and Ang II in A-10 VSMC. 
Involvement of PKB and its downstream effectors in regulating the hypertrophic and 
proliferative responses in VSMC has been suggested (Bouallegue et al. 2007a; Ivey et al. 
2008). Pharmacological blockade of PI3K activity with wortmannin was reported to inhibit 
ET-1 and Ang II-induced protein as well as DNA synthesis in VSMC (Li et al. 2006; Hashim 
et al. 2006). PKB activation results in the phosphorylation of several of its downstream 
substrates including mammalian target of rapamycin (mTOR) which has been implicated in 
the translational initiation of protein synthesis (Gingras et al. 2001). mTOR complex 1 
(mTORC1), through phosphorylation of ribosomal S6 kinases (S6K) and eukaryotic initiation 
factor 4E binding protein (eIF4EBPI) enhances translational efficiency of cap-dependant 
mRNA translation leading to enhanced protein synthesis and cell growth (Gingras et al. 
2004). PKB via its effects on cell cycle regulatory proteins such as p21cip1 and p27 kip1 is 
believed to control cell cycle progression and cell proliferation (Shin et al. 2002). 
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In conclusion, the results of this investigation demonstrate that ET-1 and Ang II 
induce the phosphorylation of PKB through a c-Src and IGF-1R PTK-dependent pathway, 
with c-Src being upstream to IGF-1R in this signaling cascade. Moreover, IGF-1R and c-Src 
appear to be key mediators of hypertrophic and proliferative responses of both ET-1 and Ang 
II in A-10 VSMC.  
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2.7 Figure legends  
Figure 1. Pharmacological blockade of IGF-1R abolishes ET-1 and Ang II-induced 
PKB phosphorylation in A-10 VSMCs.  
Serum-starved quiescent A-10 VSMC were pretreated in the absence (0) or presence of the 
indicated concentration of AG-1024 for 30 min followed by stimulation with 100nM of ET-
1 (section A) or Ang II (section B) for 5 min. Cell lysates were immunoblotted with 
phospho-specific-Ser473-PKB antibodies (top panels in each section). Blots were also 
analyzed for total PKB (middle panels of each section). Bottom panels (bar diagrams) in 
each section represent average data quantified by densitometric scanning of immunoblots 
shown in the top panel. Values are the means ± SE of at least three independent 
experiments and are expressed as percentages of phosphorylation, where phosphorylation 
observed with ET-1 alone (for section A) or Ang II alone (for section B) is defined as 
100%. P<0.05 was considered as statistically significance versus ET-1 stimulation alone for 
section A or versus Ang II alone for section B. * indicates that P<0.05; ** indicates that 
P<0.005 and † indicates that P<0.0005. 
Figure 2. Pharmacological blockade of IGF-1R attenuates ET-1 and Ang II-induced 
IGF-R phosphorylation in A-10 VSMCs.  
Serum-starved quiescent A-10 VSMC were pretreated in the absence (0) or presence of 
10µM AG-1024 for 30 min followed by stimulation with 100nM of ET-1 (section A) or 
Ang II (section B) for 5 min. Cell lysates were immunoblotted with phospho-specific-Tyr 
1131,1135,1136 IGF-1R antibodies (top panel in each section). Blots were also analyzed for total 
IGF-1R (middle panels of each section). Bottom panels (bar diagrams) in each section 
represent average data quantified by densitometric scanning of immunoblots shown in the 
top panel. Values are the means ± SE of at least three independent experiments and are 
expressed as percentages of phosphorylation, where phosphorylation observed with ET-1 
alone (for section A) or Ang II alone (for section B) is defined as 100%. P<0.05 was 
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considered as statistically significance versus ET-1 stimulation alone for section A or 
versus Ang II alone for section B. † indicates that P<0.0005. 
Figure 3. Pharmacological blockade of c-Src abolishes ET-1 and Ang II-induced PKB 
phosphorylation in A-10 VSMCs.  
Serum-starved quiescent A-10 VSMC were pretreated in the absence (0) or presence of 
10µM PP-3 or presence of the indicated concentration of PP-2 for 30 min followed by 
stimulation with 100nM of ET-1 (section A) or Ang II (section B) for 5 min. Cell lysates 
were immunoblotted with phospho-specific-Ser473-PKB antibodies (top panels in each 
section). Blots were also analyzed for total PKB (middle panels of each section). Bottom 
panels (bar diagrams) in each section represent average data quantified by densitometric 
scanning of immunoblots shown in the top panel. Values are the means ± SE of at least 
three independent experiments and are expressed as percentages of phosphorylation, where 
phosphorylation observed with ET-1 alone (for section A) or Ang II alone (for section B) is 
defined as 100%. P<0.05 was considered as statistically significance versus ET-1 
stimulation alone for section A or versus Ang II alone for section B. * indicates that 
P<0.05; ** indicates that P<0.005 and † indicates that P<0.0005. 
Figure 4.  Pharmacological blockade of c-Src attenuates ET-1 and Ang II-induced c-
Src phosphorylation in A-10 VSMCs.  
Serum-starved quiescent A-10 VSMC were pretreated in the absence (0) or presence of 
10µM PP-3 or presence of 10µM PP-2 for 30 min followed by stimulation with 100nM for 
5 min of ET-1 (section A) or Ang II (section B). Cell lysates were immunoblotted with 
phospho-specific-Tyr418-c-Src antibodies (top panels in each section). Blots were also 
analyzed for total cSrc (middle panels of each section). Bottom panels (bar diagrams) in 
each section represent average data quantified by densitometric scanning of immunoblots 
shown in the top panel. Values are the means ± SE of at least three independent 
experiments and are expressed as percentages of phosphorylation, where phosphorylation 
observed with ET-1 alone (for section A) or Ang II alone (for section B) is defined as 
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100%. P<0.05 was considered as statistically significance versus ET-1 stimulation alone for 
section A or versus Ang II alone for section B. † indicates that P<0.0005. 
Figure 5. Pharmacological blockade of c-Src attenuates ET-1 and Ang II-induced IGF-
1R phosphorylation in A-10 VSMCs.  
Serum-starved quiescent A-10 VSMC were pretreated in the absence (0) or presence of 
10µM PP-3 or presence of 10µM PP-2 for 30 min followed by stimulation with 100nM for 5 
min of ET-1 (section A) or Ang II (section B). Cell lysates were immunoblotted with 
phospho-specific-Tyr1131/1135/1136-IGF-1R antibodies (top panels in each section). Blots were 
also analyzed for total IGF-1R (middle panels of each section). Bottom panels (bar diagrams) 
in each section represent average data quantified by densitometric scanning of immunoblots 
shown in the top panel. Values are the means ± SE of at least three independent experiments 
and are expressed as percentages of phosphorylation, where phosphorylation observed with 
ET-1 alone (for section A) or Ang II alone (for section B) is defined as 100%. P<0.05 was 
considered as statistically significance versus ET-1 stimulation alone for section A or versus 
Ang II alone for section B. 
Figure 6. Pharmacological blockade of IGF-1R had no effect on ET-1 and Ang II-
induced c-Src phosphorylation in A-10 VSMCs.  
Serum-starved quiescent A-10 VSMC were pretreated in the absence (0) or presence of 
10µM AG-1024 for 30 min followed by stimulation with 100nM for 5 min of ET-1 (section 
A) or Ang II (section B). Cell lysates were immunoblotted with phosphor-specific Try418-c-
Src antibodies (top panel in each section). Blots were also analyzed for total c-Src (middle 
panels of each section). Bottom panels (bar diagrams) in each section represent average data 
quantified by densitometric scanning of immunoblots shown in the top panel. Values are the 
means ± SE of at least three independent experiments and are expressed as percentages of 
phosphorylation, where phosphorylation observed with ET-1 alone (for section A) or Ang II 
alone (for section B) is defined as 100%. P<0.05 was considered as statistically significance 
versus ET-1 stimulation alone for section A or versus Ang II alone for section B.  
  
 
87
Figure.7. Pharmacological blockade of IGF-1R or c-Src attenuates ET-1 and Ang II-
induced DNA and protein synthesis in A-10 VSMC.  
Serum-starved quiescent A-10 VSMC were stimulated with ET-1 or Ang II (100 nM). Cells 
were pretreated with or without either 5 μM of AG-1024, PP-2 or PP-3 for 30 min before 
ET-1 or Ang II stimulation. Cells were then labeled with [3H]Leucine (section A) or 
[3H]Thymidine (section B) for 20 h as described in Materials and Methods. Values are the 
means ± SE of three independent experiments and are expressed as percentage of change in 
[3H]leucine incorporated into total cellular proteins (section A) and in [3H]Thymidine 
incorporated into DNA (section B) over the basal values. P<0.05 was considered as 
statistically significance. * versus control, † versus ET-1 stimulation alone and ‡ versus 
Ang II stimulation alone.  
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Chapter 3 
Requirement of c-Src, a Non-Receptor Tyrosine Kinase 
in both Endothelin-1 and Angiotensin II-induced ERK 
1/2, JNK and p38 MAPK, as well as Egr-1 activation in 
Vascular Smooth Muscle cells. 
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3.1 Abstract 
A heightened activity of Endothelin-1 (ET-1) and angiotensin II (Ang II), key 
vasoactive peptides implicated in the maintenance of blood pressure and vascular 
homeostasis, is thought to contribute to the development of vascular pathologies, such as 
hypertension, atherosclerosis, hypertrophy and restenosis.  This occurs through the 
hyperactivation of growth promoting signal transduction pathways, including PI3K/PKB 
and the MAPK pathways, and regulation of transcription factors, such as early growth 
response factor-1 (Egr-1), which was recently shown to be expressed in atherosclerotic 
plaque.  We have previously shown that c-Src, a non-receptor protein tyrosine kinase (NR-
PTK), is an upstream regulator of ET-1 and Ang II-induced activation of PKB in vascular 
smooth muscle cells (VSMC).  However, the role of c-Src in ET-1-induced MAPK 
signaling remains controversial in VSMC. Therefore, in the present studies, we have 
investigated the involvement of c-Src in ET-1 and Ang II-induced ERK 1/2, JNK and p38 
MAPK activation, as well as Egr-1 regulation. ET-1 and Ang II-induced the 
phosphorylation of ERK 1/2, JNK and p38mapk, and enhanced the expression of Egr-1 in 
rat aortic A10 VSMC, as well as VSMC derived from thoracic aorta of adult Sprague 
Dawley rats.  This increased phosphorylation was decreased by PP-2, a specific 
pharmacological inhibitor of Src.  Further proof for the role of c-Src in this process was 
obtained by using mouse embryonic fibroblasts (MEF) deficient in c-Src (SYF). ET-1-
induced Egr-1 expression, as well as MAPK activation, was found to be downregulated in 
SYF, as compared to MEF expressing normal Src levels. In summary, these data indicate 
that c-Src PTK plays a critical role in mediating ET-1 and Ang II-induced MAPK 
phosphorylation and Egr-1 expression through a c-Src dependent mechanism in VSMC. 
Keywords: Endothelin-1, Angiotensin II, VSMC, ERK, JNK, p38 MAPK, c-Src, Egr-1. 
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3.2 Introduction 
Alterations in vascular smooth muscle cell (VSMC) growth, migration, proliferation 
and plasticity is believed to contribute to abnormal vascular functions associated with or 
leading to CVDs, such as hypertension, atherosclerosis, and stenosis after angioplasty 1-3.  
Under normal physiological conditions, vasoactive peptides, such as angiotensin II (Ang II) 
and endothelin-1 (ET-1), normalize blood pressure through the regulation of salt and/or 
water homeostasis, sympathetic nervous system modulation, as well as VSMC contraction 
and relaxation 4-7.  Increased levels of both ET-1 and Ang II, present in certain 
pathophysiological states, such as essential hypertension, obesity, or advanced stages of 
diabetes, have been suggested to contribute to the pathogenesis of CVDs, by activating 
signaling events intimately linked to migration and proliferation of VSMC 4, 8-10.  Ang II 
acts primarily through the activation of its two main receptors, Ang II type 1 receptor 
(AT1R) and Ang II type 2 receptor (AT2R), both of which are 7 transmembrane domain 
guanine nucleotide-binding protein (G Protein)-coupled receptors (GPCR) 11.  These 
receptors are primarily found in blood vessels, but also in heart, lung liver and brain tissues 
4.  ET-1 exerts its biological actions through the activation of its two receptor subtypes, ETA 
and ETB 12, 13, both of which, like the Ang II receptors, belong to the GPCR family.  GPCR 
stimulation leads to the activation of several downstream growth and proliferative signaling 
cascades, which include members of the mitogen-activated protein kinase (MAPK) family, 
as well as the phosphatidyl-inositol 3-kinase (PI3-K)/protein kinase B (PKB) pathway. 
MAPKs constitute a family of serine/threonine protein kinases which are widely 
conserved among eukaryotes, and are involved in many cellular responses, such as cell 
proliferation, cell differentiation, cell movement and cell death 14, 15.  The groups of 
vertebrate MAPK studied most extensively to date are ERK1/2, JNKs, and p38 MAPK 14, 
15.  ERK1/2 are stimulated by mitogens, such as polypeptide growth factors (IGF-1, 
platelet-derived growth factor (PDGF), colony stimulating factor-1 (CSF-1), etc.) as well as 
insulin and phorbol 12-myristate 13-acetate (PMA).  In contrast, SAPKs and p38 MAPK 
are potently induced by a wide variety of stressors, including ultraviolet irradiation, gamma 
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irradiation, anisomycin, heat shock and chemotherapeutic drugs.  Recent studies have also 
implicated SAPK/JNK and p38 MAPK in vasoactive peptide-induced proliferative 
responses 16-22.  These pathways are also activated by ischemia or reperfusion after 
ischemia, and by inflammatory cytokines 23.  Overwhelming evidence exists to support a 
vasoactive peptide-induced MAPK activation in multiple systems, including 
oligodendrocyte progenitor cells, pancreatic stellate cell, aortic and mesenteric artery-
derived VSMC, increasing cell growth and hypertrophy, leading to complications such as 
atrial fibrillation due to left ventricle hypertrophy, vascular remodelling, cardiac 
hypertrophy and coronary artery disease 24-29. 
 c-Src, also known as Src or p60c-Src, is a non-receptor protein tyrosine kinase (NR-
PTK).  In the vasculature, especially VSMC, GPCR-linked contractile responses, induced 
by Ang II and phenylephrine, have been associated with c-Src actvation 30, 31.  Furthermore, 
the use of PP-1 and PP-2, pyrazolopyrimidine-based selective inhibitors of Src family 
tyrosine kinases 32, has indicated a role of Src in mediating H2O2, ET-1 and Ang II-induced 
transactivation of the EGFR, IGF-1R and PDGFR in several cell types 33-37.  We have 
shown a role of c-Src in mediating ET-1 and Ang II-induced PKB phosphorylation, cell 
hypertrophy and proliferation 37.  Another study showed that, in VMSC derived from c-Src 
knockout mice, activation of ERK1/2 by Ang II was significantly decreased, as compared to 
VSMC from wild type mice 38, 39.  c-Src rescue in these cells through retroviral vector 
transfection caused a significant increase in Ang II-induced ERK1/2 phosphorylation, 
demonstrating that c-Src activation is necessary for Ang II-induced signal transduction in 
VSMC 39.  While both ET-1 and Ang II seem to activate PKB through the same c-Src-
dependent mechanism, a recent report has suggested that whereas Ang II activates MAPK 
signaling through a c-Src-dependent mechanism, ET-1 activates MAPK signaling through a 
c-Src-independent mechanism 38.  Despite the fact that the role of c-Src as a mediator of 
Ang II signaling is clear 37, 40, 41, its role in ET-1-induced signaling events remains 
controversial. 
 In the present studies, we examined the role of c-Src as an upstream regulator of 
both ET-1 and Ang II-induced ERK 1/2, JNK and p38 MAPK phosphorylation and 
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modulation of early response growth factor-1 (Egr-1), a transcription factor downstream of 
ERK1/2 that plays a regulatory role in several cardiovascular pathological processes, by 
down-regulating c-Src through pharmacological inhibition in aortic VSMC, as well as using 
a c-Src knockdown cell model. 
 
3.3 Materials and Methods 
3.3.1 Materials 
Chemicals.  Cell culture reagents were purchased from Gibco (Burlington, ON).  ET-1 was 
purchased from American Peptide (Sunnyvale, CA) and Ang II from Sigma Chemical 
(Oakville, ON). PP-2 and PP-3 were purchased from Calbiochem (Carlsbad, CA). The 
enhanced chemiluminescence (ECL) detection system kit was purchased from Amersham 
Pharmacia Biotech (Baie d’Urfé, QC).  
Antibodies. Phospho-SAPK/JNK (Thr183/Tyr185) (#4668), phospho-p38 MAPK 
(Thr180/Tyr182) (#4631), phospho-c-Src (Tyr416) (#2101), total SAPK/JNK (#9252), total 
GAPDH (#5174) and Anti-rabbit IgG, horseradish peroxidase-linked secondary antibody 
(#7074) were procured from Cell Signaling Technologies (Danvers, MA).  Phospho-
ERK1/2 (Thr202/Tyr204) (sc-16982-R), total ERK (sc-154), total p38 MAPK (sc-7972), 
total c-Src (sc-8056), total Egr-1 (sc-110) and anti-mouse IgG, horseradish peroxidase-
linked secondary antibody (sc-2005) were purchased from Santa Cruz Biotechnologies 
(Santa Cruz, CA). Anti-phospho-specific-c-Src (phospho-Tyr418) antibody was obtained 
from Invitrogene (Camarillo, CA). 
3.3.2Methods 
Cell culture.  Rat aorta A-10 VSMC (CRL-1476, ATCC) were maintained in 75-cm2 flasks 
culture with Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine 
serum and antibiotics at 37ºC in a humidified atmosphere of 5% CO2, as previously 
described 37.  Cells were passed upon reaching confluence with 0.5% trypsin-containing 
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0.2% EDTA and plated in 60mm dished.  Cells were grown to 90% confluence and 
incubated in serum-free DMEM 18h prior to the treatments.   
VSMC derived from thoracic aorta of eight week old Sprague Dawley rats were isolated as 
previously described 42.  Briefly, male Sprague-Dawley rats were sacrificed and the 
descending thoracic aorta was excised. Adhering fat and connective tissue were removed by 
blunt dissection. Vessels were then opened longitudinally and preincubated in DMEM 
containing 1 mg/ml type II collagenase, 0.5 mg/ml type I elastase, penicillin (100 U/ml), 
and streptomycin (100 g/ml) for 15-20 min at 37ºC. The adventitia was carefully removed 
under a dissecting microscope and the luminal surface scraped with forceps to remove 
endothelial cells. After dissection, aortas were placed in fresh enzyme solution, minced and 
incubated (37°C) for an additional 60-90 min with tituration at 30-min intervals. Solution 
was then centrifuged, and the pellet was gently resuspended in fresh DMEM containing 
10%FBS with antibiotics, and maintained in 75-cm2 flasks.  Cells were then maintained in 
the same fashion as A10 VSMC.  Cells from passages 3-8 were used for experimentation. 
Mouse embryonic fibroblasts deficient for c-Src, Yes and Fyn (SYF) (CRL-2459, ATCC) 
and expressing endogenous wild type c-Src but not Yes and Fyn (Src +/+)(CRL-2497, 
ATCC) were maintained in 75-cm2 flasks culture with Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% fetal bovine serum and antibiotics at 37ºC in a 
humidified atmosphere of 5% CO2.  Cells were passed upon reaching confluence with 0.5% 
trypsin-containing 0.2% EDTA and plated in 60mm dished.  Cells were grown to 90% 
confluence and incubated in serum-free DMEM 18h prior to the treatments. 
Cell lysis and Immunoblotting.  Cells incubated in the absence or presence of various 
agents were washed three times with ice-cold PBS and lysed in 200 µl of lysis buffer (25 
mM Tris-HCl, pH 7.5, 25 mM NaCl, 1 mM Na orthovanadate, 10 mM Na fluoride, 10 mM 
Na-pyrophosphate, 2 mM benzamidine, 2 mM ethylenebis (oxyethylenenitrolo)-tetra acetic 
acid, 2 mM ethylenediamine tetra acetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% 
Triton X-100, 0.1% sodium dodecyl sulfate (SDS) and 1% Protease Inhibitor Cocktail 
(PIC)) on ice. Cell lysates were centrifuged at 12,000g for 10 min at 4ºC. Protein 
concentrations were measured by Bradford assay. Equal amounts of protein were subjected 
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to 7.5% SDS-polyacrylamide gel (SDS-PAGE), transferred to PVDF membranes 
(Millipore, Billerica, MA) and incubated with respective primary antibodies.   The antigen-
antibody complex was detected by horseradish peroxidase-conjugated second antibody and 
protein bands were visualized by ECL. The intensity of specific bands was quantified by 
Quantity One Image Software (Bio-Rad, Hercules, CA). 
Egr-1 nuclear extraction protocol. To decrease dilution and interference by cytosolic 
proteins and to amplify the signal of Egr-1 in cell lysates, cells incubated in the absence or 
presence of pharmacological agents were lysed and nuclear protein was isolated for 
subsequent immunoblotting.  Briefly, cells were washed twice with ice-cold PBS and 
collected in 500μl of buffer solution containing 10mM Hepes, 10mM KCl, 0.1mM EDTA, 
0.1mM EGTA, 1mM PMSF, 1mM protease cocktail inhibitor and 1mM NaOV. Lysates 
were put on ice for 15 minutes before the addition of 10% NP40 detergent.  Lysates were 
then vortexed for 10 seconds at highest setting before being centrifuged at 13000RPM for 4 
minutes at 4oC. The supernatant (corresponding to the cytoplasmic fraction) was saved and 
transferred in a clean tube and stored at -80oC for future use. The pellet was resuspended in 
60μl, by pipeting up and down several times, in buffer containing 10mM Hepes, 400mM 
NaCl, 0.1mM EDTA, 0.1mM EGTA, 1mM PMSF, 1mM protease cocktail inhibitor and 
1mM NaOV. Lysates were sonicated by performing 6 cycles at 10 seconds per cycle with 
30 second intervals and then centrifuged at 13000 RPM for 5 minutes at 4oC. Pellet was 
discarded and the supernatant, corresponding to the nuclear fraction, was collected. Protein 
concentrations were measured using Bradford assay. 
Statistics.  The results presented are means ± SE of three independent experiments, 
performed in duplicate, with standard errors.  Statistical analyses were performed by 
analysis of variance (one-way ANOVA), followed by Dunnett’s multiple comparison post 
test, where applicable, using Prism 5 (GraphPAD software Inc.).  p values < 0.05 were 
considered significant. 
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3.4 Results 
3.4.1 Inhibition of c-Src PTK attenuates ET-1 and Ang II-induced 
phosphorylation of ERK 1/2 in A10 VSMC. 
Several studies have previously produced evidence supporting vasoactive peptide-
induced ERK 1/2 activation in multiple systems, including oligodendrocyte progenitor cells, 
pancreatic stellate cell, aortic and mesenteric artery-derived VSMC 24-29.  In this study, we 
confirmed that both ET-1 and Ang II, at a 100nM concentration, induced the phosphorylation 
of ERK 1/2, JNK and p38MAPK in a time dependent fashion in both A10 VSMC and 
isolated rat aortic VSMC and determined the time points at which peak phosphorylation 
occurred (data not shown).  Our lab has also recently demonstrated a role of c-Src in 
mediating ET-1 and Ang II-induced PKB phosphorylation through Tyr 418 phosphorylation 
of c-Src in VSMC, which was blocked by PP-2 (4-amino-5-(4-chlorophenyl)-7-(t-
butyl)pyrazole(3,4-d) pyrimidine), a specific blocker of Src family of PTK 37.  Here, by using 
PP-2, we have investigated a role of c-Src in ERK 1/2 phosphorylation in A10 VSMC.  As 
shown in Fig. 1, both ET-1 (panel A) and Ang II (panel B) potently enhanced the 
phosphorylation of ERK 1/2.  However, pre-treatment of A10 VSMC with PP-2 for 30 
minutes dose-dependently attenuated both ET-1 and Ang II-induced phosphorylation of ERK 
1/2.  However, PP-3 (4-amino-7-phenylpyrazole(3,4-d) pyrimidine), an inactive analog of 
PP-2, had no effect.  No alterations on the total amounts of ERK 1/2 were observed under 
these experimental conditions.  Similar experiments were performed in VSMC isolated from 
rat aorta and identical results were obtained (supplementary figure S1). 
3.4.2 ET-1 and Ang II-induced phosphorylation of JNK/SAPK and p38 
MAPK is attenuated by c-Src PTK inhibition in A10 VSMC. 
c-Jun N-terminal kinase (JNK) and p38 MAPK are both expressed in multiple cell 
types, including endothelial and VSMC.  While ERK 1/2 has been extensively studied in 
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terms of vasoactive peptide induced activation, the activation of JNK and p38mapk, being 
associated more often with inflammatory cytokines and cellular stress, is not.  Nonetheless, a 
few studies have shown an activation of JNK and p38 MAPK by Ang II and norepinephrine 
in cardiac myocytes, VSMC, and human mesangial cell.  Furthermore, the role of c-Src in the 
activation of JNK and p38 MAPK in VSMC has been examined in very few studies, which 
provide conflicting results as to the location of p38mapk in the cascade of signaling events 38, 
43.  Therefore, by using PP-2, we have investigated a role of c-Src in JNK and p38 MAPK 
phosphorylation in A10 VSMC.  Both ET-1 (panel A) and Ang II (panel B) potently 
enhanced the phosphorylation of JNK (Fig.2) and p38mapk (Fig.3).  Treatment of A10 
VSMC with PP-2 for 30 minutes prior to either ET-1 or Ang II stimulation dose-dependently 
inhibited JNK (Fig.2) and p38 MAPK (Fig.3) phosphorylation by both peptides.  PP-3, on the 
other hand, was unable to inhibit JNK or p38 MAPK phosphorylation induced by vasoactive 
peptides. No alterations on the total amounts of JNK or p38 MAPK were observed under 
these experimental conditions.  Similar experiments were performed in VSMC isolated from 
rat aorta and identical results were obtained (Supplementary figures S2 and S3). 
3.4.3 Inhibition of c-Src PTK attenuates ET-1-induced early growth 
response factor-1 (Egr-1) transcription factor expression in A10 VSMC. 
Recent studies have suggested that the Egr-1 transcription factor plays an important 
role in multiple cardiovascular pathological processes, including the pathogenesis of 
atherosclerotic lesions and neointimal thickening after vascular injury 44, 45.  Low levels of 
Egr-1 are generally found in normal vessels, yet its expression is rapidly increased in both 
endothelial and VSMC in response to injury, a state in which Egr-1 exerts potent chemotactic 
and mitogenic effects, possibly contributing to the vascular remodeling commonly observed 
in various pathological forms of vascular disease 46.  A growing number of studies have 
examined Egr-1 expression in response to Ang II in several cell types, including VSMC 47, 48, 
yet very little work has been done on ET-1-induced Egr-1 response.  Therefore, we wished to 
determine if ET-1 would upregulate Egr-1 expression in A10 VSMC. As shown in Fig.4, 
stimulation of serum-starved VSMC with 100nM ET-1 time-dependently increased 
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expression of Egr-1 protein (panel A).  To examine a role of c-Src in ET-1-induced Egr-1 
expression, cells were treated with either 10 µM PP-2 or PP-3 prior to ET-1 treatment for one 
hour.  PP-2 treatment decreased ET-1-induced Egr-1 expression in A10 VSMC (Fig.4 panel 
B) confirming the essential role of c-Src in Egr-1 expression.  PP-3, an inactive analog of PP-
2, was without any effect.  Similar experiments were performed in VSMC isolated from rat 
aorta and identical results were obtained (Supplementary figure S4). 
3.4.4 Effect of c-Src knockdown in ET-1 and Ang-II-induced ERK 1/2, 
JNK and p38  MAPK phosphorylation and Egr-1 expression 
To further confirm a role of c-Src PTK in vasoactive peptide-induced MAPK 
activation, we utilized mouse embryonic fibroblasts harvested from mouse embryos which 
have a functional null mutation in both alleles of the Src family PTK coding for c-Src (SYF) 
49.  Mouse embryonic fibroblasts expressing endogenous wild type c-Src (Src +/+) were used 
as control cells in these experiments.  Furthermore, to insure the decrease of c-Src in SYF 
cells as compared to Src +/+ cells, blots were probed with total c-Src antibody, and as seen in 
panel E of Fig.5, there is a clear decrease in c-Src content in the SYF cells as compared to the 
Src+/+ cells. 
Since previous studies have investigated a role of c-Src in Ang II-induced responses, 
we have focused on studying the uncertain role of c-Src in ET-1-induced responses.  As 
shown in Fig.5, ET-1 treatment caused a time-dependent increase of ERK 1/2 (panel A), JNK 
(panel B) and p38 MAPK (panel C) phosphorylation in c-Src +/+ cells, however, this 
response was blunted in SYF cells.  No alterations on the total amounts of ERK 1/2, JNK or 
p38 MAPK were observed under these experimental conditions.  Furthermore, to examine a 
role of c-Src in ET-1-induced Egr-1 expression, both SYF and Src+/+ cells were treated for 
1, 2 or 3 hours with 100 nM ET-1.  Cells were lysed and nuclear protein was isolated and 
immunoblotted for Egr-1.  As shown in panel D of Fig.5, ET-1-induced Egr-1 expression is 
decreased in SYF cells as compared to Src +/+ MEF.   
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3.5 Discussion 
c-Src is a member of the Src family of NR-TK, which contains at least 10 other 
members, including Blk, Brk, Fgr, Frk, Fyn, Hck, Lck, Lyn, Src, Srm, and Yes 50.  The Src 
family of NR-TK play a vital role in cell differentiation, proliferation, and survival signaling 
mechanisms, as well as in cell adhesion, morphology and motility (reviewed in 51). The 
studies performed here demonstrate a role of c-Src in both ET-1 and Ang II-induced ERK 
1/2, JNK and p38 MAPK phosphorylation, through pharmacological inhibition of c-Src in 
immortalized VSMC, primary culture of aortic VSMC derived from aorta of eight week old 
Sprague Dawley rats, as well as mouse embryonic fibroblast from c-Src knockout mice. 
The present data further suggest that both ET-1 and Ang II signal through a similar c-
Src dependent pathway, leading to MAPK activation, opposing the notion of the existence of 
2 distinct signaling pathways taken by ET-1 and Ang II, which lead to GPCR-mediated 
MAPK activation in VSMCs 38.  While Yogi et al. clearly show a role of c-Src in Ang II-
induced MAPK activation, they identified ET-1-induced ERK 1/2 and JNK phosphorylation 
as a c-Src-independent event.  Curiously, ET-1-induced p38 MAPK phosphorylation was 
inhibited in c-Src -/- mesenteric VSMC 38.  Our findings clearly demonstrate that ET-1-
induced p38 MAPK phosphorylation is inhibited by PP-2 just as potently as ET-1-induced 
ERK 1/2 and JNK phosphorylation in aortic VSMC and mouse embryonic fibroblasts.  A 
recent study showing that incubation of aortic rings with ET-1 leads to an increase in ERK 
1/2 phosphorylation, which was suppressed by co-incubation with PP-2, further supports a 
role of c-Src as an upstream regulator of MAPK activation 52.  Thus, the work presented here, 
as well as previous work from our laboratory 37 and that of others 52, supports the notion that 
c-Src is an important regulator of both ET-1 and Ang II-induced hypertrophic and 
proliferative signaling pathways in VSMCs.  This is in contrast to work showing that Src 
tyrosine kinases do not contribute to vascular trophic signaling of ET-1 53. 
Previous studies from our laboratory have detected c-Src Tyr 418 phosphorylation 
induced by ET-1, Ang II and H2O2 in as little as five minutes in VSMC 37, 54 which is in 
contrast to studies in whole aorta, where c-Src phosphorylation was detected only after 
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several hours of treatment with ET-1 52.  In these studies, it was demonstrated that both of 
these vasoactive peptides can induce the Tyr 418 phosphorylation of c-Src activity, in VSMC 
and that pharmacological inhibition of c-Src by PP-2 not only inhibited ET-1 and Ang II-
induced c-Src phosphorylation, but also inhibited IGF-1R tyrosine phosphorylation, as well 
as PKB phosphorylation and activation 37.  These studies imply that c-Src activation is 
essential in triggering IGF-1R phosphorylation by both Ang II and ET-1, and therefore 
provide a molecular basis by which the ligand-independent transactivation of IGF-1R occurs 
in VSMC, in response to vasoactive peptides 37.  Thus, our present and past findings provide 
evidence to support that ET-1 and Ang II lead to phosphorylation and subsequent activation 
of c-Src through Tyr 418 phosphorylation, and not solely through de novo synthesis of c-Src, 
as suggested by other studies 52. 
The results presented here also reveal a role of c-Src in ET-1-induced Egr-1 
expression in VSMC.  Egr-1, which plays an important role in vascular biology, belongs to 
the family of zinc finger transcription factors which also includes Egr-2, Egr-3, and Egr-4 55.  
It is an 80-82 kDa nuclear phosphoprotein expressed in multiple cell types, including both 
endothelial and VSMCs, following stimulation by either cytokines or inflammatory stimuli 
(i.e. hypoxia, shear stress, etc...) or growth factors (EGF, PDGF).  These studies lead to 
vascular remodelling and the development of vascular diseases like atherosclerosis and 
restenosis 56-58.  However, Egr-1 is very weakly expressed in normal, healthy vessel wall 
tissue.  Several studies, including one in VSMCs, have investigated the capacity of Ang II to 
stimulate Egr-1 protein and mRNA expression 59, yet few have investigated the role of ET-1-
induced Egr-1 expression.  Furthermore, these studies were not performed in VSMC, but 
either in cardiomyocytes or mouse muscle cells, and were not able to correlate ET-1-induced 
Egr-1 mRNA with an increase in functional Egr-1 protein in these cells 60, 61.  Our results 
clearly demonstrate that ET-1 treatment of VSMC and mouse embryonic fibroblasts induces 
the expression of Egr-1 protein in as little as 1 hour.  We further show that pharmacological 
blockade or genetic knockdown of c-Src PTK inhibits ET-1-induced Egr-1 expression in both 
cell types.  Therefore, to our knowledge, the results presented in this study are the first to 
explore the role of c-Src in ET-1-induced Egr-1 expression in VSMC.  ERK1/2 has also 
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proven to play an important role in Egr-1 activation in both endothelial and VSMC 59, 62 
through work demonstrating that inhibition of Egr-1 gene expression inhibits VSMC 
migration and proliferation 63.  Thus, it may be suggested that the downregulation of ET-1-
induced VSMC hypertrophy and proliferation by c-Src inhibition, demonstrated in our 
previous studies 37, may be due to its capacity to regulate MAPK signaling and Egr-1 protein 
expression.  This notion is supported by work showing that the blockade of ET-1-induced 
Egr-1 mRNA through antisense oligonucleotides (ASO) inhibited ET-1-induced hypertrophy 
in isolated rat cardiomyocytes 64. 
In summary, the results of this investigation demonstrate that ET-1 and Ang II induce 
the phosphorylation of ERK 1/2, JNK and p38 MAPK through a c-Src PTK-dependent 
pathway.  Moreover, c-Src appears to be a key mediator of ET-1-induced Egr-1 expression, 
further clarifying the signaling mechanisms implicated in mediating the hypertrophic and 
proliferative responses of both ET-1 and Ang II in aortic VSMC. 
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3.7 Figure legends  
Figure 1. Pharmacological blockade of c-Src abolishes ET-1 and Ang II-induced 
ERK1/2 phosphorylation in A10 VSMCs. Serum-starved quiescent A10 VSMC were 
pretreated in the absence (0) or presence of 10µM PP-3 or the indicated concentration of 
PP-2 for 30 minutes, followed by stimulation with ET-1 (100nM) (panel A) or Ang II 
(100nM) (panel B) for 5 min. Cell lysates were immunoblotted with phospho-specific-
Thr202/Tyr204-ERK1/2 antibodies. Blots were also analyzed for total ERK.  Bar diagrams 
in each panel represent average data quantified by densitometric scanning of immunoblots 
shown in the same panel. Values are the means ± SE of three independent experiments and 
are expressed as a fold increase in phosphorylation, where basal phosphorylation observed 
(no stimulation) is defined as 1.  P<0.05 was considered as statistically significance versus 
ET-1 stimulation alone in panel A or versus Ang II alone in panel B. * indicates that 
P<0.05; ** indicates that P<0.001 and *** indicates that P<0.0001. 
Figure 2.  Pharmacological blockade of c-Src attenuates ET-1 and Ang II-induced 
JNK phosphorylation in A10 VSMCs. Serum-starved quiescent A10 VSMC were 
pretreated in the absence (0) or presence of 10µM PP-3 or the indicated concentration of 
PP-2 for 30 minutes, followed by stimulation with ET-1 (100nM) (panel A) or Ang II 
(100nM) (panel B) for 5 min. Cell lysates were immunoblotted with phospho-specific-
Thr183/Tyr185-JNK antibodies. Blots were also analyzed for total JNK.  Bar diagrams in 
each panel represent average data quantified by densitometric scanning of immunoblots 
shown in the same panel. Values are the means ± SE of three independent experiments and 
are expressed as a fold increase in phosphorylation, where basal phosphorylation observed 
(no stimulation) is defined as 1.  P<0.05 was considered as statistically significance versus 
ET-1 stimulation alone in panel A or versus Ang II alone in panel B. * indicates that 
P<0.05; ** indicates that P<0.001 and *** indicates that P<0.0001. 
Figure 3.  Pharmacological blockade of c-Src attenuates ET-1 and Ang II-induced p38 
MAPK phosphorylation in A10 VSMCs. Serum-starved quiescent A10 VSMC were 
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pretreated in the absence (0) or presence of 10µM PP-3 or the indicated concentration of 
PP-2 for 30 minutes, followed by stimulation with ET-1 (100nM) (panel A) or Ang II 
(100nM) (panel B) for 5 min. Cell lysates were immunoblotted with phospho-specific-
Thr180/Tyr182-p38 MAPK antibodies. Blots were also analyzed for total p38 MAPK.  Bar 
diagrams in each panel represent average data quantified by densitometric scanning of 
immunoblots shown in the same panel. Values are the means ± SE of three independent 
experiments and are expressed as a fold increase in phosphorylation, where basal 
phosphorylation observed (no stimulation) is defined as 1.  P<0.05 was considered as 
statistically significance versus ET-1 stimulation alone in panel A or versus Ang II alone in 
panel B. * indicates that P<0.05; ** indicates that P<0.001 and *** indicates that 
P<0.0001.  
Figure 4.  Pharmacological blockade of c-Src attenuates ET-1-induced Egr-1 protein 
expression in A10 VSMCs. Serum-starved quiescent A10 VSMC were treated without (0) 
or with 100nM ET-1 for the indicated time periods (section A) or were pretreated in the 
absence (0) or presence of 10µM PP-3 or 10µM PP-2 for 30 minutes, followed by 
stimulation with ET-1 (100nM) (panel B).  Nuclear protein was isolated from cell lysates 
and immunoblotted by Egr-1 antibody as shown in the top panels of each section. Blots 
were analyzed for total nuclear protein by GAPDH (middle panels of each section). Bottom 
panels (bar diagrams) represent average data quantified by densitometric scanning of 
immunoblots showing in the middle panel. Values are the means ± SE of three independent 
experiments and are expressed as fold increase of protein expression where basal 
expression observed (no stimulation) is defined as 1. P<0.05 was considered as statistically 
significance versus no stimulation (0), or versus ET-1 stimulation alone in panel B. * 
indicates that P<0.05; ** indicates that P<0.001 and *** indicates that P<0.0001. 
Figure 5: ET 1-induced ERK 1/2, JNK and p38 MAPK phosphorylation, as well as 
Egr-1 expression is downregulated in SYF MEF but not in SRC +/+ MEF.  Confluent, 
serum-starved SRC +/+ and SYF MEF were treated with 100 nM ET-1 for indicated time 
points. The cells were lysed and lysates were subjected to immunoblotting using phospho-
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specific Thr 202/Tyr 204-ERK and total ERK antibodies (panel A), phospho-specific-
Thr183/Tyr185-JNK and total JNK antibodies (panel B) and phospho-specific-
Thr180/Tyr182-p38 MAPK and total p38 MAPK antibodies (panel C).  To detect Egr-1, 
nuclear protein was isolated from cell lysates and immunoblotted with Egr-1 antibody and 
GAPDH (panel D).  Immunoblots were also probed with total Src antibody to measure for 
levels of Src in SYF and Src +/+ MEF (panel E).  Values are the means ± SE of three 
independent experiments and are expressed as fold increase of protein expression where 
basal expression observed (no stimulation) is defined as 1. P<0.05 was considered as 
statistically significance versus no stimulation (0).  * indicates that P<0.05; ** indicates 
that P<0.001 and *** indicates that P<0.0001. 
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3.11 Supplementary Figure Legends 
S1. Pharmacological blockade of c-Src abolishes ET-1 and Ang II-induced ERK1/2 
phosphorylation in SD VSMCs. Serum-starved quiescent SD VSMC were pretreated in 
the absence (0) or presence of 10µM PP-3 or the indicated concentration of PP-2 for 30 
minutes, followed by stimulation with ET-1 (100nM) (panel A) or Ang II (100nM) (panel 
B) for 5 min. Cell lysates were immunoblotted with phospho-specific-Thr202/Tyr204-
ERK1/2 antibodies. Blots were also analyzed for total ERK.  Bar diagrams in each panel 
represent average data quantified by densitometric scanning of immunoblots shown in the 
same panel. Values are the means ± SE of three independent experiments and are expressed 
as a fold increase in phosphorylation, where basal phosphorylation observed (no 
stimulation) is defined as 1.  P<0.05 was considered as statistically significance versus ET-
1 stimulation alone in panel A or versus Ang II alone in panel B. * indicates that P<0.05; ** 
indicates that P<0.001 and *** indicates that P<0.0001. 
S2.  Pharmacological blockade of c-Src attenuates ET-1 and Ang II-induced JNK 
phosphorylation in SD VSMCs. Serum-starved quiescent SD VSMC were pretreated in 
the absence (0) or presence of 10µM PP-3 or the indicated concentration of PP-2 for 30 
minutes, followed by stimulation with ET-1 (100nM) (panel A) or Ang II (100nM) (panel 
B) for 5 min. Cell lysates were immunoblotted with phospho-specific-Thr183/Tyr185-JNK 
antibodies. Blots were also analyzed for total JNK.  Bar diagrams in each panel represent 
average data quantified by densitometric scanning of immunoblots shown in the same 
panel. Values are the means ± SE of three independent experiments and are expressed as a 
fold increase in phosphorylation, where basal phosphorylation observed (no stimulation) is 
defined as 1.  P<0.05 was considered as statistically significance versus ET-1 stimulation 
alone in panel A or versus Ang II alone in panel B. * indicates that P<0.05; ** indicates 
that P<0.001 and *** indicates that P<0.0001. 
S3.  Pharmacological blockade of c-Src attenuates ET-1 and Ang II-induced p38 
MAPK phosphorylation in SD VSMCs. Serum-starved quiescent SD VSMC were 
pretreated in the absence (0) or presence of 10µM PP-3 or the indicated concentration of 
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PP-2 for 30 minutes, followed by stimulation with ET-1 (100nM) (panel A) or Ang II 
(100nM) (panel B) for 5 min. Cell lysates were immunoblotted with phospho-specific-
Thr180/Tyr182-p38 MAPK antibodies. Blots were also analyzed for total p38 MAPK.  Bar 
diagrams in each panel represent average data quantified by densitometric scanning of 
immunoblots shown in the same panel. Values are the means ± SE of three independent 
experiments and are expressed as a fold increase in phosphorylation, where basal 
phosphorylation observed (no stimulation) is defined as 1.  P<0.05 was considered as 
statistically significance versus ET-1 stimulation alone in panel A or versus Ang II alone in 
panel B. * indicates that P<0.05; ** indicates that P<0.001 and *** indicates that P<0.0001. 
S4.  Pharmacological blockade of c-Src attenuates ET-1-induced Egr-1 protein 
expression in SD VSMCs. Serum-starved quiescent SD VSMC were treated without (0) or 
with 100nM ET-1 for the indicated time periods (section A) or were pretreated in the 
absence (0) or presence of 10µM PP-3 or 10µM PP-2 for 30 minutes, followed by 
stimulation with ET-1 (100nM) (panel B).  Nuclear protein was isolated from cell lysates 
and immunoblotted by Egr-1 antibody as shown in the top panels of each section. Blots 
were analyzed for total nuclear protein by GAPDH (middle panels of each section). Bottom 
panels (bar diagrams) represent average data quantified by densitometric scanning of 
immunoblots showing in the middle panel. Values are the means ± SE of three independent 
experiments and are expressed as fold increase of protein expression where basal 
expression observed (no stimulation) is defined as 1. P<0.05 was considered as statistically 
significance versus no stimulation (0), or versus ET-1 stimulation alone in panel B. * 
indicates that P<0.05; ** indicates that P<0.001 and *** indicates that P<0.0001. 
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Ang II is a powerful vasoconstricting octapeptide cleaved from angiotensin I 
(Ang I) by angiotensin converting enzyme (ACE), and is an integral part of the renin-
angiotensin-system (RAS) 456.  The principal physiological function of Ang II is the acute 
regulation of vascular tone to regulate blood pressure.  ET-1 is one of the most potent 
vasoconstrictor peptides in circulation, responsible for regulating vascular tone and blood 
pressure through various mechanisms, such as salt and water homeostasis, as well as 
affecting the sympathetic nervous system 54-56. It is produced mainly by the cardiovascular 
system, primarily by endothelial cells in the vasculature 457, but is also produced by the 
heart, kidney, posterior pituitary and central nervous system 458.  Under normal 
physiological conditions Ang II and ET-1 normalize blood pressure through the regulation 
of salt and/or water homeostasis, sympathetic nervous system modulation, as well as 
VSMC contraction and relaxation 53-56.  Increased levels of both ET-1 and Ang II, present 
in certain pathophysiological states, such as essential hypertension, obesity, or advanced 
stages of diabetes, have been suggested to contribute to the pathogenesis of CVDs, by 
activating signaling events intimately linked to migration and proliferation of VSMC 53, 57-
59.  Ang II and ET-1 both exert their biological actions through their own respective GPCR 
receptor subtypes, described earlier.  
Kinases, such as those activated by Ang II and ET-1, are amongst the highest 
represented known functions in the human genome 459.  Genome sequencing has revealed 
more than 520 protein kinases and approximately 130 protein phosphatases, which 
counteract kinase action 460.  Protein kinases can generally be separated into 2 groups, 
consisting of the tyrosine kinases, which once activated, phosphorylate substrates on 
tyrosine residues (e.g. IGF-1R, PYK2) or serine/threonine kinases, which phosphorylate 
substrates on serine and/or threonine residues (e.g. ERK1/2, PKB).  Tyrosine kinases play a 
vital role in regulating multiple intracellular signaling pathways, responsible for cellular 
metabolism, survival, growth and programmed cell death 382, 422, 461-463.  Tyrosine kinase 
activity is very well regulated in normal physiological states, yet these kinases are often 
found in altered or mutated states in pathological conditions involving uncontrolled tissue 
or cell growth, such as cancers and cardiovascular diseases, due to their regulation of 
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growth promoting pathways 460, 464, 465.  This group of tyrosine kinases can further be 
separated into two groups consisting of R-PTK and NR-PTK.  The usual mechanism of 
action consists of the R-PTK being activated through ligand binding, causing its 
dimerisation (if not already present as a dimer), which leads to the activation of its kinase 
activity, and subsequent autophosphorylation in tyrosine residues.  These phosphorylated 
tyrosine residues serve as docking sites for other anchoring proteins and/or NR-PTK, which 
help propagate the downstream signaling of the ligand 466, activating signaling cascades 
such as the PI3K/PKB and MAPK pathways.  As mentioned in earlier chapters, ligand-
independent activation, or transactivation, of R- and NR-PTK has been implicated in 
transducing the downstream effects of GPCR, leading to the stimulation of the PI3-K/PKB 
and MAPK cascades, which are involved in mediating the migratory, proliferative, and 
hypertrophic responses of ET-1 and Ang II 50, 64, 417, 462, 467.  
The results presented in this thesis demonstrate a requirement of IGF-1R in ET-1-
induced PKB phosphorylation in VSMC 64.  In these studies, AG-1024, a specific inhibitor of 
IGF-1R PTK, attenuated ET-1-induced PKB phosphorylation in a dose-dependent manner.  
ET-1 treatment also induced the phosphorylation of key tyrosine residues in the auto-
phosphorylation sites of the IGF-1R, which was blocked by AG-1024.  We have also 
provided evidence to suggest an involvement of c-Src in ET-1-induced tyrosine 
phosphorylation of IGF-1R.  We found that pre-treatment of VSMC with PP-2, a specific 
inhibitor of the Src family of PTK, significantly reduced ET-1-induced phosphorylation of 
IGF-1R.  Interestingly, this treatment also inhibited ET-1-induced PKB phosphorylation in 
VSMC.  ET-1-induced phosphorylation of IGF-1R has also been demonstrated in prostate 
cancer cell lines 468.  Similar to our observations in VSMC, c-Src activation was required to 
induce ET-1-induced PKB phosphorylation in these cell lines 468.  It thus appears that c-Src 
serves an upstream role in Ang II and ET-1-induced, ligand-independent phosphorylation of 
IGF-1R.  It should be noted that c-Src is able to increase the tyrosine phosphorylation of the 
autophosphorylation sites on the IGF-1R β subunit 469. 
Furthermore, both protein and DNA synthesis enhanced by Ang II and ET-1 were also 
attenuated by pharmacological blockade of IGF-1R by AG-1024, suggesting an important 
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role of IGF-1R in mediating PKB phosphorylation, as well as hypertrophic and proliferative 
responses induced by ET-1 in A10 VSMC 470. 
There is also some evidence indicating that transactivation of EGFR mediates the 
responses of IGF-1R in some cell types, suggesting the existence of a cross-talk between 
IGF-R and EGFR transactivation 471.  Moreover, the studies showing that dominant 
negative or antisense oligonucleotide (ASO) of IGF-1R are able to attenuate neointima 
formation in an injured carotid artery rat model 403 and reduce Ang II type 1 receptor 
(AT1R) expression and function in spontaneously hypertensive rats (SHR) 402 supports a 
potential pathogenic role of upregulated IGF-1R signalling in vascular disease. 
In addition to the PKB pathway, ET-1 and Ang II-induced GPCR stimulation leads 
to the activation of the mitogen-activated protein kinase (MAPK) family, including ERK 
1/2, JNK and p38 MAPK.  While both ET-1 and Ang II seem to activate PKB through a c-
Src-dependent mechanism, with a role of c-Src as a mediator of Ang II signaling 64, 472, 473, 
its role in ET-1-induced signaling events remains controversial 474, with recent reports 
suggesting that Ang II activates MAPK signaling through a c-Src-dependent mechanism, 
whereas ET-1 activates MAPK signaling through a c-Src-independent mechanism 418. 
The results presented in this thesis are aimed at defining a role of this NR-PTK in 
ET-1-induced MAPK signaling.  In these studies, PP-2 was found to reduce both ET-1 and 
Ang II-induced ERK 1/2, JNK and p38 MAPK phosphorylation in A10 VSMC, as well as 
in primary cultures of Sprague Dawley rat thoracic aorta.  These results are supported by 
studies showing that ET-1-induced ERK 1/2 phosphorylation is suppressed by co-
incubation with PP-2, identifying c-Src as an upstream regulator of MAPK activation in 
aortic rings 475.   
To further confirm our hypothesis that c-Src is an important modulator of ET-1-
induced MAPK signaling, we utilized mouse embryonic fibroblast harvested from mouse 
embryos which have a functional null mutation in both alleles of the Src family PTK 
coding for c-Src, Yes and Fyn (SYF), the three main members of the Src PTK family 476.  
ET-1-induced phosphorylation of all three MAPKs studied was attenuated in SYF cells, yet 
remained normal in mouse embryonic fibroblasts expressing normal c-Src.  We have also 
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demonstrated that inhibition of c-Src, by pharmacological or genetic approaches, blunted 
the expression of ET-1-induced Egr-1, a transcription factor implicated in multiple 
cardiovascular pathological processes, including the pathogenesis of atherosclerotic lesions 
and neointimal thickening after vascular injury.  Therefore, the work presented in this 
thesis, and that of others 475, provides solid evidence and supports the notion that c-Src is an 
important regulator of vasoactive peptide-induced hypertrophic and proliferative signaling 
pathways.  However, the specific participation of a precise R- or NR-PTK in mediating 
vasoactive peptide-induced responses may be dependent on the cell type and the expression 
levels of the R- and NR-PTKs in those cells. As a result, it may be possible that c-Src-
dependent and -independent pathways contribute to both ET-1 and Ang II-induced 
signaling, which may vary from cell type to cell type, and may be a possible reason for the 
discrepancy between our work and that of others. 
While the precise events that trigger the transactivation of R-/NR-PTK in response 
to vasoactive peptides are not clear, several mechanisms have been suggested.  Studies 
have shown that inhibitors of matrix metalloproteinases (MMP), such as GM6001 and 
doxycyclin, attenuated ET-1 and Ang II-induced EGFR transactivation 438, 439.  MMPs act 
mainly by disrupting the link between growth factors and their transmembrane precursors, 
as is the case for heparin-bound-EGF (HB-EGF), allowing EGF to bind to EGFR, and 
leading to tyrosine kinase activation and stimulation of hypertrophic and growth promoting 
signaling cascades 440. 
Another proposed mechanism of R-PTK transactivation by vasoactive peptides is 
through their capacity to induce the generation of reactive oxygen species (ROS).  ROS are 
formed as intermediates in redox reactions, leading from molecular oxygen (O2) to water 
(H2O).  These small, quickly-diffusible and highly-reactive molecules are classified into 
superoxide anion   (.O2-), hydroxyl radical (.OH) and hydrogen peroxide (H2O2) 477.  A 
major intracellular source of ROS is the mitochondria, which converts 1-2% of consumed 
O2 to .O2- 478.  A univalent reduction of O2 leads to .O2-, which is relatively unstable and 
short-lived because of its unpaired electron. 
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 NAD(P)H oxidase is among the primary enzymes responsible for the generation of 
.O2- 446, and is composed of many subunits, including p22phox, p47phox, gp91phox, the 
GTPase Rac and the recently-identified Nox1 and Nox4 446, 479-481.  NAD(P)H oxidase 
catalyzes .O2- production by the one electron reduction of O2, where NAD(P)H is the 
electron donor.  In addition to NAD(P)H oxidases, O2- can also be generated by 
xanthine/xanthine oxidase, lipooxygenase, and cyclooxygenase 482, 483 (Figure 11). 
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Figure 11: Key steps in the production of reactive oxygen species (ROS) by 
vasoactive peptides.  NAD(P)H oxidase catalyzes superoxide anion (.O2-) production by 
the 1 electron reduction of O2, where NAD(P)H is the electron donor.  In addition to 
NAD(P)H oxidases, O2- can also be generated by xanthine/xanthine oxidase, 
lipooxygenase, and cyclooxygenase. .O2- undergoes dismutation either spontaneously or 
by a reaction catalyzed by superoxide dismutase (SOD) to produce H2O2. Normally, it is 
scavenged by catalase and glutathione peroxidase to produce H2O.  In the presence of 
metal-containing molecules such as Fe2+, H2O2 can also be reduced to generate the 
extremely-active hydroxyl radical (.OH) that causes damage to cell components. 
(Adapted from Vardatsikos et al., Antioxid Redox Signal., 2009, 11(5):1165-90.) 
Glutathione peroxidase 
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 Under physiological conditions, .O2- undergoes dismutation either spontaneously or 
by a reaction catalyzed by superoxide dismutase (SOD) to produce H2O2 (Figure 11).  
Dismutation of .O2- by SOD is favored at low concentrations of .O2- and at high 
concentrations of SOD, which occurs under physiological conditions.  H2O2 is much more 
stable than .O2-, can cross cell membranes and has a longer half-life. Normally, it is 
scavenged by catalase and glutathione peroxidase to produce H2O 484 (Figure 11).  In the 
presence of metal-containing molecules such as Fe2+, H2O2 can also be reduced to generate 
the extremely-active hydroxyl radical (.OH) that causes damage to cell components 485 
(Figure 11).  In the glutathione peroxidase reaction, glutathione (GSH) is oxidized to 
glutathione disulfide (GSSG), which can be converted back to GSH by glutathione 
reductase in a NAD(P)H-consuming process.  Several forms of SOD are known: copper-
zinc SOD (Cu/Zn-SOD), mitochondrial or manganese SOD (Mn-SOD), extracellular SOD 
type C (EC SOD C) and iron-containing SOD (Fe-SOD) 486, 487.  Normally, the rate of ROS 
production is balanced by the rate of their elimination.  However, in pathological 
conditions, a disequilibrium between ROS generation and elimination results in increased 
ROS bioavailability, leading to oxidative stress 488.  Under these conditions, .O2- can react 
with nitric oxide (NO) to produce peroxynitrite ONOO- 489, which is reduced to form its 
conjugate acid, peroxynitrous acid (ONOOH), a reactive and unstable oxidizing species.  
NO is also implicated in the production of nitrite (NO2-), which can be oxidized to produce 
nitrogen dioxide (NO2), a nitrogen intermediate, which along with an .OH group forms 
nitrate (NO3-).  ONOO- and its metabolites are capable of tyrosine nitration in multiple 
proteins, evoking changes in their conformation, structure and catalytic activity 490. 
Ang II has also been shown to induce ROS generation in multiple cell types, 
including cardiomyocytes, endothelial cells and VSMC 444-446, which appears to play a 
direct role in Ang II-induced vascular hypertrophy through the activation of hypertrophic 
signaling pathways 447, 448. ET-1 has been also shown to activate NAD(P)H oxidase, 
resulting in ROS generation in endothelial cells 441, and increased H2O2 levels via ETA 
receptor binding in pulmonary smooth muscle cells 442.  This increase in ROS generation 
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has been linked with the ET-1-induced activation of ERK1/2, JNK, p38 MAPK, PKB and 
PYK2 203, 443.    ET-1-induced ROS generation in VSMC was suppressed by N-
Acetylcysteine (NAc), a ROS scavenger, and diphenyleneiodonium (DPI), an inhibitor of 
NAD(P)H oxidase 203.  DPI and NAc pre-treatment of VSMC also inhibited ET-1-induced 
ERK1/2, PKB, and PYK2 phosphorylation, demonstrating that ROS are critical mediators 
of ET-1-induced signaling events linked to growth-promoting proliferative and 
hypertrophic pathways in VSMCs.  Observations that both ROS e.g. H2O2, and vasoactive 
peptides, induce the tyrosine phosphorylation of IGF-1R and EGFR, and pharmacological 
blockade or genetic ablation of the R- and/or NR-PTK activity resulted in the attenuation of 
ET-1 and Ang II-induced ERK1/2 and PKB phosphorylation have suggested that ROS may 
serve as intermediates to enhance the tyrosine phosphorylation of R- and NR-PTKs 64, 415, 
421, 423, 449.  Further support for a role of ROS in modulating R/NR-PTK function has been 
provided by reports where Ang II was shown to enhance the expression of IGF-1R through 
ROS-dependant mechanism in VSMC 491. 
ROS may directly target growth factor receptors such as IGF-1R, platelet-derived 
growth factor receptor (PDGFR) and epidermal growth factor receptor (EGFR) 483, which 
can induce intracellular ROS generation 492.  Receptor tyrosine kinases have been 
implicated in Ang II signaling by Ang II type 1 receptor (AT1R)-mediated transactivation 
493. This transactivation may involve Ang II-mediated NAD(P)H-dependent ROS 
formation, followed by MAPK activation.  Furthermore, transactivation of IGF-1R and 
EGFR via Ang II has been shown to activate p38 MAPK, ERK5 and ERK 1/2 in VSMCs 
396.  Recent studies have also suggested that growth factors, such as IGF-1, signal through 
ROS-dependent transactivation of EGFR 471, and a role of NAD(P)H oxidase 4 (NOX4) in 
IGF-induced production has been demonstrated in VSMC 494.  ROS/RNS are capable of 
activating NR-PTKs, such as Src and Janus Kinase (JAK), which have been shown to play 
a role in H2O2-induced activation of p21Ras 495, as well as several transcription factors, 
such as NF-κB and activator protein-1, a transcription complex consisting of dimers of Fos-
Jun or Jun-Jun proteins 496, leading to cell growth and differentiation by activation of the 
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PI3-K-Akt/PKB signaling pathway.  Ang II-mediated MAPK and apoptosis signaling-
regulated kinase 1 (ASK1) activation may also be involved 341.   
  In addition to its effects on receptor and non-receptor PTKs, growth factor or 
vasoactive peptide-induced ROS can potentially oxidize and inactivate multiple protein 
tyrosine phosphatases (PTPases), such as PTP-1B 450and SH-2 domain-containing tyrosine 
phosphatase-2 (SHP-2) 451, in vitro, as well as in vivo 451.  PTPases catalyze the rapid 
dephosphorylation and inactivation of multiple R-/NR-PTK, including IR and the IGF-1R 
β-subunit, and their substrates 497, 498, leading to a downregulation of proliferative and 
hypertrophic signaling.  PTPase inhibition can cause a shift in the phosphorylation-
dephosphorylation cycle, leading to a net increase of tyrosine phosphorylation of R- and/or 
NR-PTK421, 422, which may contribute to the activation of the ERK1/2 and PKB signaling 
cascades.  For example, it has been reported that PTEN, which catalyzes PIP3 
dephosphorylation, becomes inactivated by oxidation of Cys 124 in its catalytic domain 
subsequent to treatment with H2O2 or ROS-generating peptides 452-455, leading to an 
increase of PIP3 levels and a subsequent increase in PKB activation.  PTPases can respond 
to oxidative stresses from the environment, as well as to intracellular ROS, generated in 
response to physiological activation of growth factor receptors 451. 
In summary, vasoactive peptides have a profound effect on ROS production and R-
/NR-PTK activation through PTPase regulation, yet vasoactive peptides also affect and 
regulate the synthesis of growth factors themselves, which further compound vasoactive 
peptide-induced proliferative effects.  For example, Ang II has been shown to increase the 
levels of IGF-1 mRNA and protein in heart and VSMC 398, 399.  Conversely, IGF-1 was also 
found to up-regulate the expression of AT1R in VSMCs 400, suggesting the existence of a 
potential cross-talk between Ang II and IGF-1 system.  This notion is further supported by 
the studies showing that IGF-1R antisense-induced reduction in IGF-1R was associated 
with an inhibition of Ang II-induced vascular responses in SHR and WKY rats 401, 402.  In 
addition, native unmodified LDL has been found to increase IGF-1 mRNA, whereas 
oxidatively-modified LDL (oxy-LDL) decreases IGF-1 mRNA and protein expression in a 
dose-dependent fashion 499.  IGF-1 also stimulates ROS-mediated transactivation of EGFR 
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via Src activation, leading to ERK-1/2 phosphorylation, which plays a critical role in 
VSMC proliferation 471.  Antioxidant treatment can inhibit IGF-1-induced EGFR 
transactivation by lowering H2O2 production 471. In VSMCs, H2O2 can enhance IGF-1R and 
Src-PTK-dependent PKB activation 500. 
 Taken together, the results presented in this body of work identify c-Src as a clear 
mediator of vasoactive peptide-induced IGF-1R, leading to increases in PKB and MAPK 
signaling, as well as Egr-1 transcription factor regulation (Figure 12).  To our knowledge, 
the results reported here are the first to identify an involvement of IGF-1R in transducing 
the downstream effects of ET-1 and Ang II in activating PKB in VSMC. They are also the 
first to explore the role of c-Src in ET-1-induced Egr-1 expression in VSMC, providing a 
possible link between vasoactive peptide-induced signaling events and the hypertrophic and 
proliferative responses they induce in pathophysiological states. 
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Chapter 5 
Conclusion 
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Overall, the studies presented in this thesis demonstrate that receptor and non-
receptor protein tyrosine kinase transactivation by ET-1 and Ang II are crucial in 
propagating downstream signaling responses induced by these vasoactive peptides.  
Although EGFR transactivation has been studied in detail with regards to vasoactive 
peptide-induced signaling, the transactivation of other receptor and/or non-receptor tyrosine 
kinases is only recently coming to light as an important mechanism implicated in ET-1 and 
Ang II-induced migratory, hypertrophic and proliferative signaling, leading to the 
deleterious effects of hypertensive states. 
We have provided evidence demonstrating that both ET-1 and Ang II can induce the 
phosphorylation and subsequent activation of IGF-1R and c-Src PTK.  We have also 
demonstrated that IGF-1R and c-Src are required for ET-1 and Ang II-induced PKB 
phosphorylation.  Our studies have placed c-Src upstream of both PKB and IGF-1R in this 
signaling mechanism.  In addition, we have provided proof that IGF-1R and c-Src are key 
mediators of ET-1 and Ang II-induced proliferation and hypertrophy of VSMC, a key 
phenomenon in the development of vascular pathologies such as atherosclerosis and 
restenosis.  Furthermore, we have provided data demonstrating that MAPK activation by 
ET-1 and ANG II is not differentially regulated, and that c-Src is implicated in the 
activation of ERK 1/2, JNK and p38 MAPK induced by both vasoactive peptides.  Our 
results also highlight for the first time the role of c-Src in the modulation of the Egr-1 
transcription factor by ET-1 in VSMC, a mechanism which has been linked to the 
hypertrophic actions of ET-1 (Figure 12).   
Despite the work presented here and those of others, the precise mechanism of 
vasoactive peptide-induced R-/NR-PTK transactivation still remains unclear; however, 
evidence points towards the implication of signal intermediates, such as matrix 
metalloproteinase and the generation of ROS, in inducing the activation and subsequent 
phosphorylation of R-/NR-PTK, through either ligand-dependent or –independent 
mechanisms.  Examples of this are the inhibition of protein tyrosine phosphatases by ROS, 
allowing for EGFR or IGF-1R phosphorylation, or the cleavage of heparin from EGF to 
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allow for EGF-induced EGFR activation.  Notwithstanding the lack of a clear explanation 
as to how R-/NR-PTK transactivation occurs, evidence is accumulating to indicate that 
activation of R-/NR-PTK play a critical role in triggering the vasoactive peptide-induced 
signaling that mediates the hypertrophic, proliferative and migratory responses in VSMC.  
Further research using pharmacological or genetic approaches will likely help to decipher 
the exact mechanisms by which R-/NR-PTK transactivation occurs, leading to potential 
developments in therapeutic tools to help restore dysregulated signaling events associated 
with vascular disorders. 
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Figure 12: Schematic model summarizing the mechanism by which ET-1 and Ang II 
induce downstream activation and modulation of PKB, ERK1/2, JNK, p38mapk and 
Egr-1, leading to subsequent hypertrophic and proliferative events in VSMCs. ET-1 
and/or Ang II receptor activation is known to generate reactive oxygen species (ROS) through 
NAD(P)H oxidase system.  ROS are able to inhibit protein tyrosine phosphatases (PTPase) 
through the oxidation of cystein residues in their catalytic domain.  Inhibition of PTPases 
favors an increase in the tyrosine phosphorylation of NR-PTK, such as c-Src, and R-PTKs, 
such as IGF-1R, resulting in the ligand-independent activation of IGF-1R, triggering the PI3-
K/PKB and MAPK signaling cascades.  Activation of PKB, ERK1/2, JNK and p38 MAPK 
leads to modulation of many downstream effectors, including transcription factors such as 
Egr-1, contributing to hypertrophy, proliferation and migration of VSMCs. 
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